Method For Providing Dna Fragments Derived From An Archived Sample

ABSTRACT

Aspects of the present invention relate to compositions and methods for providing DNA fragments from an archived sample (e.g., paraffin-embedded and/or fixed-tissue biopsies, etc). Particular aspects provide methods whereby high yields of DNA are isolated as well as a substantial portion of the DNA consists of long DNA fragments, and where the isolated genomic DNA is free of associated or cross-linked contaminants like proteins, peptides, amino acids or RNA. The methods are facile, cost-effective, an are characterized by high reproducibility and reliability. Particular aspects provide methods for providing DNA fragments derived from an archived sample, wherein the yield of DNA before, for example, an amplification step is at least 20%, and amplicons up to a length of about 1,000 base pairs are amplifiable.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority to U.S. ProvisionalPatent Application Ser. No. 60/614,697, filed 30 Sep. 2004, and entitled“Work Flow,” and which is incorporated herein by reference in itsentirety.

FIELD OF THE INVENTION

The invention relates generally to novel and substantially improvedcompositions and methods for providing DNA fragments derived from anarchived sample (e.g., paraffin-embedded and/or fixed-tissue biopsies,etc), and for analyses of same.

BACKGROUND OF ASPECTS OF THE INVENTION

Samples or biopsies are archived many times by default in diagnosticroutines. This is done in order to conserve the tissue and to prepare itfor subsequent histological examinations. Such conservation is necessaryto ensure that the biopsy has not changed after the removal, theobserved findings correspond to the situation of the patient, and toprevent degradation of cell structures. Accordingly, the tissue sampleis immediately put into a fixative for example formalin after removal.After fixation the sample is embedded into paraffin, which allows asectioning of the tissue and a subsequent further histologicalexamination.

Using these procedures, biopsies are routinely taken from patients fordiagnosing diseases and/or for studying the pattern of markersassociated with diseases. Over the last decades millions of biopsieswere collected, archived and stored in this way. These samples representa major resource for the detection or analysis of disorders or diseaseassociated alterations.

Therefore these samples are invaluable, because they allow theevaluation of diagnostic and/or prognostic indicators in retrospectivecollections.

But unfortunately, this resource is only minimally accessible bymolecular biological means, in particular by the most promising andmodern methods such as those for the analysis of the methylationpattern. This is because of difficulties in obtaining sufficiently largeamounts of high quality genomic DNA at low costs and with minimalhandling effort.

These difficulties are based on the degradation of DNA and RNA due tofixation and storage conditions of the sample or biopsy, and on theinsufficient methods for the preparation of DNA. To preservemorphological structures in the sample as well as possible, biopsies areusually fixed very well. This has the disadvantage that a lot ofproteins are covalently linked to the genomic DNA and also the genomicDNA becomes cross-linked.

Consequently, genomic DNA tends to be of small fragment size, has a lowintegrity, and is contaminated by proteins, peptides and/or amino acidswhich are cross linked with the DNA and which also interfere withfurther analysis.

Most prior art methods for the isolation of DNA from paraffin embeddedformalin-fixed tissues are based on methods for the isolation of DNAfrom fresh tissue. They are carried out as one skilled in the art wouldtreat fresh samples maybe with an additional paraffin removal step. Asit is well known, such a procedure leads only to comparably low yieldsof genomic DNA, the DNA having only a small fragment length.Furthermore, the DNA is also not suitable for more sophisticatedanalysis methods, because still a lot of interfering proteins, peptidesand/or amino acids are linked to the DNA.

Particular ‘improved’ methods are known in the art. For example U.S.Pat. No. 6,248,535 teaches a method for the isolation of nucleic acidsfrom paraffin embedded formalin-fixed tissue. According to this method,the sample gets deparaffinized, homogenized before it is heated in achaotropic solution. After mixing with chloroform, followingcentrifugation, the solution has three phases. The interphase containsthe genomic DNA.

A different method is described by GB 2369822. According to this,sections of a paraffin-embedded formalin-fixed sample are put into atube. A detergent, a wax and a tissue-digesting enzyme are added, beforethe tube is heated to about 60° C. for about 30 min. After this theenzyme is inactivated by a temperature increase to 96° C. A subsequentcentrifugation step leads to a layering inside the tube, the middlelayer containing the genomic DNA as well the RNA.

Such methods usually lead to larger amounts of genomic DNA with a lot ofcontaminating RNA and protein. In addition, the contaminants cannot beeasily removed because they are cross-linked to the genomic DNA by thefixative. Moreover, in principle, it may be possible to also isolatelonger nucleic acid fragments with these kinds of methods, but theportion of long fragments is very small.

Several proposals have been made to get longer fragments: Bonin et al.teach a filling in of single-stranded breaks after isolation of the DNAand a denaturing step before PCR amplification (Bonin S., Petrera, F.,Niccolini, B., Stanta, G. (2003) J. Clin. Pathol: Mol. Pathol. 56,184-186). According to this method fragments up to 300 bp areamplifiable.

Inadome et al. suggest the isolation of the portion of longer DNAfragments by HPLC (Inadome, Y., Noguchi, M. (2003) Diagn. Mol. Pathol.12, 231-236). This procedure leads only to very low yields of DNA.

To enlarge the amount of long DNA fragments isolated fromparaffin-embedded, formalin-fixed tissues, a whole genome applificationwas suggested by Tie et al. and Siwoski et al. (Tie, J., Serizawa, Y.,Oshida, S., Usami, R., Yoshida Y. (2005) Pathol. Int. 55, 343-347;Siwoski, A., Ishkanian, A., Garnis, C., Zhang, L., Rosin, M., Lam, W. L.(2002) Mod. Pathol. 15, 889-892.). This solution has the disadvantage ofa low reproducibility and is not applicable when DNA is going to beanalysed for methlyation as amplification erases methylation signals.

Consequently, genomic DNA isolated according to prior art methods is notsuitable for analysis of the methylation pattern as explained in detailbelow.

The importance of DNA methylation pattern analyses has been revealed inrecent years. Many diseases, in particular cancer diseases, areaccompanied by modified gene expression. This may be a mutation of thegenes themselves, which leads to an expression of modified proteins orto an inhibition or over-expression of the proteins or enzymes. Amodulation of the expression may however also occur by epigeneticmodifications, in particular by changes in the DNA methylation pattern.Such epigenetic modifications do not affect the actual DNA codingsequence. It has been found that DNA methylation processes havesubstantial implications for health, and it seems to be clear thatknowledge about methylation processes and modifications of the methylmetabolism and DNA methylation are essential for understanding diseases,for the prophylaxis, diagnosis and therapy of diseases.

The precise control of genes, which represent a small part only of thecomplete genome of mammals, involves regulation in consideration of thefact that the main part of the DNA in the genome is not coding. Thepresence of such ‘trunk’ DNA containing introns, repetitive elements andpotentially actively transposable elements, requires effectivemechanisms for their durable suppression (silencing). Apparently, themethylation of cytosine by S-adenosylmethionine (SAM) dependent DNAmethyl transferases, which form 5-methylcytosine, represents such amechanism for the modification of DNA-protein interactions. Genes can betranscribed by methylation-free promoters, even when adjacenttranscribed or not-transcribed regions are widely methylated. Thispermits the use and regulation of promoters of functional genes, whereasthe trunk DNA including the transposable elements is suppressed.Methylation also takes place for the long-term suppression of X-linkedgenes and may lead to either a reduction or an increase of the degree oftranscription, depending on where the methylation in the transcriptionunits occurs.

Nearly the complete natural DNA methylation in mammals is restricted tocytosine-guanosine (CpG) dinucleotide palindrome sequences, which arecontrolled by DNA methyl transferases. CpG dinucleotides are about 1 to2% of all dinucleotides and are concentrated in CpG islands. Accordingto an art-recognized definition, a region is considered as a CpG islandwhen the C+G content over 200 bp is at least 50% and the percentage ofthe observed CG dinucleotides in comparison to the expected CGdinucleotides is larger than 0.6 (Gardiner-Garden, M., Frommer, M.(1987) J. Mol. Biol. 196, 261-282). Typically, CpG islands have at least4 CpG dinucleotides in a sequence of a length of 100 bp.

CpG islands located in promotor regions frequently have a regulatoryfunction for the expression of the corresponding gene. For example, incase the CpG island is hypomethylated, the gene can be expressed. On theother hand, hypermethylation frequently leads to a suppression of theexpression. Normally tumour suppressor genes are hypomethylated. But ifthey become hypermethylated, their expression becomes suppressed. Thisis observed many times in tumour tissues. By contrast, oncogenes arehypermethylated in healthy tissue, whereas they are hypomethylated inmany times in tumour tissues.

The methylation of cytosine has the effect that the binding of proteinsis normally prohibited which regulate the transcription of genes. Thisleads to an alteration of the expression of the gene. Relating tocancer, the expression of genes regulating cell division are therebyalterated, for example, the expression of an apoptotic gene is downregulated, while the expression of an oncogene is up regulated.Additionally, hypermethylation may have a long term influence onregulation. Proteins, which deacetylate histones, are able to bind viatheir 5-methylcytosine binding domain to the DNA when the cytosines getmethylated. This results in a deacetylation of the histones, whichitself leads to a tighter package of the DNA. Because of that,regulatory proteins are not precluded from binding to the DNA.

Pronounced need in the art. The efficient detection of DNA methylationpatterns consequently is an important tool for developing new approachesto understand diseases, for the prevention, diagnosis and treatment ofdiseases and for the screening for disease associated targets. But onthe other hand, methods for an efficient detection of DNA methylationrequire high quality standards in regard to the starting material thegenomic DNA. Preferably, the standards are: i) DNA fragment range isbetween 150 to 1200 bp; and ii) the DNA is free of associated or crosslinked proteins, peptides, amino acids, RNA as well as of nucleotides orbases, which are not part of the DNA backbone.

Furthermore, there are also requirements with regard to the methodsaccording to which the DNA is isolated. The reason for these is that alot of samples are typically analysed for developing new approaches forthe prevention, diagnosis and treatment of a disease and for thescreening for disease associated targets. Preferably, the requirementsare: i) isolation of high quality DNA (as specified above); ii) highreproducibility; iii) high reliability, iv) ease of handling; v) lowhandling effort; and vi) low costs.

Additionally, because in general the amount of the tissue sample orbiopsy is very small, it is necessary that the methods for DNApreparation result in high yields of DNA.

Because of all these requirements, and given the prior art methods,archived samples, despite being a major resource in medical science, canonly be minimally used for the efficient analysis of the DNAmethylation. Thus a major technical need exists to efficiently makearchived samples (e.g., paraffin-embedded formalin-fixed tissues)available for the analysis of, for example, the DNA methylationpatterns.

Thus far, applicants are aware of only one attempt to solve thisproblem. WO03/083107 teaches a method for isolation of genomic DNA fromparaffin-embedded suitable for subsequent DNA methylation analysis bymethylation specific PCR (MSP). In principle the deparaffiniatedformalin-fixed sample is boiled in a citrate buffer pH 6.0, whichrecovers parts of the cytosines making them better accessible forsubsequent treatment and analysis. However this method is conflictingwith regard to the aim to provide as long as possible DNA fragments.According to this method DNA is brought into contact with a buffer ofacidic pH. As is well known in the relevant art, such treatment reducesthe integrity of DNA resulting in a random breakage of the DNA strandand therefore the length of the DNA fragments.

SUMMARY OF ASPECTS OF THE INVENTION

Aspects of the present invention relate to compositions and methods forproviding DNA fragments from an archived sample. Particular spectsprovide compositions and methods for providing DNA fragments derivedfrom an archived sample, wherein the yield of DNA before, for example,an amplification step is at least 20%, and amplicons up to a length ofabout 1,000 base pairs are amplifiable.

Additional aspects provide a method for the preparation of genomic DNAfrom archived paraffin-embedded formalin-fixed tissue samples, wherebyhigh yields of DNA are isolated as well as a substantial portion of theDNA consists of long DNA fragments. In particular aspects, the isolatedgenomic DNA is free of associated or cross-linked contaminants likeproteins, peptides, amino acids or RNA. In particular aspects, themethods are characterized by high reproducibility and high reliability.In particular aspects, the methods are easy to handle, have a lowhandling effort, and are cost-effective.

Particularly preferred embodiments provide compositions and methods isfurther characterized in that

i) DNA extracted from an archived sample is subject to a bisulfitetreatment;

ii) the yield of DNA after a bisulfite treatment step and a subsequentpurification step and before an amplification step is 30-50%;

iii) amplicons up to a length of 600 base pairs are amplifiable afterbisulfite treatment and subsequent purification; and

iv) in the average at least 10% of the DNA fragments are amplifiableafter bisulfite treatment and subsequent purification in a PCR reactionresulting in fragments of at least 110 bp length.

Additional aspects provide a test kit for carrying out the method of theinvention or an embodiment of the method of the invention. In particularaspects, the test kits comprise one or more of the following: acontainer, organic solvents for the removal of paraffin, proteinase K,buffer for the lysis of tissue, solutions and/or devices for DNAextraction, solutions and/or devices for bisulfite treatment, solutionsand/or devices for DNA purification, solutions and/or substances for DNAamplification, a manual and/or description for carrying out the methodaccording to the invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows, according to particular aspects, positions of the DNAsamples and PCR plates on a TECAN workstation.

FIG. 2 shows, according to particular aspects, results of real time PCRquantification of pooled bisulfite DNA derived from differentparaffin-embedded formalin-fixed specimens—Influence of dNTPconcentration on PCR performance (Example 11).

FIG. 3 shows, according to particular aspects, results of real time PCRquantification of pooled bisulfite DNA derived from differentparaffin-embedded formalin-fixed specimens—Influence of extension timeon PCR performance (Example 11).

FIG. 4 shows, according to particular aspects, results of real time PCRquantification of pooled bisulfite DNA derived from differentparaffin-embedded formalin-fixed specimens—Influence of polymeraseamount on PCR performance (Example 11).

FIG. 5 shows, according to particular aspects, yield of bisulfitetreated DNA after purification derived from paraffin-embeddedformalin-fixed prostate biopsies (Example 12).

FIG. 6 shows, according to particular aspects, content of amplifiableDNA after bisulfite treatment and subsequent purification (The contentis defined by the ratio of amplifiable DNA determined according toexample 10c and UV value determined according to example 10a whichreflects the total amount of DNA present in the sample; Example 12).

FIG. 7 shows, according to particular aspects, PCR amplification ofbisulfite specific amplicons ranging from 185 bp to 711 bp. A: HMWtemplate DNA (positive control). B: bisulfite treated and subsequentlypurified template DNA derived from paraffin-embedded formalin-fixedtissue. 30 ng template DNA and 1 U Taq polymerase in a total volume of25 μl were used. C: bisulfite treated and subsequently purified templateDNA derived from paraffin-embedded formalin-fixed tissue. 30 ng templateDNA and 3 U Taq polymerase in a total volume of 25 μl were used (Example13).

FIG. 8 shows, according to particular aspects, total DNA in lysatesquantified according to example 10d (CFF1 assay; data scaledlogarithmically). All data are means of four independently processedsamples per specimen including standard deviation (Example 14).

FIG. 9 shows, according to particular aspects, total DNA in extractsquantified according to example 10d (CFF1 assay; data scaledlogarithmically). All data are means of four independently processedsamples per specimen including standard deviation (example 14).

FIG. 10 shows, according to particular aspects, DNA yield afterextraction (ratio of DNA in extract and DNA in lysate). All data aremeans of four independently processed samples per specimen includingstandard deviation (Example 14).

FIG. 11 shows, according to particular aspects, total amount of DNAphysically present as determined by UV spectrophotometry (This DNAcontains amplifiable as well as non-amplifiable DNA). All data are meansof four independently processed samples per specimen including standarddeviation (Example 14).

FIG. 12 shows, according to particular aspects, content of amplifiableDNA in extracts. The content is determined by the ratio of quantifiedDNA according to example 10d (CFF1 assay) and of quantified DNAaccording to example 10a (UV value from which the total amount ofphysically present DNA is calculated)]. All data are means of fourindependently processed samples per specimen including standarddeviation (Example 14).

FIG. 13 shows, according to particular aspects, total DNA in lysatesquantified according to example 10d (CFF1 assay; data scaledlogarithmically) (Example 15).

FIG. 14 shows, according to particular aspects, total DNA in extractquantified according to example 10d (CFF1 assay; data scaledlogarithmically) (Example 15).

FIG. 15 shows, according to particular aspects, yield of DNA afterextraction (ratio of DNA in extract and DNA in lysate) (Example 15).

FIG. 16 shows, according to particular aspects, total amount of DNAphysically present as determined by UV spectrophotometry (This DNAcontains amplifiable as well as non-amplifiable DNA) (Example 15).

FIG. 17 shows, according to particular aspects, content of amplifiableDNA in extracts. The content is determined by the ratio of quantifiedDNA according to example 10d (CFF1 assay) and of quantified DNAaccording to example 10a (UV value from which the total amount ofphysically present DNA is calculated) (Example 15).

FIG. 18 shows, according to particular aspects, total yield of DNA afterbisulfite treatment and subsequent purification. The quantification wascarried out according to example 10d (CFF1 assay; data scaledlogarithmically). All data are means of two independently processedsamples per specimen.

FIG. 19 shows, according to particular aspects, total yield of DNA afterbisulfite treatment and subsequent purification. The quantification wascarried out according to example 10c (C3 assay; data scaledlogarithmically). All data are means of two independently processedsamples per specimen (Example 16).

FIG. 20 shows, according to particular aspects, total yield of DNA afterbisulfite treatment and subsequent purification. The quantification wascarried out according to example 10d (CFF1 assay; data scaledlogarithmically). All data are means of four independently processedsamples per specimen (Example 17).

FIG. 21 shows, according to particular aspects, total yield of DNA afterbisulfite treatment and subsequent purification. The quantification wascarried out according to example 10c (C3 assay; data scaledlogarithmically). All data are means of four independently processedsamples per specimen (Example 17).

DETAILED DESCRIPTION OF ASPECTS OF THE INVENTION

For achieving various technical objects, aspects the invention teachcompositions and methods for providing DNA fragments derived from anarchived sample, characterized in that the yield of DNA before anamplification step is at least 20%, and amplicons up to a length of1,000 base pairs are amplifiable. Particular aspects provide methods tofind amongst an enormous plurality of known methods for paraffinremoval, tissue lysis, DNA extraction, bisulfite treatment, DNApurification and DNA amplification those methods, which in principle canbe used to solve the technical object of the invention. Particularaspects provide suitable combinations and adjustments of these methodswith each other in a manner that actually meets the technical object(s).

Advantages of Aspects of the Invention

In particular aspects, the exemplary inventive method has the followingadvantages: It has a low handling effort, because it includes only avery limited amount of steps which has to be carried out. Additionally,it is possible to carry out the method of the invention in a platescale. Moreover the different steps can also be automated and thereforerobotics can also be used.

The execution in plate scale and the suitability of the method forautomatisation also lead to a reduction in costs. In addition the costsare further reduced by the use of devices and solutions which areavailable at low expenses.

Another advantage of the method of the invention is that every step caneasily be performed because only standard laboratory equipment isnecessary for its execution.

Because of its simpleness, its suitability for automatisation, its lowhandling effort as well as its easy handling, the method of theinvention has a high reliability and reproducibility.

In addition, DNA provided by this method is characterized by its highquality, even where an archieved paraffin-embedded formalin-fixed samplewas used as a starting material. Furthermore, DNA provided according tothis method comprises a notable fraction of long fragments (in theaverage 10% of the fragments have at least a length of 110 bp) andsurprisingly long fragments are amplifiable (up to 600 bp). The DNA isfurther characterised that only minor contaminant proteins or peptidesare linked to it. These contaminations are only so slightly that thebisulfite treatment is only faintly impaired if at all.

On the other hand, relatively high yields of DNA can be obtainedreliably from the archieved sample with an additional highreproducibility. Therefore it is possible to obtain from only very smallsamples sufficient DNA for methylation analysis.

Method of Aspects of the Invention

The method of the invention is a method for providing DNA fragmentsderived from an archived sample. According to the method of theinvention, the yield of DNA before any amplification is at least 20%.For determination of the yield of DNA, the yield of DNA of every step ofthe method according to the invention is determined. The overall yieldis then calculated by multiplication of the yields of the individualsteps as known by those skilled in the art. The yield of DNA for eachindividual step can be carried out (determined) as described in detailin the instant EXAMPLES 10, 12, and 14-18, or by any other suitablemethod known to those skilled in the art, for example UV 260/280 nm orgel electrophoresis especially in combination with a detection systemlike a phosphor imager.

Furthermore, particular aspects of the exemplary inventive arecharacterized in that amplicons up to a length of 1,000 bp areamplifiable, whether or not a bisulfite treatment is carried out.

A bisulfite treatment step carried out according to the state of the artreduces the ability of amplification of amplicons if the bisulfitetreated DNA is used as a template. However, the single steps of theexemplary inventive methods are harmonised in such a way and thebisulfite treatment step is carried out in such a way that theapplication of a bisulfite treatment has nearly no influence on theability/efficiency of amplification.

In brief, the method of the invention is a method for providing DNAfragments derived from an archived sample, which is characterized inthat

-   -   the yield of DNA before an amplification step is at least 20%,        and    -   amplicons up to a length of 1,000 base pairs are amplifiable.

At this, amplifiable means that any amplicon of a desired length can beamplified by the corresponding primers during a PCR amplification. ThePCR amplification can be standard PCR or real time PCR or any known PCRamplification known to those skilled in the art. Of course, also methodswhich lead to similar results like ligase mediated chain reaction (LCR)or the NASBA/TMA technique can be used. The amplicon is then detected bymeans of fluorescence by standard techniques, for example by means ofintercalating dyes like ethidium bromide or SYBR green or labelsattached to the used primers or nucleotides. Suitable methods fordetection are known to those skilled in the art.

In a further embodiment, the method of the invention is characterized inthat

-   -   the yield of DNA before an amplification step is 20-60%, and    -   amplicons up to a length of 600 base pairs are amplifiable.

In a particular preferred embodiment the method of the inventioncomprises a bisulfite treatment step. After the then necessary DNApurification step, the overall yield of DNA is at least 20%, preferablein the range of 30-50%. Furthermore, the DNA after bisulfite treatmentand the purification step is further characterized in that at least 5 ofthe DNA fragments are amplifiable in a PCR reaction resulting infragments of at least 110 bp in length. In a particularly preferredembodiment, this DNA is characterized in that 5-60% of the DNA fragmentsare amplifiable in a PCR reaction resulting in fragments of at least 110bp in length. In an especially preferred embodiment, an average of 10%of the purified DNA is amplifiable in a PCR reaction resulting infragments of at least 110 bp length. These values can be determined asexemplified in example 10 and 14.

Therefore, in an embodiment, the method of the invention is a method forproviding DNA fragments derived from an archived sample, characterizedin that

-   a) the DNA is extracted,-   b) the extracted DNA is treated with bisulfite-   c) the bisulfite treated DNA is purified, whereby    -   (i) the yield of purified DNA is at least 20% of the DNA        contained in the archived sample,    -   (ii) at least 5% of the purified DNA is amplifiable in a PCR        reaction generating fragments of at least 110 bp length.

In a preferred embodiment, the method of the invention is characterisedin that the yield of the DNA in step c (i) is between 30-50%

In a preferred embodiment, the method of the invention is characterisedin that in step c (ii) 5-60% of the purified DNA is amplifiable in a PCRreaction generating fragments of at least 110 bp length

In a preferred embodiment, the method of the invention is characterisedin that in step c (ii) an average of 10% of the purified DNA isamplifiable in a PCR reaction generating fragments of at least 110 bplength.

In a especially preferred embodiment, the method of the invention isfurther characterized in that in the average at least 10% of the DNAfragments are amplifiable after bisulfit treatment and subsequentpurification in a PCR reaction resulting in fragments of at least 110 bplength.

In another especially preferred embodiment, the method of the inventionis further characterized in that between 7-60% of the DNA fragments areamplifiable after bisulfite treatment and subsequent purification in aPCR reaction resulting in fragments of at least 70 bp in length. Morepreferably, in the average 15% are amplifiable after bisulfite treatmentand subsequent purification in a PCR reaction resulting in fragments ofat least 70 bp in length.

Archived Sample

According to the invention the archived sample is a paraffin embeddedand/or fixed tissue biopsy or a paraffin embedded and/or fixed tissuesection or parts thereof for example microdisseccted samples. Therebythe term “biopsy” refers to any kind of needle biopsy or any kind oftissue sample collected during a surgery. Moreover, the term “tissuesection” refers to any part of a biopsy for example derived by microtomsectioning of the biopsy.

As it is well known by those skilled in the art, it is difficult todetermine the actual weight of a tissue section. These difficulties arecaused therein that the section are usually brittle, teeny and sticky.Furthermore, it is also important to have in mind the percentage ofparaffin which surrounds the tissue. According to the invention, samplesare preferred which have a paraffin percentage of 50% or less. Typically1-6, in particularly three sections of 10 μm thickness with a tissuearea in the range of 0.7 cm×0.7 cm to 2.5 cm×3.5 cm are used as astarting material. A person with ordinary skills in the art will knowhow to adjust the method according to invention to use samples whichhave a paraffin percentage of more than 50% or in case sections are usedwith a smaller or larger tissue area. For samples obtained by biopsies,different amounts are chosen as a starting material. Typically 1-6, inparticularly three sections of 10 μm thickness of a biopsy sample areused. The biopsy sample comprises 1-6, preferable 3 biopsies embeddedinto paraffin. Typical biopsies are cylindrical having a diameter ofabout 1 cm, the length cannot be standardised. A person with ordinaryskills in the art will know to choose an sufficient amount of startingmaterial from a biopsy sample if the sample contains more biopsies. Inaddition he would also knew how to choose an equivalent amount ofnon-sectioned biopsy, which can be used according to the invention.Again, a person with ordinary skills in the art will know how to choosean appropriate amount of starting material. Of course, the method of theinvention is also applicable for samples fixed with other fixatives likeglutaraldehyd, Bouin' fixative, isopentane, or alcohol based fixativeslike methanol or ethanol.

In an embodiment of the invention, the archived sample is aformalin-fixed sample, typically embedded into paraffin. But alsoformalin treated samples which are not embedded into paraffin can beused as a starting material. Of course fresh or fresh frozen samples canalso be subject of the method according to the invention which will thanstart directly with the lysis step.

In an embodiment of the invention the archived sample is a paraffinembedded and/or fixed tissue biopsy or a paraffin embedded and/or fixedtissue section.

Steps of the Method According to the Invention

An embodiment of the invention comprises an optional paraffin removalstep, a lysis step, an optional DNA extraction step, an optionalbisulfite treatment step, an optional purification step and anamplification step. The method can be carried out in plate scale or tubescale. It can be conducted manually or by a roboter. So, it is possibleto carry out the method of the invention manually in tube scale as wellas in plate scale manually or by a roboter. This latter possibility hasthe advantage of a low handling effort and a reduction in costs.

An embodiment of the invention comprises a paraffin removal step, alysis step, a DNA extraction step, a bisulfite treatment step, apurification step and an amplification step.

In another embodiment, the archived sample is directly subjected to alysis step, wherein the paraffin is liquefied by heating. This lysisstep typically leads to DNA free from cross-links, making it possible toalso leave out the DNA extraction step and continuing with the bisulfitetreatment step if desired, followed by the amplification step.

For the two above mentioned embodiments, it is preferred that thebisulfite step can be left out as well as the subsequent purificationstep for suitable applications that may follow. Therefore in aparticular embodiment it is preferred, that the DNA extraction step iscarried out by means of Minelute™ columns which are part of the QIAampDNA Micro Kit. Very surprisingly, such a proceeding leads to theadvantage that the portion of amplificable DNA is comparably large ifthe eluate of the first step of elution from the Minelute™ columns isused (see below)

To leave out the bisulfite treatment step and the subsequent DNApurification step is also particularly preferred if a bisulfitetreatment is not necessary for the analysis of the DNA methylation forexample by use of restriction enzymes. An example for such a method isthe DMH method as it is described below or the restriction assay alsoknown as Mest evaluation method as described in DE102004029700.2 or inPCT/DE205/001109 (both references incorporated by its entirety.

In principle, for the above named embodiments, it is also possible toleave out the amplification step if it is not necessary for subsequentanalysis like methylation sensitive restriction and subsequent southernblot analysis. On the other hand, an amplification step might beadvantageous even it is not necessary for the real detection of the DNAmethylation status. This is for example the case, if only low amounts oflarge DNA fragments are provided. An amplification will in this casecause a lowering of the sensitivity of the subsequent methods for theDNA methylation analysis.

The method according to invention comprises the following steps:

-   -   a) optional, a paraffin removal step,    -   b) a lysis step,    -   c) optional, a DNA extraction step    -   d) optional, a bisulfite treatment step    -   e) optional, a purification step    -   f) an amplification step        Paraffin Removal Step

According to the invention the paraffin removal step comprises thedissolving of paraffin by an organic solvent. In a preferred embodimentthe sample is additional washed with another organic solvent whichenables afterwards a better rehydratisation. Therefore in an embodimentthe paraffin removal step comprises the dissolving of paraffin by anorganic solvent or the dissolving of paraffin by an organic solvent andwashing by another organic solvent.

In a preferred embodiment, the organic solvent which dissolves paraffinis a solvent of the group “limonene, xylene or any mixture of thesesolvents”. In particular, it is preferred that the organic solvent islimonene. This is especially favourable because limonene is lesshazardous, less harmful to health and environment than other suitablesolvents. Additionally, it is also possible to use organic solvents likebenzene, ethylbenzene, toluene, isoparaffin (also known as x-tra-solve(medite medizintechnik)) or any solvent with similar chemical propertiesor any mixture of said solvents.

A organic solvent which is suitable for washing the sample and preparingit for a better rehydratisation after dissolving paraffin is a solventof the group of “ethanol, methanol, isopropanol or any mixture of thesesolvents with each other or with water”. It is particularly preferred touse ethanol as a washing solvent after dissolving paraffin. Of coursealso additional solvents with comparable chemical properties can beused.

In an embodiment of the invention the organic solvent for dissolvingparaffin is a solvent of the group “limonene, xylene or any mixture ofthese solvents”, and wherein the washing solvent is a solvent of thegroup of “ethanol, methanol, isopropanol or any mixture of thesesolvents with each other or with water”.

In a preferred embodiment of the invention the paraffin removal stepcomprises the addition of a suitable volume of limonene to the archivedsample. The volume of limonene is thereby dependent on the amount ofsample. For 1-6 10 μm sections which are typically used as a startingmaterial (see above) 0.1-3 ml of limonene are used. A person withordinary skills in the art will know how to adjust the volume oflimonene to smaller or larger samples. After incubation, preferably forat least 5 min at 10-70° C., and centrifugation the limonene with thedissolved paraffin is removed.

In an embodiment of the invention, the paraffin removal step comprises

-   -   addition of 0.1-3 ml of limonene to the archived sample,    -   incubation for at least 5 min at 10-70° C.,    -   centrifugation, and    -   removal of the limonene.

In a particularly preferred embodiment 0.5-1.5 ml, preferably 1 ml, oflimonene is added to the archived sample in order to remove theparaffin. Subsequently the sample is incubated with agitation for 5-120min at 15-30° C., preferable for 10-60 min at room temperature. Theagitation can be continuous or is briefly repeated several times. Aftercentrifugation for at least 5,000×g for 1-20 min, preferably for 5 min,the tissue is located at the bottom of the tube and the mixture oflimonene and paraffin is removed.

In an embodiment of the invention, the paraffin removal step comprises

-   -   addition of 1 ml of limonene to the archived sample,    -   incubation for 10 min-1 h at room temperature mixing the sample,    -   centrifugation at least 5,000×g for 5 min, and    -   removal of the limonene.

In a preferred embodiment of the invention the tissue sample after theremoval of paraffin is washed with ethanol. If the typical amount ofsample (1-6 10 μm thick sections) are used, a suitable volume of ethanolfor this washing step is 0.1-3 ml. A person with ordinary skills in theart will know how to adjust this volume if smaller or larger samples areused. After the addition of ethanol, the sample is incubated at 15-30°C. for up to 10 min. But even longer incubations are possible becausethey are not unfavourable. After centrifugation, the ethanol is removedand the tissue sample is dried at 15-65° C.

In an embodiment of the invention, the washing solvent is ethanol, andthe embodiment comprises

-   -   addition 0.1-3 ml of ethanol,    -   optional, incubation for up to 10 min at 15-30° C.,    -   centrifugation,    -   removal of the ethanol, and    -   drying.

In a particularly preferred embodiment, 0.5-1.5 ml preferably 1.0 ml ofethanol is added as a washing solution. The incubation takes place for1-10 min, preferable for 10 min at room temperature with agitation. Theagitation can be continuous or is briefly repeated several times. Aftercentrifugation for at least 5,000×g for 1-20 min, preferably for 5 min,the tissue is located at the bottom of the tube and the ethanol isremoved. The tissue sample is dried at 45-65° C. for 5-60 min,preferable at 50° C. for 10-30 min.

A preferred embodiment of the invention comprises the following steps:

-   -   addition of 1 ml ethanol,    -   incubation for 10 min at room temperature mixing the sample,    -   centrifugation at least 5,000×g for 5 min,    -   removal of the ethanol, and    -   incubation for 10-30 min at 50° C.        Lysis Step

In an embodiment of the invention the lysis step is carried out by theuse of protease. This protease can be a serin protease, a thiolprotease, a carboxy protease, a metalloprotease, proteinase K or anymixture of these proteases.

Depending on the protease, the time for digestion may vary. The reasonfor this are the different activities of the proteases. According to theinvention it is preferred to choose a protease with a high enzymaticactivity. But according to the invention it is also preferred to choosea protease which is available at low cost. Therefore it is particularlypreferred to choose a protease with a high enzymatic activity/costratio. Because of that it is particularly preferred to choose proteinaseK for lysis.

In addition, the time for digestion varies also dependent on the textureand nature of the tissue sample. For example, tissues like breast tissueare digested rather quickly, because of the loose cohesion of the cells.On the hand, tissues like colon or liver tissue might need longerdigestions because of the compactness of the tissue.

Another important factor which has an significant influence on the timeof digestion is the geometrical shape of the sample. In general, sampleswith a large surficial area are easier digestable than samples with asmaller surficial area if they have the same texture and nature and ifthe same protease is used for digestion. Therefore it is preferred touse tissue sections or to cut larger tissue samples into pieces. But,according to the invention, it is also preferred to adjust the time fordigestion on the geometrical shape of the tissue samples. In doing so,it is not necessary any more to cut larger tissue sections into pieces.Because this also lowers the handling effort, it is particularlypreferred to use long times for digestion.

Longer digestions times are also particularly more preferred, because itis supposed that they enable a better removal of cross-linked proteinsor peptides form the DNA. The importance of a complete removal ofcontamined protein or peptides is already explained in detail above.According to the invention, it is preferred to lyse the tissue sampleswith proteinase K not longer than 60 h, in particular not longer than 48h because of efficiency reasons. This is usually sufficient for acomplete digestion removing all contamined proteins and peptides.

Taken the above said into account, the minimum time of digestion is 2.5h, preferably 3 h. This is especially the case for easy to digesttissues with have a large surficial area and the use of proteinase K.

Furthermore, for a better removal of contaminant proteins or peptides,it is particularly preferred to add an additional amount of proteaseafter the first 24 h of digestion. This is recommended because theenzymatic activity decreases over time because of self-digestion. Forsome tissues it might be advantageous to add additional amounts ofprotease for several times. For example for colon or prostate tissue itis particularly preferred to add three times proteinase K.

In an embodiment of the invention, the lysis step is carried out by theuse of a protease selected from the group “a serine protease, a thiolprotease, a carboxy protease, a metalloprotease, proteinase K or anymixture of these proteases”.

In a preferred embodiment the lysis step comprises the addition of0.05-1 ml of a lysis buffer to 1-10 deparaffinated formalin-fixed tissuesections of 10 μm thickness or an equal amount of a deparaffinatedformalin-fixed tissue biopsy. The lysis buffer comprises 50 mmol/l Tris(tris-hydroxymethyl-amino-methan) pH 8.0, 1 mmol/l EDTA, 0.5% Tween 20v/v. Of course, the use of any other lysis buffer as it is known bythose skilled in the art is possible. Subsequently 0.1-3 mg ofproteinase K is added. Proteinase K may be dissolved in a suitablebuffer, preferentially the used lysis buffer. This can be done byaddition of 10-100 μl of a proteinase K solution comprising 10-30 g/lproteinase K. After the addition of the protease, the mixture isagitated. The mixture is incubated for at least 2.5 h at 40-70° C.Thereafter, if desired, the proteinase K can be inactivated by heatingor by the use of inhibitors. A person with ordinary skills in the artknows how to adjust the volume of said solutions if the thickness of thesection varies or if smaller or larger amount of sample are used.

In a preferred embodiment, the lysis step comprises

-   -   addition 0.05-1 ml of lysis buffer comprising 50 mmol/l        tris-hydroxymethyl-amino-methan pH 8.0, 1 mmol/l EDTA, 0.5%        Tween v/v to 1-10 deparaffinated formalin-fixed tissue sections        or an equal amount of a deparaffinated formalin-fixed tissue        biopsy,    -   addition a 10-100 μl of proteinase K comprising 10-30 g/l        proteinase K, subsequently agitating the sample,    -   incubation for at least 2.5 h at 40-70° C., and    -   optional, inactivation of the proteinase K by heating or by use        of an inhibitor.

In a particularly preferred embodiment the lysis step comprises theaddition of 100-300 μl, preferably 190 μl of lysis buffer to 1-10deparaffinated formalin-fixed tissue sections of 10 μm thickness or anequal amount of a deparaffinated formalin-fixed tissue biopsy.Furthermore 0.45-1.5 mg, preferably 0.6 mg of proteinase K are added. Inparticular the proteinase K is added as 15-50 μl, preferably as 20 μl ofa proteinase K solution comprising 30 μg/μl proteinase K. The subsequentagitation is carried out by rigorous vortexing. After this, the mixtureis incubated for 2.5-60 h at 45-65° C., preferably for 3-48 h at 50-60°C., wherein the mixture is agitated continuously or briefly repeatedmany times. The inactivation of the proteinase K can be achieved byincubation of the mixture for 5-20 min at least at 90° C., preferablyfor 10 min at least at 95° C. Storage temperaturen alle rausnehmen!!! Ina especial variant it is preferred that at least 0.6 mg of proteinase K,for example 20 μl of a 30 μg/μl proteinase K solution after the first 24h of the incubation are added. A person with ordinary skills in the artknows how to adjust the volume of said solutions if the thickness of thesection varies or if smaller or larger amount of sample are used.

In a preferred embodiment, the lysis step comprises

-   -   addition of 190 μl of lysis buffer to 1-6 deparaffinated        formalin-fixed tissue sections or an equal amount of a        deparaffinated formalin-fixed tissue biopsy,    -   addition of 20 μl of proteinase K solution comprising 30 g/l        proteinase K, subsequent rigorously vortexing,    -   incubation for 3-48 h at 50° C.-60° C. mixing the sample, and    -   optional, addition of at least 20 μl proteinase K solution after        the first 24 h incubation at 50° C.-60° C., and    -   incubation for 10 min at least at 95° C.

In another preferred embodiment, the archived sample is directlysubjected to the lysis step which comprises the addition of 0.05-1 ml ofa lysis buffer to 1-10 deparaffinated formalin-fixed tissue sections of10 μm thickness or an equal amount of a deparaffinated formalin-fixedtissue biopsy. The lysis buffer comprises 50 mmol/l T is(tris-hydroxymethyl-amino-methan) pH 8.0, 1 mmol/l EDTA, 0.5% Tween 20v/v. Preferably it also comprises 5 ng/μl poly-dA DNA. Of course, othersuitable lysis buffers as they are known to those skilled in the art canalso be used. Subsequently the mixture is incubated for 5-20 min at40-75° C. After this, 0.15-1.2 mg of proteinase K, for example 5-40 μlof a 30 μg/μl proteinase K solution is added. The mixture is thenincubated for at least 2.5 h at 40-70° C. with agitation. Thereafter, ifdesired, the proteinase K can be inactivated by heating or by the use ofinhibitors. A person with ordinary skills in the art knows how to adjustthe volume of said solutions if the thickness of the section varies orif smaller or larger amount of sample are used.

In a preferred embodiment, the archived sample is directly subjected tothe lysis step which comprises

-   -   addition of 50-1,000 μl lysis buffer to 1-10 deparaffinated        formalin-fixed tissue sections or an equal amount of a        deparaffinated formalin-fixed tissue biopsy, the lysis buffer pH        8.0 comprising 50 mmol/l tris-hydroxymethyl-amino-methan, 1        mmol/l EDTA, 0.5% Tween v/v, and optional 5 ng/μl poly-dA DNA,    -   incubation for 5-20 min at 40-75° C.,    -   addition of 5-40 μl proteinase K solution, the proteinase K        solution comprising 30 mg/ml proteinase K,    -   incubation for at least 2.5 h at 40-70° C., and    -   optional, inactivation of the proteinase K by heating or by use        of an inhibitor.

In a particularly preferred variant 75-200 μl, preferably 100 μl oflysis buffer are added to 1-6 deparaffinated formalin-fixed tissuesections of 10 μm thickness or an equal amount of a deparaffinatedformalin-fixed tissue biopsy. After the addition, the mixture isincubated for 7-15 min at 50-70° C. in a thermomixer at 500-2,000 rpm,preferably for 10 min at 65° C. in a thermomixer at 1,000 rpm.Subsequently, 0.21-0.6 mg, preferably 0.3 mg of proteinase K, forexample 7-20 μl, preferably 10 μl of a 30 μg/μl proteinase K solution isadded. The mixture is then incubated for 2.5-60 h at 50-65° C. in athermomixer at 1,000-2,000 rpm, preferably for 3-48 h at 60° C. in athermomixer at 1,400 rpm. The proteinase K can be inactivated byincubation of the mixture for 5-20 min at least at 90° C., preferablyfor 10 min at least at 95° C. The inactivation of proteinase K can alsobe achieved by the addition of proteinase K inhibitors. A person withordinary skills in the art knows how to adjust the volume of saidsolutions if the thickness of the section varies or if smaller or largeramount of sample are used.

In a particularly preferred embodiment, the lysis step comprises

-   -   addition of 100 μl lysis buffer to 1-6 deparaffinated        formalin-fixed tissue sections or an equal amount of a        deparaffinated formalin-fixed tissue biopsy,    -   incubation for 10 min at 65° C. in a thermomixer at 1,000 rpm,    -   incubation at 50° C. in a thermomixer at 1,400 rpm    -   addition of 10 μl proteinase K solution,    -   incubation for 3-48 h at 60° C. in thermomixer at 1,000 rpm, and    -   incubation for 10 min at >95° C.

In case the archived sample is directly subjected to the lysis step, itis preferred that the DNA may be directly subjected to the bisulfitetreatment leaving out the DNA extraction step. This is in particularpreferred if the amount of archived sample is small or if a person withordinary skills in the are would expect only small yields of DNA.

DNA Extraction Step

A lot of methods are known to those skilled in the art for DNAextraction from tissue samples (Sambrook et al., Molecular Cloning: ALaboratory Manual, 2^(nd) edition, 1989, Cold Spring Harbor LaboratoryPress).

To reduce the handling effort and also to ensure a high reproducibilityas well as reliability, it is preferred to use a kit for DNA extraction.For one with ordinary skills in the art a hugh amount of kits are knownwhich might be suitable for DNA extraction.

Therefore in a first step the most promising kits were chosen forsubsequent tests. These kits are: QIAamp DNA Mini Kit, ZR genomic DNA IIkit, MagneSil Genomic, Fixed Tissue System, MagNA Pure LC DNA IsolationKit II (Tissue), Nexttec tissue kit, ChargeSwitch® Forensic DNAPurification Kit, and Charge Switch genomic DNA Purification kit.

In a second step these kits were tested in view of a DNA extraction,wherein the following criteria were used: i) a minimal handling effort;ii) a minimal length of time; iii) yield of DNA; iv) the ability ofamplification after the extraction step; and v) purity of the DNA bymeans of UV light (260 nm/280 nm ratio preferably in the range of1.7-1.9). The QIAamp DNA Mini Kit was used as a reference. Best resultswere just obtained by the QIAamp DNA Mini Kit.

Therefore, according to the invention and for best results, the QIAampDNA Mini Kit is preferably used. In addition, also kits are preferablyused which contain the same solutions and/or equivalent materials suchas columns or buffers. Such kinds of kits are for example the DNeasy 96Tissue Kit, the QIAamp 96 DNA Blood Kit, the QIAamp DSP 96 Virus MDXKit, the DNeasy Tissue Kit, the QIAamp DNA Micro Kit, QIAmp Viral RNAMini kit or the QIAamp DSP Virus Kit (all Qiagen).

Qiagen

In an embodiment of the invention the DNA extraction step ischaracterized in that the DNA to be extracted binds to silica surfaces,in particular to silica membranes.

In an embodiment, the DNA extraction step is characterized by a bindingof DNA to silica surfaces, in particular to silica membranes.

It is particularly preferred that the DNA extraction step is carried outby means of the DNeasy 96 Tissue Kit, the QIAamp 96 DNA Blood Kit, theQIAamp DSP 96 Virus MDX Kit, the DNeasy Tissue Kit, the QIAamp DNA MiniKit, or the QIAamp DNA Micro Kit, the QIAamp Viral RNA Mini or theQIAamp DSP Virus Kit (all Qiagen).

In principle also other kits are useable according to the invention aslong as they lead to similar results. Those kits are for example kitswhich are based on the “charge-switch”-technology (Invitrogen) or the“nexttec”-technology (nexttec GmbH). These can be the Nexttec tissuekit, the ChargeSwitch® Forensic DNA Purification Kit, and the ChargeSwitch genomic DNA Purification kit.

In an embodiment one or more of the following kits are used in the DNAextraction step: DNeasy 96 Tissue Kit, QIAamp 96 DNA Blood Kit, QIAampDSP 96 Virus MDX Kit, DNeasy Tissue Kit, QIAamp DNA Mini Kit, QIAamp DNAMicro Kit, QIAamp Viral RNA Mini or the QIAamp DSP Virus Kit.

In embodiments of the invention the binding buffer AL is replaced by thebinding buffers ATL or AVL. A person with ordinary skills in the artknows how to adjust the method of the invention accordingly. The buffersATL and AVL can also be premixed like the buffer AL with ethanol asknown to those skill in the art. Therefore, in embodiments of theinvention, the binding buffer AL/E is replaced by the binding buffersATL/E or AVL/E. A person with ordinary skills in the art knows how toadjust the method of the invention accordingly.

In an especially preferred embodiment, the DNA extraction step iscarried out according to the DNeasy 96 Tissue Kit or the QIAamp 96 DNABlood Kit. Also the QIAamp DSP 96 Virus MDx Kit can be used if onlysmall amounts of DNA are expected. According to this embodiment, 100-600μl of the binding buffer AL/E, ATL/E or AVL/E (Qiagen) are added to themixture derived from the lysis step. The lysate is derived from 1-10deparaffinated formalin-fixed tissue sections of 10 μm thickness or anequal amount of a deparaffinated formalin-fixed tissue biopsy. Afteragitation, the mixture is applied onto a column of a plate of the DNeasy96 Tissue Kit, the QIAamp 96 DNA Blood Kit or the QIAamp DSP 96 VirusMDX Kit (all Qiagen). The column is washed with the buffers AW1 (Qiagen)and AW2 (Qiagen), before the DNA is eluted by 20-200 μl of elutionbuffer. The elution buffer can be AE, AVE or EB (all Qiagen) or water.Typically the elution buffer is adjusted to 15-80° C. After the additionof the preheated elution buffer, the column is incubated for at least 30s at 15-40° C., before it is centrifugated. The flow-through of thecolumn contains the DNA to be extracted. A person with ordinary skillsin the art knows how to adjust the volume of the solutions if thethickness of the section varies or if smaller or larger amount of sampleare used. In an embodiment, the DNA extraction step is carried outaccording to the DNeasy 96 Tissue Kit, the QIAamp 96 DNA Blood Kit orthe QIAamp DSP 96 Virus MDx Kit comprising

-   -   addition of 100-600 μl of binding buffer AL/E, ATL/E or AVL/E to        a lysate derived from 1-10 deparaffinated formalin-fixed tissue        sections or an equal amount of a deparaffinated formalin-fixed        tissue biopsy,    -   application of the mixture onto a plate,    -   washing with washing buffer AW1 and AW2, and    -   elution by addition of 20-200 μl elution buffer AE, AVE, EB or        water adjusted to 15-80° C., incubation for at least 30 s at        15-40° C., and centrifugation.

According to this embodiment it is particularly more preferred, that300-500 μl of binding buffer AL/E, ATL/E or AVL/E are added to 100-300μl of lysate derived from to 1-6 deparaffinated formalin-fixed tissuesections of 10 μm thickness or an equal amount of a deparaffinatedformalin-fixed tissue biopsy, preferably 400 μl of binding buffer AL/Eare added to 200 μl of lysate. The shaking is performed by shaking withboth hands for 10-30 s, preferably for 15 s. After application of themixture onto a column of a plate, the plate is centrifuged for 5-20 minat 4,000-6500×g, preferably for 10 min at 5,790×g. The washing with thebuffers AW1 and AW2, respectively, is carried out by application of300-700 μl, preferably of 500 μl of washing buffer followed by acentrifugation for 5-20 min at 4,000-6500×g, preferably for 10 min at5,790×g. After the washing steps the columns of a plate are dried bycentrifugation for 10-30 min at 4,000-6,500×g, preferably for 15 min at5,790×g. The DNA is eluted by addition of 90-150 μl, preferably of 120μl of elution buffer preheated to 50-75° C., preferably to 70° C.,followed by an incubation for 1-20 min at 17-30° C., preferably for 5min at room temperature, and a subsequent centrifugation for 1-10 min at4,000-6,500×g, preferably for 2 min at 5,790×g. The flow-through of thecolumn containing the DNA can be stored +4° C. to −80° C. A person withordinary skills in the art knows how to adjust the volume of thesolutions if the thickness of the section varies or if smaller or largeramount of sample are used.

In an embodiment, the DNA extraction step comprises

-   -   addition of 400 μl of binding buffer AL/E, ATL/E or AVL/E to 200        μl lysate derived from 1-6 deparaffinated formalin-fixed tissue        sections or an equal amount of a deparaffinated formalin-fixed        tissue biopsy    -   shaking for 15 s with both hands    -   application of the mixture onto a plate,    -   centrifugation for 10 min at 5790×g    -   application of 500 μl washing buffer AW1 and subsequent        centrifugation at 5,790×g for 5 min,    -   application of 500 μl washing puffer AW2 and subsequent        centrifugation at 5,790×g for 5 min,    -   drying of the column by centrifugation at 5,790×g for 15 min,        and    -   elution by addition of 120 μl elution buffer AE, AVE or EB or        water preheated to 70° C., incubation for 5 min at room        temperature and centrifugation for 2 min at 5,790×g.

In a further especially preferred embodiment, the DNA extraction step iscarried out according to the DNeasy Tissue Kit, the QIAamp DNA Mini Kitor the QIAamp DNA Micro Kit. Also the QIAamp Viral RNA Mini or theQIAamp DSP Virus Kit can be used if only small amounts of DNA areexpected. According to this embodiment, 150-300 μl of the binding bufferAL, ATL or AVL (Qiagen) are added to the lysate derived from to 1-6deparaffinated formalin-fixed tissue sections of 10 μm thickness or anequal amount of a deparaffinated formalin-fixed tissue biopsy. Themixture is incubated for at least 5 min at 45° C.-80° C. with agitation.Subsequently, 150-300 μl of ethanol are added, after which the sample isagitated, centrifuged and applied onto a column of the DNeasy TissueKit, the QIAamp DNA Mini Kit, the QIAamp DNA Micro Kit, the QIAamp ViralRNA Mini, or the QIAamp DSP Virus Kit. After centrifugation, the columnis washed with the washing buffers AW1 and AW2. To dry the column it isfavourable to centrifuge the column, but this is not necessary. The DNAis eluted from the column by applying in one or two elution steps up to180 μl of elution buffer onto the column. The elution buffer can be AE,AVE or EB (all Qiagen) or water adjusted to room temperature. Of courseother similar buffers are also suitable as long as do not interfere withthe subsequent steps. After addition of the elution buffer, the columnis incubated at room temperature, before it is centrifuged. Theflow-through of the column contains the DNA to be extracted. A personwith ordinary skills in the art knows how to adjust the volume of thesolutions if the thickness of the section varies or if smaller or largeramount of sample are used.

In a particular embodiment, the DNA extraction step is carried out bymeans of a Minelute™ column. These columns are for example part of theQIAamp DNA Micro Kit. Very surprisingly, DNA eluted in the first step ofthe elution of extracted DNA from these columns results in betterability of amplification. As already mentioned above, the use of aMinelute™ column improves the ability of amplification if a bisulfitetreatment step and subsequent DNA purification step is carried out ornot.

In an embodiment, the DNA extraction step is carried out according tothe DNeasy Tissue Kit, the QIAamp DNA Mini Kit, the QIAamp DNA MicroKit, the QIAamp Viral RNA Mini, or the QIAamp DSP Virus Kit comprising

-   -   addition of 150-300 μl of binding buffer AL, ATL or AVL to the        lysate derived from 1-6 deparaffinated formalin-fixed tissue        sections or an equal amount of a deparaffinated formalin-fixed        tissue biopsy,    -   incubation for at least 5 min at 45° C.-80° C. agitating the        sample,    -   addition of 150-300 μl of ethanol, subsequently agitating the        sample and centrifugation,    -   application of the mixture onto a column,    -   centrifugation,    -   washing with washing puffer AW1 and AW2,    -   optional, centrifugation, and    -   elution in one or two steps by addition of up to 180 μl elution        buffer AE, AVE or EB or water adjusted to room temperature,        incubation at room temperature and centrifugation.

According to this embodiment it is particularly more preferred, that175-250 μl of binding buffer AL are added to 175-250 μl of lysate,preferable 200-210 μl of binding buffer AL, ATL or AVL are added to 210μl of lysate derived from 1-6 deparaffinated formalin-fixed tissuesections of 10 μm thickness or an equal amount of a deparaffinatedformalin-fixed tissue biopsy. The mixture is incubated for 5-25 min at50° C.-75° C. with agitation, preferably for 10 min at 56° C.-70° C.with agitation. Subsequently, 175-250 μl, preferably 200-210 ml ofethanol are added, after which the sample is agitated by pulse-vortexingfor 15 s, and centrifuged for 1-20 s at 1,000-14,000×g, preferably for 5s at 5,000×g. The mixture is then added on a column of the DNeasy TissueKit, the QIAamp DNA Mini Kit, the QIAamp DNA Micro Kit, the QIAamp ViralRNA Mini, or the QIAamp DSP Virus Kit. Subsequently the columns arecentrifuged for 0.5-10 min at 4,000-8,000×g, preferably for 1 min at6,000×g. The washing with the buffers AW1 is carried out by applicationof 300-700 μl, preferably of 500 μl of AW1 followed by a centrifugationfor 0.5-10 min at 4,000-8,000×g, preferably for 1 min at 6,000×g.Subsequently, the washing with the buffers AW2 is carried out byapplication of 300-700 μl, preferably of 500 μl of AW2 followed by acentrifugation for 1-10 min at 15,000-25,000×g, preferably for 3 min at20,000×g. To dry the column it is favourable to centrifuge the columnfor 0.5-5 min at 15,000-25,000×g, preferably for 1 min at 20,000×g, butthis is not necessary. The DNA is eluted from the column by applying20-150 μl, preferably 35-120 μl of elution buffer onto the column. Theelution buffer can be AE, AVE or EB (all Qiagen) or water adjusted toroom temperature. After addition of the elution buffer, the column isincubated at room temperature for 0.5-15 min, preferably for 1-5 min.The column is then centrifuged for 0.5-10 min at 4,000-8,000×g,preferably for 1 min at 6,000×g. The flow-through of the column containsthe DNA to be extracted. Although it is not necessary, it is favourableto carry out a second elution step, wherein 20-801, preferably 35-60 μlof elution buffer are added onto the column. The elution buffer can beAE, AVE or EB (all Qiagen) or water adjusted to room temperature. Afteraddition of the elution buffer, the column is incubated at roomtemperature for 0.5-15 min, preferably for 1-5 min. The column is thencentrifuged for 0.5-10 min at 4,000-8,000×g, preferably for 1 min at6,000×g. The flow-through of the column is combined with theflow-through of the first elution step and can be stored at 0° C.-10°C., preferably at 4° C. for no more than 2 days. If a longer storage isintended, a the flow-through is stored at −20° C. to −80° C. A personwith ordinary skills in the art knows how to adjust the volume of thesolutions if the thickness of the section varies or if smaller or largeramount of sample are used.

In an embodiment, the DNA extraction step comprises

-   -   a) addition of 200-210 μl of binding buffer AL, ATL or AVL to        210 μl lysate derived from 1-6 deparaffinated formalin-fixed        tissue sections or an equal amount of a deparaffinated        formalin-fixed tissue biopsy,    -   b) incubation for 10 min at 56° C.-70° C. mixing the sample,    -   c) addition of 200-210 μl of ethanol, pulse-vortexing for 15 s        and centrifugation for 5 s at 5,000×g,    -   d) application of the mixture onto a column,    -   e) centrifugation for 1 min at 6,000×g    -   f) application of 500 μl washing puffer AW1 and subsequent        centrifugation at 6,000×g for 1 min    -   g) application of 500 μl washing buffer AW2 and subsequent        centrifugation at 20,000×g for 3 min,    -   h) optional, centrifugation at 20,000×g for 1 min using new        tubes, and    -   i) elution by a first addition of 35-120 μl elution buffer AE,        AVE or EB or water adjusted to room temperature, incubation for        1-5 min at room temperature and centrifugation for 1 min at        6,000×g, and an optional second addition of 35-60 μl elution        buffer AE, AVE or EB or water adjusted to room temperature,        incubation for 1-5 min at room temperature and centrifugation        for 1 min at 6,000×g.

An alternative to the last embodiment is a variant, wherein it isfavourable to dry the column after the washing step with buffer AW2 bybeating the column on a kleenex tissue on the bench with a subsequentcentrifugation for 0.5-10 min at 4,000-8,000×g, preferably for 1 min at6,000×g. After this the elution is carried out by applying 25-200 μl,preferably of 50-150 μl of elution buffer onto the column. The elutionbuffer can be AE, AVE or EB (all Qiagen) or water preheated to 30-50°C., preferably to 40° C. After addition of the elution buffer, thecolumn is incubated at room temperature for 0.5-15 min, preferably for1-5 min. The column is then centrifuged for 0.5-10 min at 4,000-8,000×g,preferably for 1 in at 6,000×g. The flow-through containing DNA is againapplied onto the same column. After the addition, the column isincubated at room temperature for 0.5-5 min, preferably for 1 min. Thecolumn is then centrifuged for 0.5-10 min at 4,000-8,000×g, preferablyfor 1 min at 6,000×g. This proceeding has the advantage that a higherrecovery of DNA can be eluted from the column not extending the elutionbuffer. A person with ordinary skills in the art knows how to adjust thevolume of the solutions if the thickness of the section varies or ifsmaller or larger amount of sample are used.

In a particular embodiment, steps h) and i) of the DNA extraction stepare replace by the following steps k) and l), respectively:

-   -   k) optional, beating the column on a kleenex tissue on the bench        with a subsequent centrifugation at 6,000×g for 1 min,    -   l) elution by addition of 50-150 μl of buffer AE or water        preheated to 40° C., incubation for 1-5 min at room temperature,        centrifugation at 6,000×g for 1 min, repeated application of        this first eluate onto the column, incubation for 1 min at room        temperature and centrifugation at 6,000×g for 1 min.        Bisulfite Treatment Step

In an embodiment the bisulfite treatment step is essentially carried outas described in WO05/038051 (this reference is incorporated by itsentirety). According to this, in one embodiment DNA is reacted with abisulfite reagent, characterized in that said reaction is carried out inthe presence of a compound out of the group of dioxane, one of itsderivatives and a similar aliphatic cyclic ether.

In another embodiment DNA is reacted with a bisulfite reagent,characterized in that said reaction is carried out in the presence of acompound of the following formula:

n=1-35000m=1-3R1=H, Me, Et, Pr, BuR2=H, Me, Et, Pr, Bu

Preferred are thus n-alkylene glycol compounds, particularly theirdialkyl ethers, and especially diethylene glycol dimethyl ether (DME).

The bisulfite conversion may take place both in solution as well as alsoon DNA bound to a solid phase. Preferably sodium disulfite (=sodiumbisulfite/sodium aetabisulfite) is used, since it is more soluble inwater than sodium sulfite. The disulfite salt disproportionates inaqueous solution to the hydrogen sulfite anions necessary for thecytosine conversion. When bisulfite concentration is discussed below,this refers to the concentration of hydrogen sulfite and sulfite anionsin the reaction solution. For the method according to the invention,concentration ranges of 0.1 to 6 mol/l are possible. Particularlypreferred is a concentration range of 1 to 6 mol/l, and mostparticularly preferred, 2-4 mol/l. However, when dioxane is used, themaximal concentration of bisulfite that can be used is smaller (seebelow). In selecting the bisulfite concentration, one must consider thata high concentration of bisulfite leads to a high conversion, but alsoleads to a high decomposition rate due to the lower pH.

Dioxane can be utilized in different concentrations. Preferably, thedioxane concentration amounts to 10 to 35% (vol/vol), particularlypreferred is 20 to 30%, and most particularly preferred is 22 to 28%,especially 25%. A dioxane concentration higher than 35% is problematic,since this results in a formation of two phases within the reactionsolution. In the particularly preferred embodiments with a dioxaneconcentration of 22-28%, the final preferred bisulfite concentrationamounts to 3.3 to 3.6 mol/l, and in the most particularly preferredembodiment with a dioxane concentration of 25%, it amounts to 3.5 mol/l(see Examples).

The n-alkylene glycol compounds according to the invention can beutilized in a different concentration range. DME is preferably used inconcentrations between 1-35% (vol/vol). There is preferably between 5and 25%, and most preferably 10% DME.

The preferred scavengers utilised according to the invention arechromane derivatives, e.g., 6-hydroxy-2,5,7,8,-tetramethylchromane2-carboxylic acid (also known as: Trolox-C™). Further scavengers arelisted in the patent application WO 01/98528 (=DE 100 29 915; =U.S.application Ser. No. 10/311,661; incorporated herein in its entirety).

The bisulfite conversion can be conducted in a wide temperature rangefrom 0 to 95° C. However, as at higher temperatures the rates of boththe conversion and decomposition of the DNA increase, in a preferredembodiment the reaction temperature lies between 0-80° C., preferablybetween 30-80° C. Particularly preferred is a range between 50-70° C.;most particularly preferred between 57-65° C. The optimal reaction timeof the bisulfite treatment depends on the reaction temperature. Thereaction time normally amounts to between 1 and 18 hours (see: Grunau etal. 2001, Nucleic Acids Res. 2001, 29(13):E65-5; incorporated byreference herein in its entirety). The reaction time is ordinarily 4-6hours for a reaction temperature of 60° C.

In a particularly preferred embodiment of the method according to theinvention, the bisulfite conversion is conducted at mild reactiontemperatures, wherein the reaction temperature is then clearly increasedfor a short time at least once during the course of the conversion. Inthis way, the effectiveness of the bisulfite conversion can besurprisingly clearly be increased. The temperature increases of shortduration are named “thermospikes” below. The “standard” reactiontemperature outside the thermospikes is denoted as the basic reactiontemperature. The basic reaction temperature amounts to between 0 and 80°C., preferably between 30-80° C., more preferably between 50-70° C.,most preferably between 57-65° C., as described above.

The reaction temperature during a thermospike is increased to over 85°C. by at least one thermospike. The optimal number of thermospikes is afunction of the basic reaction temperature. The higher the optimalnumber of thermospikes is, the lower is the basic reaction temperature.At least one thermospike is necessary in each case. And, on the otherhand, in principle, any number of thermospikes is conceivable. Ofcourse, it must be considered that with a large number of temperatureincreases, the decomposition rate of the DNA also increases, and anoptimal conversion is no longer assured. The preferred number ofthermospikes is thus between 1 and 10 thermospikes each time, dependingon the basic reaction temperature. A number of two to 5 thermospikes isthus particularly preferred. The thermospikes increase the reactiontemperature preferably to 85 to 100° C., particularly preferably to90-100° C., and most preferably to 94° C.-100° C.

The duration in time of the thermospikes also depends on the volume ofthe reaction batch. It must be assured that the temperature is increaseduniformly throughout the total reaction solution. For a 20 μl reactionbatch when using a thermocycler a duration between 15 seconds and 1.5minutes, especially a duration between 20 and 50 seconds is preferred.In a particular preferred embodiment the duration is 30 seconds.Operating on a volume of 100 μl the preferred range lies between 30seconds and 5 minutes, especially between 1 and 3 minutes. Particularlypreferred are 1.5-3 minutes. For a volume of 600 μl, a duration of 1 to6 minutes, is preferred, especially between 2 and 4 minutes.Particularly preferred is a duration of 3 minutes. A person skilled inthe art will easily be able to determine suitable durations ofthermospikes in relation to a variety of reaction volumes. Theabove-described use of thermospikes leads to a significantly betterconversion rates in the bisulfite conversion reaction, even when theabove-described denaturing solvents are not utilized.

In a preferred variant 10-60 μl of the solution containing the extractedgenomic DNA is mixed with 50-120 μl of bisulfite solution. The bisulfitesolution has a pH in the range of 4.7 to 6.5, preferably in the range of5.0 to 6.0, and particularly preferred in the range of 5.45 to 5.50. Thebisulfite solution comprises hydrogensulfite in a concentration of3.5-6.0, preferably in a concentration of 4.4-5.3, and particularlypreferred in a concentration of 4.83-4.93 mol/l. For Example, such kindof bisulfite solution can be obtained by adding 4.708 g of sodiumdisulfite and 1.128 g of sodium sulfite to 10 ml of water. Afterdissolving of the salts, the final volume is about 12 ml. To the mixtureof genomic DNA solution and the bisulfite solution 8-45 μl of an organicradical scavenger solution is added. The organic radical scavengersolution comprises an organic solvent and 50-1.000 mmol/l, preferably100-750 mmol/l, and particularly preferred 158-500 mmol/l of the radicalscavenger 6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid or anyother suitable radical scavenger. After the addition of the radicalscavenger solution, a temperature protocol is applied for 3-8 h. Theprotocol is characterized in that the reaction is conducted in atemperature range of 0-80° C. with additional 2-5 temperature increases(thermospikes) for 1-10 min to 85-100° C. including an initialtemperature increase (thermospike) to 85-100° C.

In an embodiment, the bisulfite treatment step comprises

-   -   mixing of 10-60 μl of the solution containing the genomic DNA        with 50-120 μl of bisulfite solution, the bisulfite solution        having a pH in the range of 5.45 to 5.50 comprising 4.83-4.93        mol/l hydrogensulfite,    -   addition of 8-45 μl of an organic radical scavenger solution,        the organic radical scavenger solution comprising an organic        solvent and 158-500 mmol/l        6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid, and    -   applying a temperature protocol for 3-8 h, characterized in that        the reaction is conducted in a temperature range of 0-80° C.        with additional 2-5 temperature increases for 1-10 min to 85 to        100° C. including an initial temperature increase to 85-100° C.

In a particularly preferred embodiment the bisulfite step is carried outas described in the following: 44-50 μl of a solution containing theextracted genomic DNA are mixed with 83-95 μl of a bisulfite solution.The bisulfite solution has a pH in the range of 5.45 to 5.50 andcomprises hydrogensulfite in a concentration of 4.83-4.93 mol/l. ForExample, such kind of bisulfite solution can be obtained by adding 4.708g of sodium disulfite and 1.128 g of sodium sulfite to 10 ml of water.After dissolving of the salts, the final volume is about 12 ml. Afterthe addition of the bisulfite solution 13-15 μl of a DME solution areadded, the DME solution comprising 250-1.000 mmol/l, preferably 350-750mmol/l, and particularly preferred 500 mmol/l6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid dissolved indiethyleneglycoldimethylether (DME). Thereafter a temperature protocolis applied for 4-7 h. The protocol is characterized in that the reactionis conducted in a temperature range of 57-65° C. with additional 2-5temperature increases (thermospikes) for 3-5 min to 94-100° C. includingan initial temperature increase (thermospike) to 94-100° C.

In an preferred embodiment, the bisulfite treatment step comprises

-   -   mixing of 44-50 μl of solution containing the genomic DNA with        83-95 μl of the bisulfite solution    -   addition of 13-15 μl of DME solution, the DME solution        comprising 500 mmol/l        6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid        dissolved in diethyleneglycoldimethylether, and    -   applying a temperature protocol for 4-7 h, characterized in that        the reaction is conducted in a temperature range of 57-65° C.        with additional 2-5 temperature increases for 3-5 min to        94-100° C. including an initial temperature increase to 94-100°        C.

In another particularly preferred embodiment 15-20 μl of solutioncontaining the isolated genomic DNA is mixed with 60-85 μl of abisulfite solution. The bisulfite solution has a pH in the range of 5.45to 5.50 and comprises hydrogensulfite in a concentration of 4.83-4.93mol/l. After the addition of the bisulfite solution 25-35 μl of dioxanesolution is added. The dioxane solution comprises 50-500 mmol/l,preferably 75-300 mmol/l, and particularly preferred 158 mmol/l6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid dissolved in1,4-dioxane. Thereafter a temperature protocol is applied for 4-7 h. Theprotocol is characterized in that the reaction is conducted in atemperature range of 57-65° C. with additional 2-5 temperature increases(thermospikes) for 3-5 min to 94-100° C. including an initialtemperature increase (thermospike) to 94-100° C.

In a preferred embodiment, the bisulfite treatment step comprises

-   -   mixing of 15-20 μl of solution containing the genomic DNA with        60-85 μl of the bisulfite solution,    -   addition of 25-35 μl of dioxane solution, the dioxane solution        comprising 158 mmol/l        6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid        dissolved in 1,4-dioxane,    -   applying a temperature protocol for 4-7 h, characterized in that        the reaction is conducted in a temperature range of 57-65° C.        with additional 2-5 temperature increases for 3-5 min to        94-100° C. including an initial temperature increase to 94-100°        C.        DNA Purification Step

After the bisulfite conversion is completed, the DNA is desulfonated andpurified. Different methods are known for this purpose (e.g., see: DE101 54 317 A1=U.S. Ser. No. 10/416,624; Grunau et al. 2001, loc. cit.).Normally, the reaction solution is first treated with sodium hydroxide.Subsequently a neutralization and alcohol precipitation of the DNA arecarried out.

In a preferred embodiment of the above-described embodiments accordingto the invention, the purification is performed by means of a gelfiltration, e.g., with Sephadex-G25 columns or with Sephadex-G50columns. The bisulfite salt can be removed very effectively in this way,without the need for further washing steps. In a second preferredembodiment, the purification is conducted via DNA-binding surfaces,e.g., via the Wizard DNA purification resin of Promega (see: Kawakami etal., Journal of the National Cancer Institute, Vol. 92, No. 22, 2000,pp. 1805-11). A third preferred embodiment utilizes magnetic particlesfor purification, e.g., with the help of the Magna-Pure process. Thesepurification methods lead to particularly good results in combinationwith the n-alkylene glycol compounds according to the invention,particularly with DME. The purification is conducted according to themanufacturer's instructions. It is known to the person skilled in theart that an even further increased yield may be attainable by variationof the manufacturer's instructions by using standard experiments.Correspondingly, optimized protocols are also part of this invention.Further technical instructions for purifying nucleic acids via gelfiltration, DNA-binding surfaces and magnetic particles are known to theperson skilled in the art and are provided, e.g., from themanufacturer's instructions.

In a most particularly preferred embodiment, purification is conductedby means of an ultrafiltration. Such a procedure has several technicaladvantages and results in a surprisingly successful purification of theconverted DNA. The recovery rate of the converted DNA which wasinitially derived from an archieved sample is very high (>25%).Ultrafiltration also has other advantages. For instance, purification isvery flexible with respect to the volume of the samples to be used. Inaddition, the bisulfite salts can be removed almost completely.Furthermore, a desulfonation can be performed on the filter membrane,which additionally results in a savings in time.

Different commercially available ultrafiltration systems are known tothe person skilled in the art, which may be used for the methodaccording to the invention. In a preferred embodiment, Microcon™ columnsof Millipore are used.

It is known to the person skilled in the art that other procedures maybe indicated with other ultrafiltration systems, and that a good yieldcan also be obtained by varying the above-indicated conditions. Thecorresponding embodiments are also part of this invention.

In addition bisulfite treated DNA can also be purified according to theinvention by means of the ability of DNA to bind to silica surfaces, inparticular to silica membranes. Because of their high reliability andreproducability and also to reduce the handling effort silica based kitsare preferred. For one with ordinary skills in the art a hugh amount ofkits are known which might be suitable for bisulfite treated DNApurification.

Therefore, in a first step the most promising kits were chosen. Thesekits are: QIAamp Viral RNA Mini, Zymo Spin IC columns in combinationwith buffer supplied with the QIAamp Viral RNA Mini kit, StrataPrep PCRpurification, AutoSeq G50, MicroSpin G25, ChargeSwitch® Forensic DNAPurification Kit, and Charge Switch genomic DNA Purification kit. In asecond step these kits were test according to the following criteria: i)a minimal handling effort; ii) a minimal length of time; iii) yield ofDNA; and iv) concentration of sulfite in the DNA solution afterpurification. As a reference, the purification by means of a Microcon™device (example 2d) was used. Comparably good results as by means of aMicrocon™ device were just obtained with the QIAamp Viral RNA Mini kit.

In addition, also kits are preferably used which contain the samesolutions and/or equivalent materials such as columns or buffers. Thesekits are the DNeasy 96 Tissue Kit, the QIAamp 96 DNA Blood Kit, theQIAamp DSP 96 Virus MDX Kit, the DNeasy Tissue Kit, the QIAamp DNA MiniKit, the QIAamp DNA Micro Kit, the QIAamp Viral RNA Mini or the QIAampDSP Virus Kit (all Qiagen). These kits are all based on binding of DNAto silica surfaces.

For purification after the bisulfite treatment, the manufacturer'sinstructions are each amended in preferred embodiments by addition of analkaline hydrolytic step. This alkaline hydrolytic step is carried outby incubation with an alkaline solution comprising a high content of analcohol.

According to the invention the alkaline solution comprises sodiumhydroxide or any other hydroxides with similar chemical properties likepotassium hydroxyde or any mixture of these as well as ethanol or anyother alcohol with similar chemical properties like isopropanol or anymixture of these. In particular, it is preferred that the alkalinesolution comprises sodium hydroxide and ethanol. It is especiallypreferred that the concentration of sodium hydroxide is in the range of0.1-0.3 mol/l, preferably 0.15-0.25 mol/l, and particularly preferred0.2 mol/l, while the content of ethanol is in the range of 60-95%,preferably 75-93%, and particularly preferred 90%. According to theinvention, the recovery rate of converted DNA is as good as the recoveryrate obtained with Microcon™ devices (>25%).

According to the invention also other kits may be used, for exampleother kits which are based on DNA binding to silica surfaces, inparticular to silica membranes. In principle also other kits are useableas long as they lead to similar results. Those kits are for example kitswhich are based on the “charge-switch”-technology (Invitrogen). Thesecan be the ChargeSwitch® Forensic DNA Purification Kit, and ChargeSwitch genomic DNA Purification kit.

According to the invention, the DNA purification step follows thebisulfite treatment step. In case the bisulfite treatment step is notcarried out, this purification step might be dispensible and thereforeit is not necessary according to the invention to carry out this step.

In a preferred embodiment of the invention the purification step iscarried out by means of the DNeasy 96 Tissue Kit, the QIAamp 96 DNABlood Kit, the DNeasy Tissue Kit, the QIAamp DNA Mini Kit, and theQIAamp DNA Micro Kit. Also the QIAamp DSP 96 Virus MDx Kit, QIAamp ViralRNA Mini or the QIAamp DSP Virus Kit can be used. These kits arefavourable in case only small amounts of DNA are expected. According tothe invention also devices and solutions of other kits can be used ifthey lead to similar results regarding the quality and quantity ofpurificated DNA. For example, this can be devices and solutions of kitswhich are based on the “charge-switch”-technology (invitrogen).According to this embodiment, the bisulfite treated sample is mixed with500-620 μl binding buffer, the binding buffer comprising 1-50 ng/μl,preferably 5-25 ng/μl, particularly preferred 10 ng/μl RNA or acomparable amount of any nucleic acid dissolved in the buffer AVL. Afterthis 500-620 μl of ethanol are added. The mixture is then incubated at0-37° C. for 5-20 min, before it is applied onto a column of a plate ofthe DNeasy 96 Tissue Kit, the QIAamp 96 DNA Blood Kit, or the QIAamp DSP96 Virus MDx Kit or onto a column of the DNeasy Tissue Kit, the QIAampDNA Mini Kit, the QIAamp DNA Micro Kit, the QIAamp Viral RNA Mini, theQIAamp DSP Virus Kit. In any case the DNA binds to a column. Thereafterthe column is washed with 300-1,000 μl washing buffer AW1. This isfollowed by an alkaline hydrolysis, wherein 450-550 μl of a solutioncontaining 0.2 mol/l sodium hydroxide and 90% ethanol is applied for10-25 min at 15-26° C. to the column and therewith to the DNA.Afterwards the column is washed with 300-1,000 μl of washing buffer AW2,before the DNA is eluted form the column by addition of 50-150 μl of oneof the elution buffers AE, AVE, EB oder water.

It is also possible to carry out the purification step with a bindingbuffer comprising not any RNA or any comparable amount of any nucleicacid. Corresponding embodiments are also part of the invention.

In an embodiment of the invention, the purification step is carried bymeans of the DNeasy 96 Tissue Kit, the QIAamp 96 DNA Blood Kit, theQIAamp DSP 96 Virus MDx Kit, the DNeasy Tissue Kit, the QIAamp DNA MiniKit, the QIAamp DNA Micro Kit, the QIAamp Viral RNA Mini, the QIAamp DSPVirus Kit, comprising

-   -   mixing of the bisulfite treated sample with 500-620 μl binding        buffer, optionally the binding buffer containing 10 ng/μl RNA        dissolved in the buffer AVL,    -   addition of 500-620 μl ethanol,    -   incubation at 0-37° C. for 5-20 min,    -   binding of the DNA onto a plate of the DNeasy 96 Tissue Kit, the        QIAamp 96 DNA Blood Kit, or the QIAamp DSP 96 Virus MDx Kit or        onto a column of the DNeasy Tissue Kit, the QIAamp DNA Mini Kit,        the QIAamp DNA Micro Kit, the QIAamp Viral RNA Mini, the QIAamp        DSP Virus Kit,    -   washing with 300-1,000 μl washing buffer AW1,    -   treatment with 450-550 μl of a solution containing 0.2 mol/l        sodium hydroxide and 90% ethanol for 10-25 min at 15-26° C.,    -   washing with 300-1,000 μl washing buffer AW2,    -   elution with 50-150 μl of one of the elution buffers AE, AVE, EB        oder water.

In a particularly preferred embodiment 100-200 μl of bisulfite treatedsample is mixed with 520-600 μl binding buffer AVL optionally comprising10 ng/μl RNA, preferably 140 μl of bisulfite treated sample is mixedwith 560 μl of binding buffer. After this 520-600 μl, preferably 560 μlof ethanol are added. The mixture is then centrifuged at 750-2000×g atleast for 1 s, preferably at 1.450×g for 1 s. After this it is incubatedat 15-25° C. for 7-15 min, preferably at room temperature for 10 min.Subsequently, it is added onto a column of a plate of the DNeasy 96Tissue Kit, the QIAamp 96 DNA Blood Kit, or the QIAamp DSP 96 Virus MDxKit or onto a column of the DNeasy Tissue Kit, the QIAamp DNA Mini Kit,the QIAamp DNA Micro Kit, the QIAamp Viral RNA Mini, or the QIAamp DSPVirus Kit. After centrifugation of the plate at 4,000-6,000×g for 1-10min, preferably at 5,790×g for 4 min, or of the column at >15,000×g for0.5-10 min, preferably for 20,000×g for 1 min, the DNA is bound to acolumn. Thereafter the column is washed with 300-750 μl, preferably with500 μl of washing buffer AW1. Subsequently the plate is centrifuged at4,000-6,500×g for 1-5 min, preferably at 5.790×g for 2 min and thecolumn is centrifuged at >15,000×g for 0.5-5 min, preferablyfor >20,000×g for 1 min, respectively. This is followed by an alkalinehydrolysis, wherein 470-530 μl, preferably 500 μl of a solutioncomprising 0.2 mol/l sodium hydroxide and 90% ethanol is added for 11-20min at 17-24° C., preferably for 15 min at room temperature to thecolumn and therewith to the DNA. This solution is withdrawn bycentrifugation of the plate at 4,000-6,500×g for 1-5 min, preferably at5.790×g for 2 min and of the column at >15,000×g for 0.5-5 min,preferably for >20,000×g for 1 min, respectively. Although it is notnecessary it can be favourable to repeat the washing step including thesubsequent centrifugation step with the washing buffer AW1 as it isdescribed above. However the column is washed by addition of 300-750 μl,preferably 500 μl of washing buffer AW2. This is followed by acentrifugation of the plate at 4,000-6,500×g for 5-30 min, preferably at5.790×g for 15 min and of the column at >15,000×g for 0.5-10 min,preferably for 20,000×g for 3 min, respectively. In addition, afterremoval of the flow-through the column is centrifuged at >15,000×g for0.5-5 min, preferably for 20,000×g for 1 min. The elution of the DNAfrom a column of a plate is carried out by addition of 75-170 μl,preferably 120 μl of elution buffer which can be AE, AVE or EB (allQiagen) or water each preheated to 60-80° C., preferably to 70° C. Theplate is incubated for 1-20 min at 15-30° C., preferably for 5 min atroom temperature, before it is centrifuged at 4,000-6,500×g for 0.5-20min, preferably at 5,790×g for 2 min. The elution of the DNA from acolumn of the DNeasy Tissue Kit, the QIAamp DNA Mini Kit, the QIAamp DNAMicro Kit, the QIAamp Viral RNA Mini, or the QIAamp DSP Virus Kit iscarried out as in the following: In a first application 25-150 μl,preferably 35-120 μl of elution buffer is added. The elution buffer canbe AE, AVE or EB (all Qiagen) or water each adjusted to 15-30° C.,preferably to room temperature. After incubation for 0.5-20 min at15-30° C., preferably for 1-5 min at room temperature, the column iscentrifuged for 0.5-5 min at 4,000-8,000×g, preferably for 1 min at6,000×g. Although it is not necessary, it might be favourably to carryout a second elution step. In doing so, 25-75 μl, preferably 35-60 μl ofthe above specified elution buffer is added. Again, the column isincubated for 0.5-20 min at 15-30° C., preferably for 1-5 min at roomtemperature, before it is centrifuged for 0.5-5 min at 4,000-8,000×g,preferably for 1 min at 6,000×g. The flow-through of the first andsecond elution step containing the DNA are combined.

In a preferred embodiment, the DNA purification step comprises

-   -   mixing of 140 μl of bisulfite treated sample with 560 μl binding        buffer,    -   addition of 560 μl ethanol,    -   centrifugation at 1.450×g for 1 s,    -   incubation at room temperature for 10 min,    -   application of the reaction mixture in one or two steps onto a        plate of the DNeasy 96 Tissue Kit, the QIAamp 96 DNA Blood Kit,        or the QIAamp DSP 96 Virus MDx Kit or onto a column of the        DNeasy Tissue Kit, the QIAamp DNA Mini Kit, the QIAamp DNA Micro        Kit, the QIAamp Viral RNA Mini, the QIAamp DSP Virus Kit,    -   centrifugation of the plate at 5.790×g for 4 min or of the        column at >20,000×g for 1 min,    -   application of 500 μl buffer AW1 and subsequent centrifugation        of the plate at 5.790×g for 2 min or of the column at >20,000×g        for 1 min,    -   application of 500 μl of a solution containing 0.2 mol/l sodium        hydroxide and 90% ethanol, incubation for 15 min at room        temperature and subsequent centrifugation of the plate at        5.790×g for 2 min or of the column at >20,000×g for 1 min,    -   optional, application of 500 μl buffer AW1 and subsequent        centrifugation of the plate at 5.790×g for 2 min or of the        column at >20,000×g for 1 min,    -   application of 500 μl of buffer AW2 and subsequent        centrifugation of the plate at 5.790×g for 15 min or of the        column at 20,000×g for 3 min,    -   centrifugation of the column at 20,000×g for 1 min,    -   elution of the DNA from the plate by application of 120 μl        elution buffer AE, AVE or EB or water preheated to 70° C.,        incubation for 5 min at room temperature and centrifugation for        2 min at 5,790×g or elution of the DNA from a column by a first        application of 35-120 μl elution buffer AE, AVE or EB or water        adjusted to room temperature, incubation for 1-5 min at room        temperature and centrifugation for 1 min at 6,000×g, and an        optional second application of 35-60 μl elution buffer AE, AVE        or EB or water adjusted to room temperature, incubation for 1-5        min at room temperature and centrifugation for 1 min at 6,000×g.

In a preferred embodiment the purification step is carried out by meansof a Microron™ filter device (Millipore). This is done essentially asdescribed in the manufacturer's instruction with an additional alkalinehydrolysis step and some modifications. The sample after the bisulfitetreatment is adjusted with water to a volume of 350-500 μl, before it isapplied to a Microron™ filter device which detains the DNA. Thereafter25-1,000 μl of a solution comprising 0.1-0.3 mol/l, preferably 0.15-0.25mol/l, and particularly preferred 0.2 mol/l sodium hydroxide areapplied, wherein it is favourable but not necessary to incubate thealkaline solution for 3-25 min at 15-26° C. The device is then washedwith 200-1,000 μl TE buffer. The TE buffer has a pH of 8.0 and comprises10 mmol/l Tris (tris-hydroxymethyl-amino-methan) and 0.1 mmol/l EDTA.The DNA is removed from the device by means of 30-100 μl of TE bufferpreheated to 40-65° C. The buffer on the device is incubated for 5-25min at 10-60° C. and will then contain the DNA.

In an embodiment, the purification step is carried out by means of aMicroron™ filter device, comprising

-   -   adjustment of the sample after the bisulfite reaction with water        to a volume of 350-500 μl,    -   application of the DNA onto a Microron™ filter device,    -   treatment with 25-1,000 μl of 0.2 mol/l sodium hydroxide,        optional incubation for 3-25 min at 15-26° C.,    -   washing with 200-1,000 μl TE buffer, the TE buffer pH 8.0        containing 10 mmol/l tris-hydroxymethyl-amino-methan and 0.1        mmol/l EDTA,    -   removal of the DNA by means of 30-100 μl TE buffer preheated to        40-65° C. incubated for 5-25 min at 10-60° C.

In a particularly preferred embodiment the sample after bisulfitereaction is adjusted with water to a volume of 370-450 μl, preferably of400 μl for purification. The mixture is then added to a Microron™ filterdevice. Subsequently the device is centrifuged at 10,000-18,000×g for5-30 min, preferably at 14,000×g for 15 min. Although it is notnecessary it is favourable to follow with 1-2 repetitions of a washingstep. For each washing step 400 μl TE buffer as described above areadded and subsequently the device is centrifuged at 10,000-18,000×g for5-30 min, preferably at 14,000×g for 12 min. Afterwards 50-700 μl,preferably 100-400 μl of 0.2 mol/l sodium hydroxide are added to thedevice. Although not necessary it is favourable to incubate the solutionof the device for 5-20 min at 15-30° C., preferably for 10 min at roomtemperature. Subsequently the device is centrifuged at 10,000-18,000×gfor 5-30 min, preferably at 14,000×g for 10-12 min. After this thedevice is washed for 1-4 times as described before. The DNA is recoveredby elution in one or two steps. Thereby 30-85 μl, preferably by 37.5-75μl of the TE buffer preheated to 45-60° C., preferably to 50° C. areadded. The buffer on the device is then incubated for 7-15 min at 12-55°C., preferably for 10 min at 15-50° C., before the device is invertedand centrifuged at 500-5,000×g at 0.5-20 min, preferably at 1,000×g for5 min. This embodiment is essentially carried out as it is described inWO05/038051 (this reference is incorporated by its entirety).

In a preferred embodiment, the purification step comprises

-   -   adjustment of the sample after the bisulfite reaction with water        to a volume of 400 μl,    -   application of the mixture onto a Microcron™ filter device and        subsequent centrifugation at 14,000×g for 15 min,    -   optional, 1-2 repetitions of the following washing step:    -   application of 400 μl TE buffer, the TE buffer pH 8 containing        10 mmol/l tris-hydroxymethyl-amino-methan and 0.1 mmol/l EDTA,        subsequent centrifugation at 14,000×g for 12 min,    -   application of 100-400 μl of 0.2 mol/l sodium hydroxide,        optional incubation for 10 min at room temperature, and        subsequent centrifugation at 14,000×g for 10-12 min    -   1-4 repetitions of the following: application of 400 μl water or        TE buffer and subsequent centrifugation at 14,000×g for 12 min    -   elution in one or two steps by application of 37.5-75 μl TE        buffer preheated to 50° C., incubation for 10 min at 15-50° C.,        and subsequent inversion of the Microron™ filter device and        centrifugation at 1,000×g for 5 min.        Amplification Step

In an embodiment of the invention the amplification step comprises adetection of positions which are methylated in the genomic DNA of thearchived sample. Alternatively, it also comprises a detection ofpositions which are unmethylated in the genomic DNA of the archivedsample. Of course, it is also possible to detect simultaneouslypositions which are methylated and to detect positions which areunmethylated in the genomic DNA of the archived sample by theamplification step.

It is especially preferred that the methylation pattern is analysed bymeans of bisulfite sequencing, the COBRA method, the Ms-SNuPE(Methylation-sensitive Single Nucleotide Primer Extension) method, theMSP (Methylation Specific PCR) method, including the nested MSP method,the HeavyMethyl™ method, the MethyLight™ method, or the QM assay. Ofcourse, if desired, it is also possible to combine two or more of thesemethods.

In an embodiment of the invention, the amplification step is carried outby one or more of the following methods and/or by a combination of oneor more of the following methods with each other: PCR, the bisulfitesequencing method, the COBRA method, the Ms-SNuPE (Methylation-sensitiveSingle Nucleotide Primer Extension) method, the MSP (MethylationSpecific PCR) method, the nested MSP method, the HeavyMethyl™ method,the MethyLight™ method, or the QM assay.

According to the invention, a better ability of amplification is givenif one or more of the following amendments are made in comparison tonormal conditions as a person with ordinary skills in the art wouldprobably choose them with respect to the methods specified above: i)increase in the concentration of the polymerase activity; ii) increasein the concentration of each nucleotide, whereby simultaneously theconcentration of magnesium chloride has also be adjusted as explainedbelow; and iii) elongation of the time for the elongation and annealingstep as explained below. This is the case for bisulfite treated DNAderived from archieved samples as well as for non-bisulfite treatedgenomic DNA derived from archieved samples.

In a preferred embodiment of the invention the amplification step iscarried out with use of a DNA polymerase and comprises one or more ofthe following: A) The DNA polymerase concentration is in the range of0.05-0.3 U/μl of the reaction mixture. B) The concentration of eachnucleotide is in the range of 200-800 μmol/l. Thereby the concentrationof magnesium chloride (MgCl₂) in the reaction mixture is adjusted to theconcentration of nucleotides as it is well known for those skilled inthe art. C) The time for elongating the template DNA is in the range of0.1-1.0 s/bp of the template DNA. This time usually comprises for a PCRthe elongation step as well as the annealling step if the case may be.If the annealling is performed at temperatures below 53° C., this timecorresponds only to the elongation step.

In an embodiment, the method of the invention includes a method foramplifying DNA derived from an archived sample, comprising one or moreof the following:

-   -   the polymerase concentration is in the range of 0.05-0.3 U/μl,    -   the concentration of each nucleotide is in the range of 200-800        μmol/l,    -   the time of the elongation step is in the range of 0.1-1.0 s/bp.

In a particularly preferred embodiment the amplification step comprisesone or more of the following: A) A polymerase concentration in the rangeof 0.08-0.25 U/μl, preferably the concentration is 0.15 U/μl in thereaction mixture. B) The concentration of each nucleotide is in therange of 350-650 μmol/l, preferably the concentration of each nucleotideis 400 μmol/l in the reaction mixture. As already explained before theconcentration of magnesium chloride (MgCl₂) in the reaction mixture isthereby adjusted to the concentration of the nucleotides as it is wellknown for those skilled in the art. C) The time for elongating thetemplate DNA is in the range of 0.25-0.75 s/bp of the template DNA,preferably it is 0.5 s/bp of the template DNA. As already described,this time usually comprises for a PCR the elongation step as well as theannealling step if the case may be. If the annealing is performed attemperatures below 53° C., this time corresponds only to the elongationstep.

In a preferred embodiment, the amplification step comprises one or moreof the following:

-   -   the polymerase concentration is 0.15 U/μl,    -   the concentration of each nucleotide is 400 μmol/l,    -   the time of the elongation step is 0.5 s/bp.

In a preferred embodiment of the invention, the amplification step iscarried out in order to amplify a defined fragment, a subfraction offragments or to amplify the whole genome. For this, one or more of themethods as they are known to those skilled in the art can be used. Forthis, the amplification step can be carried out by amplificationreactions which are non-PCR based methods for example by the NASBA/TMAtechnique. But more preferably, ligase mediated chain reaction (LCR),and in particular polymerase chain reaction (PCR) methods are used.

Preferably, such an amplification is used for an enrichment of the DNAof interest carrying the epigenomic information of the archieved sample.Thereafter any method for methylation analysis can be performed, inparticular the bisulfite sequencing method, the COBRA method, theMs-SNuPE (Methylation-sensitive Single Nucleotide Primer Extension)method, the MSP (Methylation Specific PCR) method, the nested MSPmethod, the HeavyMethyl™ method, the MethyLight™ method, or the QMassay.

Furthermore, it is also preferred that after an amplification of adefined fragment, a subfraction of fragments or the whole genome theamplified DNA is subject to additional analyses, for example for theanalysis of point mutations or SNPs.

In principle, according to the invention it is possible that theamplification reaction mixtures comprise more than two primers.Therefore the amplification will result in more than one amplicon. Incase the amplification is carried out by PCR, such a procedure is knownas multiplex PCR by those skilled in the art. Such a procedure is inparticular advantageous if only small amounts of DNA are available.Additional it has also the advantage of a reduction of costs, loweringthe handling effort, and shorting of the experiment, e.g. resultsearlier obtained.

Embodiments for Small Amounts of an Archived Sample as Starting Material

In an embodiment of the invention, small amounts of an archived sampleare used as starting material. Such small amounts can be any part of atissue of an archived sample. This tissue part is in the following sizerange: The area is between 0.025-50 mm², preferably between 0.05-10 mm²,and most preferably between 0.1-3 mm². Thereby the thickness of thetissue part is in the range of 5-20 μm, preferably in the range of 7-13μm, and most preferably the tissue part has a thickness of 10 μm. Ofcourse, tissue parts with other dimensions are also applicable. If thetissue part is of a different volume, a person with ordinary skills inthe art will know how to adjust the following embodiments for smallamounts of an archived sample as starting material.

Microdissection

In an preferred embodiment, cell of an archived sample aremicrodissected. Therefore a section of an archived sample in the rangeof 5-20 μm, preferably in the range of 7-13 μm, and most preferably of10 μm thickness is mounted on a slide as specified below. Themicrodissection can be done for example by means of a laser captureprocessing. But any other method known to those skilled in the art is aswell suitable.

Various methods for microdissection by means of a laser captureprocessing are known to those skilled in the art (for example Eltoum IA, Siegal G P and Frost A R. 2002. Microdissection of histologicsections: past, present, and future. Adv Anat Pathol. September;9(5):316-22). In a preferred embodiment, the laser capture method is theAutoPix™ LCM System (Arcturus, USA). In brief, a film is thermally fusedto the respective tissue area by means of a laser, whereby the tissuearea is dissected.

In another preferred embodiment, the laser mediated microdissection iscarried out by mounting the tissue section onto a membrane coated slidefor example onto MembraneSlides (P.A.L.M. Microlaser Technologies AG,Germany).

In further preferred embodiment, the tissue section is mounted onto aconventional microscopic slide. After this the tissue section issubjected to a staining before the desired areas are microdissected. Ofcourse, also similar procedures are also applicable as long as theyenable the identification of desired parts of the sample, in particularas long as they enable the identification of desired cell or group ofcells in the sample. Such a staining can be for example also ahematoxylin-eosin staining, a methylene blue staining, a hemalum-eosinstaining, an azan staining, a periodic acid-schiff staining, a prussianblue staining, a Masson-Goldner staining, a Ladewig staining, aelastica-van Gieson staining, a Gomori staining, a methyl greenstaining, a nuclear fast red staining, a Evans blue staining, alight-green SF yellowish staining, a Wright's staining, a May-Grunwaldstaining, a toluidine blue 0 staining, an azure B staining, a Giemsastaining or any other histological or histopathological staining. Butalso any immunohistological staining can be used, for example any kindof staining which is based on antibodies or on DNA or RNA hybridisation.These staining methods are well described and are well known to thoseskilled in the art. The corresponding embodiments are herewith enclosedin the method according to the invention. Of course, any staining can becompletely omitted if it is not desired or suitable for microdissection.

Microdissection is carried out by means of a Microbeam instrument(P.A.L.M. Microlaser Technologies AG, Bernried, Germany). But alsosimilar instruments which enable a dissection of single cells, of groupof cells or of tissue parts can be used according to the invention.These techniques are well known to those skilled in the art and aretherefore herewith included as preferred embodiments.

The dissected material is collected in tubes preferably with adhesivecaps for further processing. The adhesive caps can be any kind ofadhesive caps for example Adhesive Caps 200 (P.A.L.M. MicrolaserTechnologies AG, Bernried, Germany). Because of the microdissection noremoval of paraffin is necessary.

In another preferred embodiment, the dissected material is collected inthe cap of a normal tube which contains the below specified volume oflysis buffer.

Lysis Step

In an embodiment, the microdissected sample material is subjected to alysis step. Therefore 20 μl lysis buffer (50 mmol/l Tris-HCl, pH 8.0, 1mmol/l EDTA, 0.5 v/v % Tween, 10 ng/μl poly-dA, 3 mg/ml proteinase K)were carefully added to the cap. As already described above, other lysisbuffers as they are known to those skilled in the art are alsoapplicable. The tubes were closed carefully avoiding a loosening of thedrop from the cap. Subsequently the tubes were incubated for 1-48 h,preferably for 5-24 h, and most preferably for 12 h at 40-80° C.,preferably at 50-70° C., and most preferably at 60° C. This can be donefor example in a waterbath, thermomixer or PCR cycler. If a PCR cycleris used, preferably also the lid of the cycler is set to sametemperature as the cycler, because the sample material is located at thecaps.

After incubation the sample is centrifuged to transfer the lysed sampleto the bottom of the tube.

In an preferred embodiment, the amount of lysis buffer is adjusted tothe sizes of the dissected material. This is characterized in that atleast the dissected material is completely covered by the lysis buffer.After lysis of the material, the lysis buffer is concentrated to 20 μlby vacuum centrifugation, lyophilisation or any other suitable methodsas they are known to those skilled in the art.

Bisulfite Treatment

In an embodiment, the lysed sample is then directly subjected tobisulfite treatment because of the small amount of starting material andhence DNA. For bisulfite treatment, 9-70 μl, preferably 12-52 μl, andmorst preferably 38 μl bisulfite solution are added to the cap. Abisulfite solution is used as it is already described above.Subsequently the bisulfite solution at the cap is incubated for 0.5-15min, preferably for 2-10 min, and most preferably for 5 min at 0-80° C.,preferably at 10-40° C., in particular preferably at 15-30° C., and mostpreferably at room temperature. The addition and incubation of thebisulfte solution at the cap dissolves any remaining DNA in the cap.After the incubation, the sample is centrifuged.

In an preferred embodiment, the addition of bisulfite solution iscarried by two steps which resemble themselves. This has the advantagethat all DNA attached to the cap is subject for further processing. Inthe first step, 9-35 μl, preferably 12-26 μl, and morst preferably 19 μlbisulfite solution are added to the cap. A bisulfite solution is used asit is already described above. Subsequently the bisulfite solution atthe cap is incubated for 0.5-15 min, preferably for 2-10 min, and mostpreferably for 5 min at 0-80° C., preferably at 10-40° C., in particularpreferably at 15-30° C., and most preferably at room temperature. Theaddition and incubation of the bisulfte solution at the cap dissolvesany remaining DNA in the cap. After the incubation, the sample iscentrifuged, before again bisulfite solution is added in a second stepwhich is a repetition of the first step.

Thereafter, in an embodiment, 2-12 μl, preferably 4-8 μl, and mostpreferably 6 μl of DME solution as it is described above are added. Thebisulfite conversion is in the following conducted as described alreadyabove. The corresponding embodiments for small amounts of startingmaterial are herewith enclosed. In a particular embodiment the followingtemperature protocol is applied: 5 min 99° C., 22 min 60° C., 3 min 99°C., 97 min 60° C., 3 min 99° C. and 177 min 60° C. Therefore one or morewaterbath, thermomixer or PCR cycler are used.

DNA Purification

In an embodiment, the DNA after bisulfite treatment is purified.Therefore methods for purification of small amounts of DNA as they areknown to those skilled in the art can be used. In a preferred embodimentthe purification is carried out by means of Zymo-Spin IC columns (ZymoResearch, USA). Therefore, 75-250 μl, preferably 125-210 μl, and mostpreferably 166 μl of buffer AVL, AL or ATL (all Qiagen, Germany) wereadded to the Zymo-Spin IC columns. Thereafter the bisulfite reaction mixis added to the column. The used pipett tip can be placed in therespective bisulfite reaction tube for further use in order to avoid DNAloss due to drops sticking at the tip, but this is not strictlynecessary according to the invention. According to the invention also anew pipett tip may be used. In addition, 20-170, preferably 60-120 μl,and most preferably 90 μl of buffer AVL, AL or ATL are added to theempty bisulfite reaction tube and subsequently transferred to thecorresponding Zymo-Spin IC column. The bisulfite reaction mix and thetransferred buffer AVL, AL or ATL are mixed in the columns by pipettingup and down several times. Subsequently, the mixture is incubated in thecolumn for 1-30 min, preferably for 3-15 min, and most preferably for 10min at 0-60° C., preferably at 10-40° C., in particular preferably at15-30° C., and most preferably at room temperature. After thisincubation, 175-400 μl, preferably 225-275 μl, most preferably 250 μl ofethanol are added to the columns and mixed. Subsequently the column iscentrifuged for 0.5-10 min, preferably for 1-5 min, most preferably for1 min at 10,000-20,000×g, preferably for 14,000-18,000×g, and mostpreferably for 16,000×g. The column is then transferred to a new 2 mlcollection tube. After this, 250-750 μl, preferably 350-650 μl, and mostpreferably 500 μl of a buffer or solution comprising 0.2 mol/l NaOHand/or 90% v/v ethanol are added to the column. Also instead, suitablebuffers or solutions as they are already described above can be used. Inthe following the column is centrifuged for 0.5-10 min, preferably for1-5 min, most preferably for 1 min at 10,000-20,000×g, preferably for14,000-18,000×g, and most preferably for 16,000×g. The column is thentransferred to a new 2 ml collection tube. After this, 250-750 μl,preferably 350-650 μl, and most preferably 500 μl of buffer AW1 (Qiagen,Germany) are added to each column. Again, the column is centrifuged for0.5-10 min, preferably for 1-5 min, most preferably for 1 min at10,000-20,000×g, preferably for 14,000-18,000×g, and most preferably for16,000×g and transferred to a new 2 ml collection tube. Thereafter,250-750 μl, preferably 350-650 μl, and most preferably 500 μl of bufferAW2 (Qiagen, Germany) are added to each column. Again, the column iscentrifuged for 0.5-15 min, preferably for 1-8 min, most preferably for3 min at 10,000-20,000×g, preferably for 14,000-18,000×g, and mostpreferably for 16,000×g. Afterwards, the column is placed in acollection tube for DNA elution which is suitable for further analysis.The elution is carried out by one step. Therefore, the DNA is eluted bythe addition of 15-50 μl, preferably of 20-30 μl, and most preferably of25 μl of water or of buffer AE, AVE or EB (all Qiagen) prewarmed to30-70° C., preferably 40-60° C., and most preferably to 50° C.Thereafter the column is incubated for 0-10 min, preferably for 1-5 min,most preferably for 1 min, before it is centrifuged for 0.5-10 min,preferably for 1-5 min, most preferably for 1 min at 1,000-10,000×g,preferably for 4,000-8,000×g, and most preferably for 6,000×g.

In a preferred embodiment, the elution is carried out in two steps. In afirst step, the DNA is eluted by the addition of 7.5-25 μl, preferablyof 10-15 μl, and most preferably of 12.5 μl of water or of buffer AE,AVE or EB (all Qiagen) prewarmed to 30-70° C., preferably 40-60° C., andmost preferably to 50° C. Thereafter the column is incubated for 0-10min, preferably for 1-5 min, most preferably for 1 min, before it iscentrifuged for 0.5-10 min, preferably for 1-5 min, most preferably for1 min at 1,000-10,000×g, preferably for 4,000-8,000×g, and mostpreferably for 6,000×g. Afterwards the second elution step is carriedout as a repetition of the first elution step.

Subsequent Analysis

In an embodiment, DNA is quantificated directly after lysis or afterbisulfite treatment and subsequent purification by means of a real timeassay (see example 10).

In an embodiment of the invention the lysed sample is directly subjectto subsequent analysis without any bisulfite treatment or any DNApurification. This is in particular preferred if a bisulfite treatmentis not necessary for subsequent analysis. For example for the analysisof the methylation pattern by means of restriction enzymes. Examples forsuch methods are as already mentioned the DMH method or the restrictionassay also known as MestVal method (see above).

In an preferred embodiment, the DNA after bisulfite treatment andsubsequent purification is subject to subsequent analysis oramplification. In an particular embodiment it is preferred that thesubsequent analysis is an analysis of the methylation pattern of theoriginal DNA derived from the archived sample.

For the analysis or amplification of bisulfite treated and purified DNAderived from small amounts of an archived sample refer to the said aboveaccording to the amplification step. Corresponding embodiments areincluded herewith.

Test Kits

The subject of the present invention is also a kit, comprising one ormore of the following:

-   -   A container.    -   One or more organic solvents for removal of paraffin. This can        be a solvent which dissolves paraffin and is a solvent of the        group “limonene, xylene or any mixture of these solvents”. Of        course, the kit may comprise organic solvents like benzene,        ethylbenzene, toluene or solvents with similar chemical        properties or any mixture of these solvents. Furthermore the kit        may comprise one or more organic solvents which are suitable for        washing the sample after dissolving paraffin and which enable a        better rehydratisation of the sample. Such kind of solvent or        solvents is a solvent of the group of “ethanol, methanol,        isopropanol or any mixture of these solvents with each other or        with water”. Of course, the kit may also comprise solvents with        comparable chemical properties.    -   Protease in solution or as a powder. This protease can be a        serin protease, a thiol protease, a carboxy protease, a        metalloprotease, proteinase K or any mixture of these proteases.        In a preferred variant of the kit the protease is proteinase K        in from of a powder or dissolved in an appropriate solution.    -   One or more lysis buffer, the lysis buffer comprising 50 mmol/l        Tris (tris-hydroxymethyl-amino-methan) pH 8.0, 1 mmol/l EDTA,        0.5% Tween 20 v/v. Of course, the kit may also comprise any        other lysis buffer with similar properties. Such a buffer may        include detergents and/or chaotropic salts.    -   One or more solutions for DNA extraction. According to the        invention the kit may comprise one or more of the following        buffers: a) binding buffer AL/E (Qiagen); b) binding buffer AL        (Qiagen); c) binding buffer ATL (Qiagen); d) binding buffer AVL        (Qiagen); e) ethanol, preferentially at least 96% pure        ethanol; f) washing buffers AW1 (Qiagen); g) washing buffer AW2        (Qiagen); h) elution buffer AE (Qiagen); i) elution buffer AVE        (Qiagen); j) elution buffer EB (Qiagen); k) water    -   One or more devices for DNA extraction. According to the        invention the kit may comprise one or more of the following        plates or columns as they are part of the following kits: DNeasy        96 Tissue Kit, QIAamp 96 DNA Blood Kit, QIAamp DSP 96 Virus MDx        Kit, DNeasy Tissue Kit, QIAamp DNA Mini Kit, QIAamp DNA Micro        Kit, QIAamp Viral RNA Mini or QIAamp DSP Virus Kit (all Qiagen).        According to the invention also devices of other kits may        comprise to a kit of the invention. For example this can be        devices which are based on the “nexttec”-technology (nexttec) or        the “charge-switch”-technology (invitrogen). If the case may be,        the kit comprises also additional solutions suitable for        extracting DNA.    -   One or more solutions for bisulfite treatment. This can be any        solution as described in WO05/038051. Preferably the kit may        comprise:        A) A bisulfite solution with a pH in the range of 4.7 to 6.5,        preferably in the range of 5.0 to 6.0, and particularly        preferred in the range of 5.45 to 5.50. The bisulfite solution        comprises hydrogensulfite in a concentration of 3.5-6.0,        preferably in a concentration of 4.4-5.3, and particularly        preferred in a concentration of 4.83-4.93 mol/l. For example,        such kind of bisulfite solution can be obtained by adding 4.708        g of sodium disulfite and 1.128 g of sodium sulfite to 10 ml of        water. Of course, as known to those skilled in the art, a kit        may also comprise solutions with other concentrations. As the        case may be, appropriate volumes have then to be taken. After        dissolving of the salts, the final volume of the solution is        about 12 ml. Therefore the kit may comprise sodium disulfite        and/or sodium sulfite each alone or combined in form of salts or        dissolved in solution.        B) Additionally a kit may comprise water.        c) An organic radical scavenger solution comprising an organic        solvent and 50-1.000 mmol/l, preferably 100-750 mmol/l, and        particularly preferred 158-500 mmol/l of the radical scavenger        6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid or any        other suitable radical scavenger as described in WO01/98528 or        WO05/038051. For preferred variants of the kit, a kit may        comprise a DME solution comprising 250-1.000 mmol/l, preferably        350-750 mmol/l, and particularly preferred 500 mmol/l        6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid        dissolved in diethyleneglycoldimethylether (DME) or a dioxane        solution comprising 50-500 mmol/l, preferably 75-300 mmol/l, and        particularly preferred 158 mmol/l        6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid dissolved        in 1,4-dioxane.    -   One or more devices for bisulfite treatment. This can be any        device as described in WO01/98528 or WO05/038051.    -   One or more solutions for DNA purification. This can be in part        the same solutions as described above as for the DNA extraction.        According to the invention the kit may comprise one or more of        the following buffers:        A) Binding buffer AVL (Qiagen), the binding buffer AVL may        comprise 1-50 ng/μl, preferably 5-25 ng/μl, particularly        preferred 10 ng/μl RNA or a comparable amount of any nucleic        acid.        B) Ethanol, preferentially at least 96% pure ethanol.        C) Washing buffer AW1 (Qiagen).        D) Washing buffer AW2 (Qiagen).        E) One or more solutions suitable for an alkaline hydrolysis.        Preferably such kind of solution comprises 0.1-0.3 mol/l,        preferably 0.15-0.25 mol/l, and particularly preferred 0.2 mol/l        sodium hydroxide and 60-90%, preferably 75-90%, and particularly        preferred 90% ethanol. It is further preferably that such kind        of solutions comprise 0.1-0.3 mol/l, preferably 0.15-0.25 mol/l,        and particularly preferred 0.2 mol/l sodium hydroxide.        F) Elution buffer AE (Qiagen);        G) Elution buffer AVE (Qiagen);        H) Elution buffer EB (Qiagen);        I) Water.    -   One or more devices for DNA purification. According to the        invention this can be the same device as already described for        the extraction of DNA. It is preferable that the kit may        comprise one or more of the following plates or columns as they        are part of the following kits: DNeasy 96 Tissue Kit, QIAamp 96        DNA Blood Kit, QIAamp DSP 96 Virus MDx Kit, DNeasy Tissue Kit,        QIAamp DNA Mini Kit, QIAamp DNA Micro Kit, QIAamp Viral RNA Mini        or QIAamp DSP Virus Kit (all Qiagen). Also Zymo Spin columns I,        II and/or III may be comprised. According to the invention also        devices of other kits may comprise to a kit of the invention.        For example this can be devices which are based on the        “charge-switch”-technology (invitrogen). If the case may be, the        kit comprises also additional solutions suitable for extracting        DNA. According to the invention the kit may also comprise        columns or devices with are based on the Microcon™ technology.    -   solutions and/or substances for DNA amplification. According to        the invention this may be one or more of the following:        A) One or more primers, which are suitable for the amplification        of one or more DNA amplificates, amongst others the primer or        primers can be modified, for example with a label for detection        as well known by a person skilled in the art like the dye FAM,        Cy 3, Cy 5, biotin, digoxigenin,        B) One or more probes, which can be used to specifically record        the amplification of one or more amplificates for example in a        real-time-assay, amongst others the probe or probes can be        modified, for example with a quencher and/or a label for        detection as well known by a person skilled in the art like the        dye FAM or the quencher BHQ black hole or dabcyl,        C) One or more blockers, which are nucleic acids and can be used        to block the binding of a specific primer or the replication by        DNA polymerase, amongst others the blocker or blockers can be        modified, for example with 3′phosphate as well known by a person        skilled in the art,        D) One or more reaction buffers, which are suitable for a PCR        reaction,        E) Nucleotides, which can be DATP, dCTP, dTTP, dUTP and dGTP or        any derivative of these nucleotides,        F) MgCl₂ as a substance or in solution and/or any other        magnesium salt, which can be used to carry out a DNA polymerase        replication,        G) DNA polymerase, for example Taq DNA polymerase or any other        polymerase with or without proof-reading activity,        H) Dye or quencher, which can be used for the detection of the        amplificates as known in the art, for example an intercalating        dye like SYBR Green or a dye for linkage to a primer or probe or        blocker like the dye FAM or the quencher BHQ black hole or        dabcyl,    -   a manual and/or description to carry out the method of the        invention or only to carry an embodiment of the method according        to the invention, and/or    -   any reagent, solution, device and/or instruction which is useful        for realisation of an assay according to the invention.

Subject of the invention is a test kit for carrying out a methodaccording to one or more of the embodiments of the inventions,comprising

-   -   a container    -   organic solvents for removal of paraffin,    -   proteinase K and/or buffer for lysis,    -   solutions and/or devices for DNA extraction,    -   solutions and/or devices for bisulfite treatment,    -   solutions and/or devices for DNA purification,    -   solutions and/or substances for DNA amplification    -   a manual and/or description for carrying out the method of the        invention.        Use of the Methods and Test Kits

The methods and test kits disclosed herein are preferably used for thedetection of the DNA methylation status of a sample taken from a tissueof a diseased or healthy person or of a person who's status of health isnot determined so far regarding a defined disease. In a particularlypreferred manner the so determined DNA methylation statuses are thencompared with each other and/or with a reference DNA methylation status.

Therefore the invention also comprises the use of the method accordingto one or more of the embodiments or of a test kit according to theinvention for the detection of the DNA methylation status.

In case the status of health of a person from whom the sample is derivedis not or only insufficiently determined so far, the results of the DNAmethylation status analysis can be used to determine the status ofhealth of said person regarding a specific disease or anypredispositions for a specific disease. Therefore it is particularlypreferred that the DNA methylation status is used for diagnosing adisease or for diagnosing a predisposition for a disease. Furthermore,it is also particularly preferred that the DNA methylation status isused for diagnosing a progression of a disease, if the status of healthof a person regarding said specific disease has been already beendetermined.

According to the invention, the use of the methods and kits describedherein are especially preferred if the disease is a cancer disease.

The use of methods and kits described herein is in particular preferred,if the use is characterized in that the DNA methylation states is usedfor diagnosing a disease, for diagnosing a predisposition for a diseaseand/or for diagnosing a progression of a disease, wherein in particularthe disease is a cancer disease.

The use of methods and kits described herein is in particular preferred,if it is characterized in that it is predicted if the health status of aperson will be positively or negatively be influenced by a drug orchemical substance or not. This is particularly preferred if the use ofthe methods and kits described herein is characterized in that the DNAmethylation status is used for predicting if the health status of aperson will be positively or negatively influenced by a drug or chemicalsubstance or not. The use is especially preferred if the health statusis characterised by a disease, a predisposition for a disease and/or bya progression of a disease. This is most especially preferred if thedisease is a cancer disease.

The use of the methods and kits described herein is especially preferredif the DNA methylation status is characterized in that positions aremethylated or non-methylated compared to normal conditions and if asingle defined disease or a predisposition for a single defined diseaseexists. Of course, the use of the methods and kits described herein isalso preferred if the DNA methylation status may also be characterizedin that positions are methylated or non-methylated compared to variouslevels of diseased conditions and if a gradually progressive diseaseexists.

The use of methods and kits described herein is especially preferred, ifthe DNA methylation status is characterized in that positions aremethylated or non-methylated compared to normal conditions if a singledefined disease exists.

If status of health of a person from whom the sample is derived isindependently determined from the DNA methylation status, the results ofthe DNA methylation status analysis can be used to identify a diseasespecific DNA methylation status. Such disease specific DNA methylationstatus may include one or more sites of a potential DNA methylationand/or the knowledge of the presence or absence of a methylation at CGdinucleotides, in case of the presence or absence of a particulardisease. Therefore it is particularly preferred to use any method or kitdescribed herein for the identification of an indication-specifictarget. According to this, a) DNA of an archived sample originating froma diseased tissue is prepared and the DNA methylation status isdetermined; b) DNA of a sample originating from a healthy tissue isprepared and the DNA methylation status is determined; c) aindication-specific target is defined as differences in the DNAmethylation status of a DNA derived from a diseased tissue in comparisonto a DNA derived from a healthy tissue. Thereby the sample of thediseased tissue and the sample of the healthy tissue can originate fromdifferent persons. Preferably these persons are relatives. It isparticularly preferred that the sample of the diseased tissue and thesample of the healthy tissue originate from the same person, and it isespecially preferred that the samples originate from adjacent tissues.

Of course, in the same manner also indication-specific targets can beidentified which are specific for a predisposition for a disease orwhich are specific for a progression of a disease.

The use according to one or more of the embodiments or of a test kitaccording to the invention is preferred for identifying anindication-specific target, wherein

-   -   a) DNA of an archived sample originating from a diseased tissue        is prepared and the DNA methylation status is determined,    -   b) DNA of sample originating from a healthy tissue is prepared        and the DNA methylation status is determined,    -   c) a indication-specific target is defined as differences in the        DNA methylation status of a DNA derived from a diseased tissue        in comparison to a DNA derived from a healthy tissue.

The use of the methods or kits described herein is preferred if theindication-specific target is a protein, peptide or RNA or any otherendogenous bioactive substance as for example hormones.

In particular, the use is preferred if the indication-specific target isa protein, peptide or RNA.

The said use is preferred if a per se known modulator of the protein,peptide, RNA or other endogenous bioactive substance is assigned to thespecific indication of the diseased tissue.

In particular, a use is preferred wherein a per se known modulator ofthe protein, peptide or RNA is assigned to the specific indication ofthe diseased tissue.

Furthermore, the use of such a modulator is particularly preferred forpreparing a pharmaceutical composition in case of a specific indication.This is especially preferred if the specific indication is a specificcancer indication.

In particular, the use of the modulator assigned to the specificindication of the diseased tissue is preferred for preparing apharmaceutical composition with a specific indication, in particular aspecific cancer indication.

The methods and test kits disclosed herein are preferable used for thediagnosis and/or prognosis of adverse events for patients orindividuals, whereby diagnosis means diagnose of a adverse event, apredisposition for a adverse event and/or a progression of a adverseevents. These adverse events belong to at least one of the followingcategories: undesired drug interactions; cancer diseases; CNSmalfunctions, damage or disease; symptoms of aggression or behavioraldisturbances; clinical, psychological and social consequences of braindamage; psychotic disturbances and personality disorders; dementiaand/or associated syndromes; cardiovascular disease, malfunction ordamage; malfunction, damage or disease of the gastrointestinal tract;malfunction, damage or disease of the respiratory system; lesion,inflammation, infection, immunity and/or convalescence; malfunction,damage or disease of the body as an abnormality in the developmentprocess; malfunction, damage or disease of the skin, of the muscles, ofthe connective tissue or of the bones; endocrine and metabolicmalfunction, damage or disease; headaches or sexual malfunction.

The methods and test kits disclosed herein are also preferable used fordistinguishing cell types, tissues or for investigating celldifferentiation. These serve in a particularly preferred manner foranalysing the response of a patient to a drug treatment.

Methods for DNA Methylation Analysis

The following methods for the detection of the DNA methylation are allpreferred embodiments of the invention. These methods allow fordetermination of the methylation state of one or a plurality of CpGdinucleotides (e.g., CpG islands) within a DNA sequence. Such methodsinvolve, among other techniques, the DMH method, DNA sequencing ofbisulfite-treated DNA, a number of PCR based methylation assays, some ofthem—known as COBRA, MS-SNuPE, MSP, nested MSP, HeavyMethyl™,MethyLight™ and QM assay

-   -   are described in more detail now:

DMH METHOD. The DMH method is carried out according to the invention asit is described in principle in Huang et al. (Huang et al., Hum MolGenet, 8:459-470, 1999), in U.S. Ser. No. 09/497,855, in DE102005007185.6, in DE102005025 240.0, in DE102005036500.0, or in U.S.60/710,556 (all incorporated by its entirety). According to these,genomic DNA is fragmented by restriction endonucleases before it issubject to a DNA microarray of cloned CpG islands.

But the DMH method may also include several improvements: Afterisolation of the DNA, an enrichment of methylated or unmethylated DNAtakes place by different means. This means can be one or more of thefollowing: for example restriction endonucleases or proteins, peptidesor oligomers which specially bind to CpG dinucleotide either specific onmethylated or on non-methylated CpG dinucleotides. Four variants ofenrichment by means of restriction endonucleases are especiallypreferred:

The enrichment by use of only methylation specific restriction enzymeswithout a previous addition of non-methylation specific restrictionenzymes but with a subsequent selective amplification of fragments inthe range of 50-5.000 bp via linker (also known as adapters by thoseskilled in the art). Preferred restriction enzymes are of the group“BisI, BstUI, BshI236I, AccII, BstFNI, McrBC, MvnI, HpaII (HapII), HhaI,AciI, SmaI, HinP1I, HpyCH4IV and mixtures of two or more of theaforesaid enzymes”.

Another enrichment is performed by at first, the restriction of DNA byone or more non-methylation specific restriction enzymes; secondly,fragments smaller than 50 bp are discarded and subsequently linker areligated on each end of every fragment; thirdly, the fragments providedwith linker are subject to a restriction by one or more methylationspecific restriction enzymes; and fourthly, the resulted fragments aresubjected to an amplification, wherein only fragments are amplifiedwhich are not restricted in step three. According to this procedurefragments of 50-5.000 bp are enriched. It is thereby preferably thatthree different methylation specific restriction enzymes are used, oneor more of the methylation specific restriction enzymes have arestriction site in the length of 4 bp, in particular which do notcontain any CG. The non-methylation specific restriction enzymes areselected from the group “MseI, BfaI, Csp6I, Tru1I, Tvu1I, Tru9I, Tvu9I,MaeI, XspI and mixtures of two or more of the aforesaid enzymes”.Preferably a mixture of MseI, BfaI and Csp6I is used. The methylationspecific restriction enzymes can be any enzyme which either cutsmethylation specifically unmethylated or methylated DNA. Preferably themethylation specific enzyme is selected from the group of “BisI, BstUI,BshI236I, AccII, BstFNI, McrBC, MvnI, HpaII (HapII), HhaI, AciI, SmaI,HinP1I, HpyCH4IV, EagI and mixtures of two or more of the aforesaidenzymes”. In particular the use of BstUI, HpaII, HpyCH4IV and HinP1I ispreferred.

Besides that, an enrichment is also possible according to the method of“NotI representation” as exemplified in WO02/086163. According to this,DNA is restricted by suitable enzymes like BamHI of BglII. Afterinactivation of the enzymes, the fragments are circularized by selfligation, before they are subject to another restriction by NotI whichonly cut its unmethylated recognition side. Through this, fragments withonly unmethylated NotI recognition sites are linearised onto whichspecific linker are ligated. Therefore it is possible to amplify thosefragments. In principle this method can also be adjusted to othermethylation specific restriction enzymes as listed above.

As the fourth procedure of enrichment by the means of restrictionendonucleases, the MS AP-PCR (Methylation Sensitive Arbitrarily-PrimedPolymerase Chain Reaction) is preferred. This technique is well known inthe art and was described the first time by Gonzalgo et al., CancerRes., 57:594-599, 1997. In principle, genomic DNA is subject to anrestriction digestion, for example HpaII. The resulting fragments arethen subject to an amplification wherein random primers are used whichare rich in CG dinucleotides. According to this, DNA regions areamplified which are rich in CG dinucleotides.

An enrichment of methylated or non-methylated DNA can also occur bymeans of proteins, peptides or oligomers which specifically bind tomethylated or non-methylated DNA. The binding can be sequence specificor unspecific. However, unbound DNA is separated by bound DNA throughthe binding. Depending on which kind of DNA is of interest, methylatedor non-methylated DNA, or which kind of DNA is bound, the bound orunbound DNA fraction is further analysed. These means proteins may beused which specifically bind unmethylated DNA, as well as proteins whichspecifically bind methylated DNA. Furthermore, it is possible to bindthat DNA, which is later analysed. Therefore the unbound DNA is removedbefore the bound DNA is released from the protein. On the other hand itis also possible to let bind the background DNA to the proteins andthereby it is removed from the reaction mixture. Of course, it is alsopossible to carry out such an enrichment in two subsequent steps wherebythe order is not relevant. In one step, proteins which specifically bindunmethylated DNA and in the other step, proteins which specifically bindmethylated DNA are used. Such a proceeding has the advantage thatsimultaneously unmethylated DNA and methylated DNA are enriched whileDNA with no or only a view CpG positions is removed.

An enrichment can be achieved by proteins which methylation specificallybind to DNA and also by the use of their domains or peptides. Suchproteins can be for example MeCP2, MBD1, MBD2, MBD4 and Kaiso. The laterbinds sequence specifically namely on symmetrical methylated CpGpCpGpositions. Exemplary the Methyl-CpG-binding domain of MeCP2 protein orthe CXXC-3 domain of the MBD1 protein is mentioned as suitable domainsfor enrichment (for an overview: Shiraishi et al., Anal Biochem. 2004Jun. 1; 329 (1):1-10; Hendrich and Tweedie, Trends Genet. 2003 May, 19(5): 269-77; Jørgensen et al., Molecular and Cellular Biology, 2004,3387-3395; all incorporated by its entirety).

Typically, the proteins, domains or peptides are bound to a solidsurface for example on beads which enable a separation of by means of abatch procedure or by a column chromatography (Cross et al., NatureGenetics, 1994 (6) 236-244; Shiraishi et al., Anal Biochem. 2004 Jun. 1;329 (1):1-10). Biochemical Methods which have to be applied are known tothose skilled in the art. This may for example include the use of biotinor histidine tags (for example Gretch et al., Anal Biochem., 1987, (163)270-7; Janknecht et al., Prc Nat. Acad Sci, 1991, (88) 8972-6).

Moreover, an enrichment can also be achieved by methylation specificantibodies for example by means of the anti 5-methylcytosine antibodyavailable from Abcam Inc. Again the enrichment can be performed in abatch procedure or by column chromatography. Details are known topersons skilled in the art (for example: Fisher et al., Nucleic AcidsRes. 2004, 32(1), 287-97). On the hand, an enrichment can also beachieved by immunoprecipitation with methylation specific antibodies andsuitable secondary antibodies, followed by a proteinase K treatment.

Another variant of enrichment is the chromatin immunoprecipitation(ChIP). Details are known to those skilled in the art (for example:Matarazzo et al., Biotechniques, 2004, 37(4), 666-8, 670, 672-3.)According to this, a immunoprecipitation is carried out with antibodieswhich are specific for 5-methylcytosine binding proteins like MeCP2,MBD1, MBD2, MBD4 or Kaiso. Thereby the proteins are fixed onto the DNAbefore the antibodies are added. In particular it is preferred to purifythe DNA first and then add the DNA binding proteins. It is alsoparticularly preferred to apply a suitable physical method likeultracentrifugation before the second precipitation step. A suitable kitis available from Panomics, Inc.

Furthermore, an enrichment can be achieved by triplex binding oligomers,which can PNA- or DNA-Oligomers. This method is described in detail inWO04/113564. In principle, a triplex-binding oligomer is brought incontact with DNA. Thereafter it preferentially forms a triple helix withunmethylated DNA in comparison to methylated DNA. From this advantage istaken for enrichment.

In principle, a DNA may be fragmentated randomly or non-randomly beforeit is subject to enrichment by any method using proteins, peptides oroligomers. This is done as it is known by those skilled in the art.Fragmentation can be performed randomly for example with sonification orshearing. But is also can be performed non-randomly, preferentially bythe use of methylation specific restriction endonucleases, in particularof the group of “BisI, BstUI, BshI236I, AccII, BstFNI, McrBC, MvnI,HpaII (HapII), HhaI, AciI, SmaI, HinP1I, HpyCH4IV and any mixture of twoor more of the aforesaid enzymes”.

A further reduction of complexity can be achieved by physical methodswhich are applied before or after an amplification. Such physicalmethods can for example be gel electrophoresis, size-exclusionchromatography or filtration.

After enrichment of the DNA, the fragments are labelled preferentiallywith a suitable fluorescent dye. Such a dye enables selective one or twodimensional scanning. Typically Cy3 and/or Cy5 are used as dyes. Butalso other suitable dyes are known to those skilled in the art.Furthermore, it is preferred that the fragments are labelled withbiotin, which interacts with another substance in the actually detectionprocess. Thereby it is necessary to carry out two arrays which arecompared with each other.

The labelling is carried out preferentially by means of anamplification, in particular whole genome amplifications. Severalsuitable methods are known by those skilled in the art.

The labelled fragments are then subject to a DNA microarray which can beeither a array of cloned CpG islands or array of oligonucleotides. Theoligonucleotides of the oligonucleotide microarray can be anyoligonucleotide suitable for the detection of methylation ornon-methylation of CpG dinucleotides. Preferably the oligonucleotidesare design after fragments derived according to the following twostrategies:

According to the first strategy, A) the genome of an organism of desireis analysed for first fragments, which are flanked by recognition sitesof non-methylation specific restriction enzymes of interest and whichare in the range of 100-1.200 bp. B) Second fragments are then selectedunder those first fragments which have no more than 50%, preferably nomore than 20% of repeats. These two steps A) and B) can be performed inarbitrary order. Additionally, C) the second selected fragments areanalysed for the presence of recognition sites of methylation specificrestriction endonucleases of interest. Those second fragments whichinclude such a recognition site are then selected as third fragments.Again, the steps A), B) and C) can be performed in arbitrary order.

According to the second strategy, A) the genome of an organism of desireis analysed for first fragments, which are flanked by recognition sitesof methylation specific restriction enzymes of interest and which are inthe range of 100-1.200 bp. B) Second fragments are then selected underthose first fragments which have no more than 50%, preferably no morethan 20% of repeats C) The second selected fragments are analysed forthe presence of recognition sites of methylation specific restrictionendonucleases of interest. Those second fragments which include such arecognition site are then selected as third fragments. Again, the stepsA), B) and C) can be performed in arbitrary order.

Fragments selected according to these strategies can match fragmentsobtained by the enrichment procedures. The sequence of theoligonucleotides of the array is chosen from the selected fragments, sothat they would hybridise to the selected fragments or so that they areidentical to them and therefore would hybridise to the counter strand.These oligonucleotides are then synthesised on the array or are linkedto it after the synthesis. Typically 3-30 oligonucleotides are derivedfrom one fragment, whereby it is possible that the oligonucleotidesequences are overlapping. Preferably the oligonucleotides have adefined distance between each other so that a so called “tiling array”results, similar as described by Kapranov et al., Science, 2002,296(5569):916-9.

According to the DMH method, fragments hybridized on the immobilizedoligonucleotides contain preferably nucleic acid sequences, whichmethylation positions are non-methylated or methylated in case of adefinite disease in comparison to the normal condition. Theoligonucleotides do not have to necessarily encode for the methylationpositions by themselves, although it is possible. Moreover, it ispossible that a oligonucleotide array carries different sets ofoligonucleotides, suitable for the detection of different diseases or ofpredispositions for a disease or of the susceptibility for side effectsfor a definitive medical treatment. Additionally, it is also possible topredict the type, the aggressiveness or the progression of a disease orfor the effectiveness of a medical treatment, in case it is based onmethylation differences. Further conclusions can be made by comparisonof the results obtained by means of an oligonucleotide array accordingto the DMH method with a results obtained with arrays with differentoligonucleotide set, for example oligonucleotide sets suitable for SNPanalysis.

BISULFITE SEQUENCING. DNA methylation patterns and 5-methylcytosinedistribution can be analyzed by sequencing analysis of a previouslyamplified fragment of the bisulfite treated genomic DNA, as described byFrommer et al. (Frommer et al. Proc. Natl. Acad. Sci. USA 89:1827-1831,1992). As the bisulfite treated DNA is amplified before sequencing, theamplification procedure according to the invention may be used incombination with this detection method.

COBRA. COBRA analysis is a quantitative methylation assay useful fordetermining DNA methylation levels at specific gene loci in smallamounts of genomic DNA (Xiong & Laird, Nucleic Acids Res. 25:2532-2534,1997). Briefly, restriction enzyme digestion is used to revealmethylation-dependent sequence differences in PCR products of sodiumbisulfite-treated DNA. Methylation-dependent sequence differences arefirst introduced into the genomic DNA by standard bisulfite treatmentaccording to the procedure described by Frommer et al. (Proc. Natl.Acad. Sci. USA 89:1827-1831, 1992) or as described by Olek et al (OlekA, Oswald J, Walter J. (1996) Nucleic Acids Res. 24: 5064-6). PCRamplification of the bisulfite converted DNA is then performed usingmethylation unspecific primers followed by restriction endonucleasedigestion, gel electrophoresis, and detection using specific, labeledhybridization probes. Methylation levels in the original DNA sample arerepresented by the relative amounts of digested and undigested PCRproduct in a linearly quantitative fashion across a wide spectrum of DNAmethylation levels. In addition, this technique can be reliably appliedto DNA obtained from microdissected paraffin-embedded tissue samples.Typical reagents (e.g., as might be found in a typical COBRA-based kit)for COBRA analysis may include, but are not limited to: PCR primers forspecific gene (or methylation-altered DNA sequence or CpG island);restriction enzyme and appropriate buffer; gene-hybridization oligo;control hybridization oligo; kinase labeling kit for oligo probe; andradioactive nucleotides. Additionally, bisulfite conversion reagents mayinclude: DNA denaturation buffer; sulfonation buffer; DNA recoveryreagents or kits (e.g., precipitation, ultrafiltration, affinitycolumn); desulfonation buffer; and DNA recovery components.

Additionally, restriction enzyme digestion of PCR products amplifiedfrom bisulfite-converted DNA is also used, in the method described bySadri & Hornsby (Nucl. Acids Res. 24:5058-5059, 1996)

The bisulfite conversion and amplification procedure according to theinvention may be used in combination with this detection method.

Ms-SNuPE (Methylation-sensitive Single Nucleotide Primer Extension). TheMs-SNuPE technique is a quantitative method for assessing methylationdifferences at specific CpG sites based on bisulfite treatment of DNA,followed by single-nucleotide primer extension (Gonzalgo & Jones,Nucleic Acids Res. 25:2529-2531, 1997). Briefly, genomic DNA is reactedwith sodium bisulfite to convert unmethylated cytosine to uracil whileleaving 5-methylcytosine unchanged. Amplification of the desired targetsequence is then performed using PCR primers specific forbisulfite-converted DNA, and the resulting product is isolated and usedas a template for methylation analysis at the CpG site(s) of interest.Small amounts of DNA can be analyzed (e.g., microdissected pathologysections), and it avoids utilization of restriction enzymes fordetermining the methylation status at CpG sites.

Typical reagents (e.g., as might be found in a typical Ms-SNuPE-basedkit) for Ms-SNuPE analysis may include, but are not limited to: PCRprimers for specific gene (or methylation-altered DNA sequence or CpGisland); optimized PCR buffers and deoxynucleotides; gel extraction kit;positive control primers; Ms-SNuPE primers for specific gene; reactionbuffer (for the Ms-SNuPE reaction); and radioactive nucleotides.Additionally, bisulfite conversion reagents may include: DNAdenaturation buffer; sulfonation buffer; DNA recovery regents or kit(e.g., precipitation, ultrafiltration, affinity column); desulfonationbuffer; and DNA recovery components.

The bisulfite conversion and amplification procedure according to theinvention may be used in combination with this detection method.

MSP. MSP (methylation-specific PCR) allows for assessing the methylationstatus of virtually any group of CpG sites within a CpG island,independent of the use of methylation-sensitive restriction enzymes(Herman et al. Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996; U.S. Pat.No. 5,786,146). Briefly, DNA is modified by sodium bisulfite convertingall unmethylated, but not methylated cytosines to uracil, andsubsequently amplified with primers specific for methylated versusunmethylated DNA.

MSP primer pairs contain at least one primer, which hybridizes to abisulfite treated CpG dinucleotide. Therefore, the sequence of saidprimers comprises at least one CpG dinucleotide. MSP primers specificfor non-methylated DNA contain a “T’ at the 3′ position of the Cposition in the CpG. Preferably, therefore, the base sequence of saidprimers is required to comprise a sequence having a length of at least 9nucleotides which hybridizes to the bisulfite converted nucleic acidsequence, wherein the base sequence of said oligomers comprises at leastone CpG dinucleotide. MSP requires only small quantities of DNA, issensitive to 0.1% methylated alleles of a given CpG island locus, andcan be performed on DNA extracted from paraffin-embedded samples.Typical reagents (e.g., as might be found in a typical MSP-based kit)for MSP analysis may include, but are not limited to: methylated andunmethylated PCR primers for specific gene (or methylation-altered DNAsequence or CpG island), optimized PCR buffers and deoxynucleotides, andspecific probes. The bisulfite conversion and amplification procedureaccording to the invention may be used in combination with thisdetection method.

NESTED MSP (Belinsky and Palmisano in US application 20040038245).Considering the apparent conflict of requiring high specificity of theMSP primer to sufficiently differentiate between CG and TG positions butallowing for a mismatch in order to create a unique restriction site itis preferred to use an amended version of MSP, known as nested MSP, asdescribed in WO 02/18649 and US patent application 20040038245 byBelinsky and Palmisano. This method to detect the presence ofgene-specific promoter methylation, comprises the steps of: expandingthe number of copies of the genetic region of interest by using apolymerase chain reaction to amplify a portion of said region where thepromoter methylation resides, thereby generating an amplificationproduct; and using an aliquot of the amplification product generated bythe first polymerase chain reaction in a second, methylation-specific,polymerase chain reaction to detect the presence of methylation. Inother words a non methylation specific PCR is performed prior to themethylation specific PCR. The bisulfite conversion and amplificationprocedure according to the invention may be used in combination withthis detection method.

HEAVYMETHYL™. (WO 02/072880; Cottrell S E et al. Nucleic Acids Res. 2004Jan. 13; 32(1):e10) A further preferred embodiment of the methodcomprises the use of blocker oligonucleotides. In the HeavyMethyl™ assayblocking probe oligonucleotides are hybridized to the bisulfite treatednucleic acid concurrently with the PCR primers. PCR amplification of thenucleic acid is terminated at the 5′ position of the blocking probe,such that amplification of a nucleic acid is suppressed where thecomplementary sequence to the blocking probe is present. The probes maybe designed to hybridize to the bisulfite treated nucleic acid in amethylation status specific manner. For example, for detection ofmethylated nucleic acids within a population of unmethylated nucleicacids, suppression of the amplification of nucleic acids which areunmethylated at the position in question would be carried out by the useof blocking probes comprising a ‘CpA’ or ‘TpA’ at the position inquestion, as opposed to a ‘CpG’ if the suppression of amplification ofmethylated nucleic acids is desired.

For PCR methods using blocker oligonucleotides, efficient disruption ofpolymerase-mediated amplification requires that blocker oligonucleotidesnot be elongated by the polymerase. Preferably, this is achieved throughthe use of blockers that are 3′-deoxyoligonucleotides, oroligonucleotides derivatized at the 3′ position with other than a “free”hydroxyl group. For example, 3′-O-acetyl oligonucleotides arerepresentative of a preferred class of blocker molecule.

Additionally, polymerase-mediated decomposition of the blockeroligonucleotides should be precluded. Preferably, such preclusioncomprises either use of a polymerase lacking 5′-3′ exonuclease activity,or use of modified blocker oligonucleotides having, for example, thioatebridges at the 5′-terminii thereof that render the blocker moleculenuclease-resistant. Particular applications may not require such 5′modifications of the blocker. For example, if the blocker- andprimer-binding sites overlap, thereby precluding binding of the primer(e.g., with excess blocker), degradation of the blocker oligonucleotidewill be substantially precluded. This is because the polymerase will notextend the primer toward, and through (in the 5′-3′ direction) theblocker—a process that normally results in degradation of the hybridizedblocker oligonucleotide.

A particularly preferred blocker/PCR embodiment, for purposes of thepresent invention and as implemented herein, comprises the use ofpeptide nucleic acid (PNA) oligomers as blocking oligonucleotides. SuchPNA blocker oligomers are ideally suited, because they are neitherdecomposed nor extended by the polymerase.

Preferably, therefore, the base sequence of said blockingoligonucleotide is required to comprise a sequence having a length of atleast 9 nucleotides which hybridizes to the chemically treated nucleicacid sequence, wherein the base sequence of said oligonucleotidescomprises at least one CpG, TpG or CpA dinucleotide.

The bisulfite conversion and amplification procedure according to theinvention may be used in combination with this detection method.

Preferably, real-time PCR assays are performed specified by the use ofsuch primers according to the invention. Real-time PCR assays can beperformed with methylation specific primers (MSP-real time) asmethylation-specific PCR (“MSP”; as described above), or withnon-methylation specific primers in presence of methylation specificblockers (HM real-time) (“HEAVYMETHYL™”, as described above). Real-timePCR may be performed with any suitable detectably labeled probes. Fordetails see below. Both of these methods (MSP or HM) can be combinedwith the detection method known as MethyLight™ (a fluorescence-basedreal-time PCR technique) (Eads et al., Cancer Res. 59:2302-2306, 1999),which generally increases the specificity of the signal generated insuch an assay. Whenever the real-time probe used is methylation specificin itself, the technology shall be referred to as MethyLight™, a widelyused method.

Another assay makes use of the methylation specific probe, the so called“QM” (quantitative methylation) assay. A methylation unspecific,therefore unbiased real-time PCR amplification is performed which isaccompanied by the use of two methylation specific probes (MethyLight™)one for the methylated and a second for the unmethylated amplificate.That way two signals are generated which can be used to a) determine theratio of methylated (CG) to unmethylated (TG) nucleic acids, and at thesame time b) the absolute amount of methylated nucleic acids can bedetermined, when calibrating the assay with a known amount of controlDNA.

MethyLight™. The MethyLight™ assay is a high-throughput quantitativemethylation assay that utilizes fluorescence-based real-time PCR(TaqMan.™) technology that requires no further manipulations after thePCR step (Eads et al., Cancer Res. 59:2302-2306, 1999). Briefly, theMethyLight™ process begins with a mixed sample of genomic DNA that isconverted, in a sodium bisulfite reaction, to a mixed pool ofmethylation-dependent sequence differences according to standardprocedures (the bisulfite process converts unmethylated cytosineresidues to uracil). Fluorescence-based PCR is then performed either inan “unbiased” (with primers that do not overlap known CpG methylationsites) PCR reaction, or in a “biased” (with PCR primers that overlapknown CpG dinucleotides) reaction. Sequence discrimination can occureither at the level of the amplification process or at the level of thefluorescence detection process, or both.

The MethyLight™ assay may be used as a quantitative test for methylationpatterns in the genomic DNA sample, wherein sequence discriminationoccurs at the level of probe hybridization. In this quantitativeversion, the PCR reaction provides for unbiased amplification in thepresence of a fluorescent probe that overlaps a particular putativemethylation site. An unbiased control for the amount of input DNA isprovided by a reaction in which neither the primers, nor the probeoverlie any CpG dinucleotides. Alternatively, a qualitative test forgenomic methylation is achieved by probing of the biased PCR pool witheither control oligonucleotides that do not “cover” known methylationsites (a fluorescence-based version of the “MSP” technique), or witholigonucleotides covering potential methylation sites.

The MethyLight™ process can by used with a “TaqMan®” probe in theamplification process. For example, double-stranded genomic DNA istreated with sodium bisulfite and subjected to one of two sets of PCRreactions using TaqMan® probes; e.g., with either biased primers andTaqMan® probe, or unbiased primers and TaqMan® probe. The TaqMan® probeis dual-labeled with fluorescent “reporter” and “quencher” molecules,and is designed to be specific for a relatively high GC content regionso that it melts out at about 10° C. higher temperature in the PCR cyclethan the forward or reverse primers. This allows the TaqMan® probe toremain fully hybridized during the PCR annealing/extension step. As theTaq polymerase enzymatically synthesizes a new strand during PCR, itwill eventually reach the annealed TaqMan® probe. The Taq polymerase 5′to 3′ endonuclease activity will then displace the TaqMan® probe bydigesting it to release the fluorescent reporter molecule forquantitative detection of its now unquenched signal using a real-timefluorescent detection system.

Variations on the TaqMan™ detection methodology that are also suitablefor use with the described invention include the use of dual-probetechnology (LightCycler™) or fluorescent amplification primers (Sunrise™technology). Both these techniques may be adapted in a manner suitablefor use with bisulfite treated DNA, and moreover for methylationanalysis within CpG dinucleotides.

Typical reagents (e.g., as might be found in a typical MethyLight™-basedkit) for MethyLight™ analysis may include, but are not limited to: PCRprimers for specific bisulfite sequences, i.e. bisulfite convertedgenetic regions (or bisulfite converted DNA or bisulfite converted CpGislands); probes (e.g. TaqMan® or LightCycler™) specific for saidamplified bisulfite converted sequences; optimized PCR buffers anddeoxynucleotides; and a polymerase, such as Taq polymerase.

The bisulfite conversion and amplification procedure according to theinvention may be used in combination with this detection method.

The fragments obtained by means of the amplification can carry adirectly or indirectly detectable label. Preferred are labels in theform of fluorescence labels, radionuclides, or detachable moleculefragments having a typical mass, which can be detected in a massspectrometer. Where said labels are mass labels, it is preferred thatthe labeled amplificates have a single positive or negative net charge,allowing for better detectability in the mass spectrometer. Thedetection may be carried out and visualized by means of, e.g., matrixassisted laser desorption/ionization mass spectrometry (MALDI) or usingelectron spray mass spectrometry (ESI).

Matrix Assisted Laser Desorption/Ionization Mass Spectrometry(MALDI-TOF) is a very efficient development for the analysis ofbiomolecules (Karas & Hillenkamp, Anal Chem., 60:2299-301, 1988). Ananalyte is embedded in a light-absorbing matrix. The matrix isevaporated by a short laser pulse thus transporting the analyte moleculeinto the vapour phase in an unfragmented manner. The analyte is ionizedby collisions with matrix molecules. An applied voltage accelerates theions into a field-free flight tube. Due to their different masses, theions are accelerated at different rates. Smaller ions reach the detectorsooner than bigger ones. MALDI-TOF spectrometry is well suited to theanalysis of peptides and proteins. The analysis of nucleic acids issomewhat more difficult (Gut & Beck, Current Innovations and FutureTrends, 1:147-57, 1995). The sensitivity with respect to nucleic acidanalysis is approximately 100-times less than for peptides, anddecreases disproportionally with increasing fragment size. Moreover, fornucleic acids having a multiply negatively charged backbone, theionization process via the matrix is considerably less efficient. InMALDI-TOF spectrometry, the selection of the matrix plays an eminentlyimportant role. For desorption of peptides, several very efficientmatrixes have been found which produce a very fine crystallisation.There are now several responsive matrixes for DNA, however, thedifference in sensitivity between peptides and nucleic acids has notbeen reduced. This difference in sensitivity can be reduced, however, bychemically modifying the DNA in such a manner that it becomes moresimilar to a peptide. For example, phosphorothioate nucleic acids, inwhich the usual phosphates of the backbone are substituted withthiophosphates, can be converted into a charge-neutral DNA using simplealkylation chemistry (Gut & Beck, Nucleic Acids Res. 23: 1367-73, 1995).The coupling of a charge tag to this modified DNA results in an increasein MALDI-TOF sensitivity to the same level as that found for peptides.

The amplificates may also be further detected and/or analysed by meansof oligonucleotides constituting all or part of an “array” or “DNA chip”(i.e., an arrangement of different oligonucleotides and/or PNA-oligomersbound to a solid phase). Such an array of different oligonucleotide-and/or PNA-oligomer sequences can be characterized, for example, in thatit is arranged on the solid phase in the form of a rectangular orhexagonal lattice. The solid-phase surface may be composed of silicon,glass, polystyrene, aluminum, steel, iron, copper, nickel, silver, orgold. Nitrocellulose as well as plastics such as nylon, which can existin the form of pellets or also as resin matrices, may also be used. Anoverview of the Prior Art in oligomer array manufacturing can begathered from a special edition of Nature Genetics (Nature GeneticsSupplement, Volume 21, January 1999, and from the literature citedtherein). Fluorescently labeled probes are often used for the scanningof immobilized DNA arrays. The simple attachment of Cy3 and Cy5 dyes tothe 5′-OH of the specific probe are particularly suitable forfluorescence labels. The detection of the fluorescence of the hybridizedprobes may be carried out, for example, via a confocal microscope. Cy3and Cy5 dyes, besides many others, are commercially available.

The bisulfite conversion and amplification procedure according to theinvention may be used in combination with this detection method.

Furthermore, additional methods for methylation analysis are known bypersons skilled in the art. Such methods are for example methods inwhich bisulfite treated DNA is subject to DNA array based analysismethods as described in WO 99/28498, WO 01/38565, or in WO 02/18632.

All references cited herein are incorporated in their entirety.

EXAMPLES Example 1 a) Paraffin Removal Step

Chemical Needed:

Limonenel45, Fluka Chemika, Art Nr. 89188

Procedure:

-   -   1. Spin safe look or screw cap reaction tubes (containing 1-5        sections of a paraffin-embedded formalin-fixed tissue) for 1 min        at 5,000×g    -   2. Add 1 ml limonene to each tube. Push all pieces into the        liquid. In some cases sample material is already very brittle        with small pieces of paraffin/tissue in tube—make sure that        material sticking to the tube cap goes back into the tube.    -   3. 1 h incubation at room temperature at 1,000 rpm in        thermomixer, vortex vigorously at least 3 times during        incubation.    -   4. Place tubes into centrifuge and spin at 16,000 rcf        (=16,000×g) for 5 min, the tissue will pellet at the tube        bottom.    -   5. Use a 1 ml pipet to suck up the limonene from each sample.        Great care should be taken not to disturb the pellet! Place        pipet tip opposite the pellet onto the tube and gently allow        limonene to enter the pipet tip; for removal of last droplets a        yellow tip should be used.    -   6. If the tissue settles only weakly at the bottom (i.e. not        forming a nice pellet) do the following:        -   repeat centrifugation again for 5 min on Eppendorf 5417            centrifuge at max speed (>20,000 rcf)        -   then repeat the removal of limonene: make sure the pipet tip            is pressed against the bottom of the tube and limonene is            removed very slowly such as not to suck in the tissue.            Remove as much limonene as possible.            b) Lysis Step

Prepare a larger volume of the lysis buffer (0.5 or 1 l), depending onthe number of samples to be processed for a project. This buffer can bestored at room temperature for 3 months. Check for contamination andcarry out filter sterilization of an aliquot before each use.

Chemicals:

TRIS (tris-hydroxymethyl-amino-methan), Merck, Art. Nr. 1.01549.0500,

MW=121.14 g/mol

Prepare a 1 mol/l Stock Solution:

dissolve 121.14 g in 800 ml H₂O and adjust to pH 8.0 with HCl and fillup to 1 l

EDTA (ethylendiaminetetraacetic acid),

Sodium EDTA (Titriplex III) from Merck, Art. Nr. 159294

MW=372.24 g/mol

Prepare a 0.5 mol/l stock solution: Dissolve 186.1 g in 800 ml H₂O andadjust to pH 8.0 with NaOH, fill up to 1 l.

Tween (Tween 20), Fluka, Chemika Art Nr. 93773

This detergent is added to the buffer in volume percent. To add Tween tothe buffer take 1 ml of Tween (in 2 ml tube), warm it at 50° C. and adddesired volume to buffer with a widened pipet tip.

Lysis buffer composition: 50 mmol/l TrisHCl, pH 8.0, 1 mmol/l EDTA,

0.5% Tween (volume %)

Proteinase K, Roth

Always prepare a fresh 30 mg/ml stock solution in H₂O. The size of thestock solution should be adjusted to the number of samples to beprocessed. For example 300 mg proteinase K dissolved in 10 ml H₂O willbe sufficient for ˜400 samples.

Procedure:

-   -   1. Add 190 μl of the prepared lysis buffer to each sample. It is        important to ensure that all sample material is covered by lysis        buffer.    -   2. Add 20 μl of the prepared proteinase K solution.    -   3. Vortex the tube rigorously to ensure proper mixing of sample        with lysis buffer and proteinase K. Make sure the tube caps are        tightly closed—otherwise loss of liquid will happen!    -   4. Incubate at 60° C., shaking 1,000 rpm (thermoshaker).    -   5. Incubate for 40 to 48 hours, no further additions of        proteinase K necessary.    -   6. Spin in the morning and the evening of each day to remove        droplets from the cap, vortex vigorously.    -   7. Incubate samples at >95° C. for 10 min in to order to        inactive proteinase K. For this, set the thermomixer at a        temperature of 99° C., since the real temperature at the highest        setting is some degrees below the indicated temperature.        -   (active proteinase K in the lysate will reduce PCR            performance, especially if lysate is used directly for            quantitation of genomic DNA by real time PCR)            Quality Check of Lysis (During Lysis)

After lysis step 5, there should be a homogeneous, maybe turbid solutionin the tube with no visible pieces of tissue left. However, should therebe visible pieces of tissues in MANY of the samples left after the firstON-incubation additional proteinase K step and increase of lysis volumeshould be considered. If only individual samples have some undigestedmaterial left this may be neglected. Have a careful look!

Storage:

Lysed samples may be stored at either −20° C. or −80° C. (depending onstorage time) or be used immediately for downstream processing.

c) DNA Extraction Step

Equipment Needed:

-   -   plate centrifuge (Sigma or Qiagen, capable of up to 5,758×g        (6,000 rpm))    -   pipettors for volumes of from 10 μl to 1,000 μl (multichannel        for large volumes)    -   waste container for DNA flowthrough (e.g. bowl with DNA-off)

Material Needed:

-   -   Dneasy 96 Tissue Kit (Qiagen #69581 or 69582)    -   pipet tips (100 μl, 1,000 μl)    -   15 ml and 50 ml Falcon tubes

Chemicals Needed:

-   -   ethanol, molecular biology grade        Procedure:

Make sure by respective labeling, that all plates in an assembly areturned in the same direction (well A1 over well A1 etc.)

-   1. Distribute 400 μl AL/E in collection microtubes and transfer    lysate (200 μl) to the tubes; seal tubes with caps for collection    tubes; use plate lid to fix tubes in rack-   2. Mix by shaking 15 s with BOTH hands; spin shortly (let centrifuge    reach 1, 450×g and stop);-   3. Place the DNeasy 96 plate on an S-block (seal unused wells of    DNeasy plate with AirPore Tape sheet). Carefully apply the mixture    from step 2 onto columns. Seal with AirPore Tape. Centrifuge at    5,790×g for 10 min. If there's still fluid visible on membranes, add    centrifugation step.-   4. Remove the tape. Add 500 μl AW1. Seal with new AirPore Tape    sheet. Empty S-block. Spin for 5 min at 5,790×g.-   5. Remove the tape. Add 500 μl AW2. Seal with new AirPore Tape    sheet. Empty S-block. Spin for 15 min at 5,790×g, this should leave    the membrane dried.-   6. Place DNeasy plate on elution microtube plate. To elute DNA add    120 μl buffer AE or ddH₂O preheated to 70° C. to each well. Seal the    plate with a new AirPore Tape sheet. Incubate for 5 min at room    temperature. Spin for 2 min at 5,790×g.-   7. Seal elution microtubes with caps provided. Store at −20° C. or    −80° C. (depending on storage time)    d) Bisulfite Treatment Step and e) DNA Purification Step    Equipment Needed:    -   Thermocycler (e.g. Eppendorf, Tetrad)    -   Plate centrifuge (Sigma or Qiagen, capable of up to 5,700×g)    -   Pipettors for volumes of from 10 μl to 1,000 μl (multichannel        Eppendorf+Matrix pipettors)        Material Needed:    -   PCR-plates+cap strips    -   QIAamp 96 DNA Blood Kit (Qiagen #51161 for 4 plates or 51162 for        12)    -   Additional round well blocks and caps (1 needed additional for        each purification of 96 samples; #19576 for 24 plates)    -   QIA Buffer AVL (#19073 for 155 ml, 560 μl per sample needed)    -   pipet tips (100 μl, 1,000 μl, Eppendorf+Matrix)    -   15 ml and 50 ml Falcon tubes    -   waste container for DNA-flowthroughs (e.g. bowl with DNA-off)        Chemicals Needed:    -   sodium bisulfite (Na₂S₂O₅, 190.1 g/mol), Merck 1.06528.0500    -   sodium sulfite, anhydrous (Na₂SO₃, 126.04 g/mol), Fluka 71988    -   ddH₂O molecular biology grade (0.2 μm filtered, DEPC-treated,        autoclaved, free of DNases- and RNases)    -   diethyleneglycoldimethylether (DME), Merck 8.02934.0250    -   6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (250.29        g/mol), Aldrich 23,881-3    -   ethanol, molecular biology grade    -   sodium hydroxide pellets (NaOH, 40.0 g/mol), Merck 1.06482.1000

Preparation of solutions (sufficient for 80 reactions, always to beprepared freshly!):

Bisulfite solution: Sodium disulfite (4.708 g) and sodium sulfite (1.128g) are dissolved by adding 10 ml ddH₂O (the solution is 4.9 M). Thefinal volume is around 12 ml. Check pH of the solution—if it is notbetween 5.45 and 5.5, discard solution and repeat preparation. Shakerigorously and if needed, heat the solution to 50° C. in a waterbaththan vortex at maximum speed for 30 sec. Repeat this procedure as oftenuntil the salt is completely dissolved.

DME-radical scavenger solution: Dissolve 125.3 mg of6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid by adding 1.0 mlDME. Vortex rigorously in order to ensure that no undissolved particlesremain. DME is hazardous and potentially carcinogenic. Therefore takeappropriate precautions when handling this chemical. If only few samplesare to be bisulfite treated, prepare smaller volumes.

Desulfonation buffer: Dissolve 0.8 g sodium hydroxide in 10 ml ddH₂O toprepare a 2 mol/l stock-solution. For the desulfonation buffer mix 1.0ml 2 mol/l sodium hydroxide and 9.0 ml ethanol. The solution has toprepared freshly before each purification!

Procedure Bisulfite Reaction (final volume of 140 μl):

Pipet the following solutions into PCR-plates in the order shown.

-   -   1. 44 μl buffer/water containing the DNA to be bisulfite treated    -   2. 83 μl bisulfite solution (pipetting of bisulfite and sample        can be interchanged)    -   3. 13 μl DME solution, containing the radical scavenger    -   4. mix thoroughly    -   5. place in 0.2 ml wells of thermocycler. Use cap-strips to        close wells!

Temperature program in a thermocycler

-   -   5:00 min denaturation of DNA at 99° C.    -   22:00 min incubation at 60° C.    -   3:00 min denaturation of DNA at 99° C.    -   1:27:00 hours incubation at 60° C.    -   3:00 min denaturation of DNA at 99° C.    -   2:57:00 hours incubation at 60° C.    -   cooling at 20° C.

DNA purification by using a combination of QIAamp Viral RNA Mini Kit andQIAamp 96 DNA Blood Kit:

1. Preparation of Binding Buffer AVL

-   -   Add 1 ml of buffer AVL to 310 μg of lyophilized carrier RNA.        Dissolve thoroughly.    -   Transfer to the buffer AVL bottle (30 ml), and mix thoroughly        before using buffer AVL for the first time.    -   This buffer can be stored at 2-8° C. for future use up to 6        months. However, if a precipitate develops, then redissolve by        heating at 80° C. no longer than 5 min. This should be done no        more than a total of 6 times. Cool to room temperature before        use. An aliquot of prepared buffer AVL can also be stored at        room temperature for up to 2 weeks.        2. Preparation of Binding Conditions    -   For each sample two wells have to be used; these should be on 2        round well blocks in order to keep the original layout (e.g.        well A1 of bisulfite plate will be split into 70 μl in well A1        block 1 and 70 μl in well A1 block 2, see illustration below).    -   Into each well of blocks pipet 280 μl of prepared buffer        AVL/carrier RNA.    -   Add 70 μl DNA/bisulfite solution from PCR-plate, place DNA        directly into buffer and pipet up and down 3 times to ensure        complete transfer of DNA and mixing.    -   Add 280 μl Ethanol. Seal the wells by using caps for blocks. Mix        vigorously by shaking with BOTH hands for at least 15 sec.        (Ethanol tends to refuse to mix with fluids based on water!!!)    -   Alternatively, if DNA-amounts are very critical: Pipett only 200        μl into blocks, use remaining 80 μl to wash wells of        bisulfitation-plate after transfer of DNA.    -   Spin briefly at 1,450×g (reach 1,450×g and stop) to get the        drops down. Incubate at room temperature for 10 minutes.        3. Binding    -   Both wells are loaded subsequently onto ONE column (see        illustration above)    -   Place QIAamp 96 plate on top of an S-block    -   apply 630 μl of the first well per sample QIAamp 96 plate    -   Seal plate with a AirPore Tape sheet, spin at 5,790×g for 4 min    -   Empty the S-block    -   Repeat binding with second well of each sample onto the same        column like first well (load, seal, spin, empty S-block)        4. Washing and 5. Desulfonation    -   Place QIAamp 96 plate of S-block    -   Add 500 μl buffer AW1    -   Seal the plate with new AirPore Tape sheet    -   Spin at 5,790×g for 2 min    -   Empty S-block, place plate on S-block    -   Add 500 μl 0.2 mol/l NaOH to the QIAamp 96 plate    -   Seal with a fresh AirPore Tape sheet, incubation for 15 min at        room temperature.    -   Centrifuge at 5,790×g for 1 min.    -   Empty S-block    -   add 500 μl AW2    -   Seal the plate with new AirPore Tape sheet    -   Spin at 5,790×g for 15 min        6. Elution    -   Place QIAqmp 96 plate on rack of elution microtubes.    -   Add 100 μl AE or ddH₂O preheated to 70° C.    -   Seal plate with a new AirPore sheet and incubate at room        temperature for 5 min    -   Spin at 5,790×g for 4 min    -   Seal tubes with caps

The DNA can then be further amplified and analysed by means of thesensitive methods for DNA methylation analysis.

Example 2

All steps will be done in the tubes that the samples are provided in,i.e. the tubes provided by the supplier of the samples, these can beboth 1.5 and 2.0 ml (preferred) tubes. Please double check that tubeformats fit into the centrifuge.

The solvents and buffers can be delivered with either single channelpipettes or multipettes

a) Removal of Paraffin

Chemical Needed:

Limonenel45, Fluka Chemika, Art Nr. 89188

Procedure:

-   1. Add 1 ml limonene to each tube (containing 1 to 5 slides of    paraffin-embedded formalin-fixed surgery sample). Push all pieces    into the liquid. In some cases sample material is already very    brittle with small pieces of paraffin/tissue in tube—make sure that    material sticking to the tube cap goes back into the tube.-   2. 1 h incubation at room temperature at 1,000 rpm, vortex    vigorously at least 3 times during incubation.-   3. Place tubes into centrifuge and spin at 16,000 rcf (=16,000×g)    for 5 min, the tissue will pellet at the tube bottom.-   4. Use a 1 ml pipet to suck up the limonene from each sample. Great    care should be taken not to disturb the pellet! Place pipet tip    opposite the pellet onto the tube and gently allow limonene to enter    the pipet tip, in some cases it can be easier to remove the entire    volume in two rather than one pipetting steps. It is o.k. if small    amounts (up to 50 μl) of limonene remain in tube.-   5. If the tissue settles only weakly at the bottom (i.e. not forming    a nice pellet) do the following:    -   repeat centrifugation again for 5 min on Eppendorf 5417        centrifuge at max speed (>20,000 rcf)    -   then repeat the removal of limonene: make sure the pipet tip is        pressed against the bottom of the tube and limonene is removed        very slowly such as not to suck in the tissue. Remove as much        limonene as possible.

Leave out ethanol step, if it was possible to remove nearly all limonene(if there are 50 μl left, this will be ok)

-   6. Add 1 ml of ethanol (purity>99%).-   7. Vortex, 10 min incubation at room temperature at 1,000 rpm.-   8. Place tubes into centrifuge and spin at 16,000 rcf for 5 min, the    tissue will pellet again at the tube bottom.-   9. Use pipet to suck up the ethanol, great care should be taken not    to disturb the pellet! Place pipet tip opposite the pellet onto the    tube wall and gently allow ethanol to enter the pipet tip.-   10. Remove as much of ethanol as possible with the pipet.-   11. Residual ethanol not removed by pipetting must be evaporated by    incubation in a thermomixer at 50° C. This may take between 10 to 30    min, but take care not to overdry the samples.

No drying needed, if ethanol step was left out.

b) Lysis Step

Prepare a larger volume of the lysis buffer (0.5 or 1 l), depending onthe number of samples to be processed for a project.

This buffer can be stored at room temperature for 3 months. After thistime it is prudent to prepare a fresh buffer.

Chemicals:

TRIS (tris-hydroxymethyl-amino-methan), Merck, Art. Nr. 1.01549.0500,

MW=121.14 g/ml

Prepare a 1 mol/l Stock Solution:

Dissolve 121.14 g in 800 ml H₂O and adjust to pH 8.0 with HCl and fillup to 1 l.

EDTA (ethylendiaminetetraacetic acid),

Sodium EDTA (Titriplex III) from Merck, Art. Nr. 159294

MW=372.24 g/mol

Prepare a 0.5 mol/l Stock Solution:

Dissolve 186.1 g in 800 ml H₂O and adjust to pH 8.0 with NaOH, fill upto 1 l.

Tween (Tween 20), Fluka, Chemika Art Nr. 93773

This detergent is added to the buffer in volume percent. To add Tween tothe buffer take 1 ml of Tween (in 2 ml tube), warm it at 50° C. and adddesired volume to buffer with a widened pipet tip.

Lysis Buffer Composition:

50 mmol/l TrisHCl, pH 8.0, 1 mmol/l EDTA, 0.5% Tween (volume %)

Proteinase K, Roth

Prepare a 30 mg/ml stock solution in H₂O. The size of the stock solutionshould be adjusted to the number of samples to be processed. Forexample: 300 mg proteinase K dissolved in 10 ml H₂O will be sufficientfor −400 samples.

Proteinase K can be stored at 4° C. for up to one week safely. If moresamples will be processed it is recommended to prepare fresh solutionsrepeatedly.

Procedure:

-   1. Add 190 μl of the prepared lysis buffer to each sample. It is    important to ensure that all sample material is covered by lysis    buffer.-   2. Add 20 μl of the prepared proteinase K solution.-   3. Vortex the tube rigorously to ensure proper mixing of sample with    lysis buffer and proteinase K. Make sure the tube caps are tightly    closed—otherwise loss of liquid will happen!-   4. Incubate at 50° C., shaking 1,000 rpm (thermoshaker).-   5. Incubate for 40 to 48 h, no further additions of Proteinase K    necessary.-   6. Spin in the morning and the evening of each day to remove    droplets from the cap, vortex vigorously.    Quality Check of Lysis (During Lysis):

After these lysis steps, there should be a homogeneous, maybe turbidsolution in the tube with no visible pieces of tissue left. However,should there be visible pieces of tissues in MANY of the samples leftafter the first ON-incubation additional proteinase K step and increaseof lysis volume should be considered. If only individual samples havesome undigested material left this may be neglected. Have a carefullook!

-   7. Incubate samples at >95° C. for 10 min in to order to inactive    proteinase K. For this set the temperature of the thermomixer at 99°    C., since the real temperature at the highest setting is some    degrees below the indicated temperature. (Active proteinase K in the    lysate will reduce PCR performance, especially if lysate is used    directly for quantitation of genomic DNA by RT-PCR).-   8. Lysed samples may be stored at either −20° C. or −80° C.    (depending on storage time) or be used immediately for downstream    processing.    c) DNA Extraction with QIAGEN DNeasy Tissue Kit    Approximate Duration for 30 Samples:

Preparation of devices and materials: 15 min; Preparation: 30 min;Procedure: 1.5 h

The Following Devices are Needed:

centrifuge, e.g. model Eppendorf 5417R; Eppendorf pipettes and/orMultipettes; 1.5 ml and 2 ml reaction-tubes; thermomixer.

The Following Reagents are Needed:

paraffin sample lysates (˜210 μl or more, if lysis buffer+proteinase Kwere added, the actual volumes may differ slightly, lower volumes mayoccur because aliqots were taken for quantitation, evaporation loss.Also larger volume may occur because lysed tissue amount was more thanaverage)

Ethanol for molecular biology (96-100%)

DNeasy kit (Qiagen cat nr. 69504 [50 columns] or 69506 [250 columns])

Preparation (Before Starting the Actual Extraction):

-   1. Mix buffer AL thoroughly by shaking before use. Buffer AL is    stable for 1 year when stored at room temperature. If a precipitate    has formed in buffer AL, dissolve by incubating at 70° C.-   2. Buffer AW 1 is supplied as a concentrate. Add the appropriate    amount of ethanol (96-100%) before first use (these amounts differ    for the 69504 and 69506 kits, respectively). Buffer AW 1 is stable    for 1 year when stored closed at room temperature.-   3. Buffer AW 2 is supplied as a concentrate. the appropriate amount    of ethanol (96-100%) before first use (these amounts differ for the    69504 and 69506 kits, respectively). Buffer AW 2 is stable for 1    year when stored closed at room temperature.-   4. If samples were frozen after tissue lysis make sure the samples    are equilibrated to room temperature.-   5. Heat a thermomixer to 70° C.-   6. All centrifugation steps should be carried out at room    temperature.-   7. Be careful not to cause spills when using the Multipette instead    of single pipettors.    Extraction Procedure:-   1. Add 210 μl (if lysate had a larger volume: 1 volume of lysis    buffer+proteinase K volume used) of buffer AL to the tube (1.5 or    2.0 ml) containing the lysate, mix thoroughly by vortexting. Place    tube into a thermomixer and incubate at 70° C., shaking at 1,000 rpm    for 10 min.-   2. Add 210 μl (if lysate had a larger volume: again 1 volume of    lysis buffer+proteinase K volume used) ethanol (96-100%) to the    sample, and mix by pulse-vortexing for 15 sec. After mixing, briefly    centrifuge the tube to remove drops from the inside of the lid.-   3. Carefully apply the mixture from step 2 (up to 700 μl will fit    into the column, include precipitates!) onto a DNeasy spin column    which is already placed into a 2 ml collection tube (Qiagen    provided) without wetting the rim. Close the cap, and centrifuge at    6,000×g (=rcf, or 8,000 rpm) for 1 min. Place the DNeasy spin column    in a clean 2 ml collection tube (Qiagen provided), and discard the    tube containing the filtrate.-   4. If lysates were larger than 210 μl the column has be loaded a    2^(nd) time: place into a fresh 2 ml tube, add remaining volume of    the mixture from step 2, spin like in step 3-   5. Carefully open the spin column and add 500 μl buffer AW 1 (this    stays the same for large lysates, too) without wetting the rim.    Close the cap and centrifuge at 6,000×g for 1 min. Place the spin    column in a clean 2 ml collection tube (provided), and discard the    collection tube containing the filtrate.-   6. Carefully open the spin column and add 500 μl Buffer AW 2 without    wetting the rim. Close the cap and centrifuge at full speed 20,000×g    (14,000 rpm) for 3 min.-   7. Optional: Discard the filtrate. In order to avoid carry over of    ethanol, new tubes (not provided by Qiagen) should be used.    Centrifuge again for 1 min at 20,000×g (14,000 rpm).-   8. Place the DNeasy spin column in a clean and already labeled 1.5    ml reaction-tube (not provided by Qiagen), and discard the    collection tube containing the filtrate. Carefully open the DNeasy    spin column and add 60 μl of elution buffer AE (at room temperature)    to the center of the column. Incubate at room temperature for 1 min,    then centrifuge at 6,000×g (8,000 rpm) for 1 min. Add again 60 μl of    new elution buffer to the column center, incubate for 1 min and    centrifuge at 6,000×g for 1 min using the same tube. Final volume is    120 μl (sufficient for 2 bis-reactions with new protocol), though    some loss may occur due to liquid retention on column.-    If final DNA concentration is not critical, also larger elution    volumes can be chosen (volumes to be defined project-specifically!)-   9. If samples are used for bisulfite treatment within the next 2    days keep them at +4° C. in a fridge. For long term storage −20° C.    is recommended.

Analysis:

-   -   An aliqot of the eluate (3 μl) is used to quantiate the DNA        concentration using a genomic real time PCR assay. UV        quantitation is optional.        d) Bisulfite Treatment and e) DNA Purification with Microron™        Device        Equipment Needed:    -   thermo cycler (e.g. Eppendorf, Tetrad)    -   centrifuge (capable of up to 14,000×g)    -   pipettors for volumes of 100 μl and 1,000 μl        Material Needed:    -   Microcon Centrifugal Filter devices, Microcon® YM-30        (Millipore/Amicon 42410) pipet tips (100 μl, 1,000 μl)    -   200 μl PCR-tubes (e.g. Eppendorf 0030 124.359)    -   1.5 ml tubes (e.g. Eppendorf 0030 120.086)    -   15 ml and 50 ml Falcon tubes        Chemicals Needed:    -   sodium bisulfite (Na₂S₂O₅, 190.1 g/mol), Merck 1.06528.0500    -   sodium sulfite, anhydrous (Na₂SO₃, 126.04 g/mol), Fluka 71988    -   ddH₂O molecular biology grade (0.2 μm filtered, DEPC-treated,        autoclaved, free of DNases- and RNases)    -   diethyleneglycoldimethylether (DME), Merck 8.02934.0250    -   6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (250.29        g/mol), Aldrich 23,881-3    -   Tris-hydroxymethyl-aminomethan (C₄H₈O₂, M=121.14 g/mol), Merck        1.01549.0500    -   sodium hydroxide pellets (NaOH, 40.0 g/mol), Merck 1.06482.1000    -   EDTA (Titriplex® III, C₁₀H₁₄N₂O₈Na₂*2H₂O, 372.24 g/mol), Merck        1.08418.0250        Preparation of Solutions (Sufficient for 80 Reactions):

Bisulfite solution: Sodium disulfite (4.708 g) and sodium sulfite (1.128g) are dissolved by adding 10 ml ddH₂O (the solution is 4.9 M). Thefinal volume is around 12 ml. Check pH of the solution—if it is notbetween 5.45 and 5.5, discard solution and repeat preparation. Shakerigorously and if needed, heat the solution to 50° C. in a waterbaththan vortex at maximum speed for 30 sec. Repeat this procedure as oftenuntil the salt is completely dissolved.

DME-radical scavenger solution: dissolve 125.3 mg of6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid by adding 1.0 mlDME. Vortex rigorously in order to ensure that no undissolved particlesremain. DME is hazardous and potentially carcinogenic. Therefore takeappropriate precautions when handling this chemical. If only few samplesare to be bisulfite treated, prepare smaller volumes.

NaOH 0.2 mol/l: Dissolve 0.32 g sodium hydroxide in 40 ml ddH₂O. TEbuffer: 10 mmol/l Tris/0.1 mmol/l EDTA, pH 8

General:

-   -   This procedure is designed to be applied in 200 μl PCR-tubes.        The total number of samples is limited by the number of tubes        that can be handled in the thermocyclers, centrifuges, etc.    -   The working solutions should not be stored over prolonged        periods of time. It is best to prepare them fresh and scale the        solutions according to the number of samples to be processed.    -   All solutions collected as waste in this procedure should be        collected e.g. in a glass bottle and finally discarded as        halogen-free organic solvents        Procedure Bisulfite Treatment:

Pipet the following solutions into PCR-tubes in the order shown.

-   -   1. 50 μl buffer/water containing the DNA to be bisulfite        treated.    -   2. 95 μl bisulfite solution.    -   3. 15 μl DME solution, containing the radical scavenger.

The total volume of the reaction mixture is 160 μl! Tightly close thecaps of PCR-tubes!

Temperature Program:

-   -   5:00 min denaturation of DNA at 99° C.    -   22:00 min incubation at 50° C.    -   3:00 min denaturation of DNA at 99° C.    -   1:27:00 hours incubation at 50° C.    -   3:00 min denaturation of DNA at 99° C.    -   2:57:00 hours incubation at 50° C.    -   Cooling at 20° C.    -   Due to the high molarity of the bisulfite salts some of the salt        may precipitate. These precipitates will not affect the        bisulfite reaction.        Procedure DNA Purification:    -   After incubation is over, transfer reaction solution (160 μl)        into 1.5 ml collection tube.    -   Add 120 μl ddH₂O to the reaction tube. Mix by pipetting up and        down and transfer solution into the same collection tube.    -   Repeat this step with additional 120 μl ddH₂O!    -   Close caps, vortex intensively and spin shortly to remove drops        from lid.    -   Take all of this solution (400 μl) and pipet it into the sample        reservoir of an assembled Microcon filter device—do not touch        the membrane with the pipet tip!    -   Seal with the attached cap.    -   Place the assembly into the centrifuge, align the cap strap        towards the center of the rotor and spin 15 min at 14,000×g.    -   After the spin, take out assembly and discard flowthrough.    -   PLEASE NOTE: The centrifugation efficacies may vary depending on        the particular centrifuge model and instrument used. Therefore        for all centrifugation steps always check whether the sample        volume passed through the membrane! If needed, increase the spin        times in 2 min steps.    -   For desulfonation add 400 μl 0.2 mol/l NaOH to the membrane    -   place assembly back to centrifuge and spin 12 min at 14,000×g.        Take out assembly and discard flowthrough.    -   For washing add 400 μl ddH₂O    -   place assembly back to centrifuge and spin 12 min at 14,000 g.        Take out assembly and discard flowthrough.    -   repeat this step two additional times!    -   PLEASE NOTE: After this the membrane should look moist, but        should not be covered by a visible volume of liquid.    -   For elution take filter assembly out of centrifuge.    -   Add 75 μl of prewarmed TE buffer (50° C.) into the sample        reservoir. (Note: If the total amount of is critical, elution        should be performed by 2 subsequent elution steps, e.g. 2×37.5        μl—should be defined prior to each study).    -   Incubate for 10 min at room temperature while shaking in a        thermomixer at 1,000 rpm.    -   Invert the filter device and place it into a new Microcon 1.5 ml        tube.    -   Elute DNA from membrane by spinning 5 min at 1,000 g.    -   Optional: If desired transfer DNA to a new tube—the lid of        Microcon tubes tends to open quickly.    -   Store DNA at −80° C. for long term storage or at +4° C. for        immediate use.

Example 3

All steps will be done in the tubes that the samples are provided in.The tubes can be both 1.5 and 2.0 ml tubes. Please double check thattube formats fit into the centrifuge.

The solvents and buffers can be delivered with either single channelpipettes or multipettes

a) Removal of Paraffin

Chemical Needed:

Limonenel45, Fluka Chemika, Art Nr. 89188

Procedure:

-   -   1. Add 1 ml limonene to each tube (containing 1 to 5 sections of        a paraffin-embedded formalin-fixed tissue). Push all pieces into        the liquid. In some cases sample material is already very        brittle with small pieces of paraffin/tissue in tube. Make sure        that material sticking to the tube cap goes back into the tube.    -   2. 1 h incubation at RT at 1,000 rpm, vortex vigorously at least        3 times during incubation.    -   3. Place tubes into centrifuge and spin at 16,000 rcf        (=16,000×g) for 5 min, the tissue will pellet at the tube        bottom.    -   4. Use a 1 ml pipet to suck up the limonene from each sample.        Great care should be taken not to disturb the pellet! Place        pipet tip opposite the pellet onto the tube and gently allow        limonene to enter the pipet tip. In some cases it can be easier        to remove the entire volume in two rather than one pipetting        steps.

It is o.k. if small amounts (up to 50 μl) of limonene remain in tube.

-   -   5. If the tissue settles only weakly at the bottom (i.e. not        forming a nice pellet) do the following:        -   Repeat centrifugation again for 5 min on Eppendorf 5417            centrifuge at max speed (>20,000 rcf)        -   Then repeat the removal of limonene: Make sure the pipet tip            is pressed against the bottom of the tube and limonene is            removed very slowly such as not to suck in the tissue.            Remove as much limonene as possible.

Leave out Ethanol step, if it was possible to remove nearly all limonene(if there are 50 μl left, this will be ok).

-   -   6. Add 1 ml of Ethanol (purity>99%).    -   7. Vortex, 10 min incubation at RT at 1,000 rpm.    -   8. Place tubes into centrifuge and spin at 16,000 rcf for 5 min.        The tissue will pellet again at the tube bottom.    -   9. Use pipet to suck up the ethanol, great care should be taken        not to disturb the pellet! Place pipet tip opposite the pellet        onto the tube wall and gently allow ethanol to enter the pipet        tip.    -   10. Remove as much of Ethanol as possible with the pipet.    -   11. Residual ethanol not removed by pipetting must be evaporated        by incubation in a thermomixer at 50° C. This may take between        10 to 30 min, but take care not to overdry the samples.

No drying needed, if ethanol step was left out.

b) Lysis Step

Prepare a larger volume of the lysis buffer (0.5 or 1 l), depending onthe number of samples to be processed for a project. This buffer can bestored at room temperature for 3 months. After this time it is prudentto prepare a fresh buffer.

Chemicals:

TRIS (tris-hydroxymethyl-amino-methan), Merck, Art. Nr. 1.01549.0500,

MW=121.14 g/ml

Prepare a 1 mol/l Stock Solution:

dissolve 121.14 g in 800 ml H₂O and adjust to pH 8.0 with HCl and fillup to 1 l.

EDTA (ethylendiaminetetraacetic acid),

Sodium EDTA (Titriplex III) from Merck, Art. Nr. 159294

MW=372.24 g/mol

Prepare a 0.5 mol/l Stock Solution:

Dissolve 186.1 g in 800 ml H₂O and adjust to pH 8.0 with NaOH, fill upto 1 l.

Tween (Tween 20), Fluka, Chemika Art Nr. 93773

This detergent is added to the buffer in volume percent. To add Tween tothe buffer take 1 ml of Tween (in 2 ml tube), warm it at 50° C. and adddesired volume to buffer with a widened pipet tip.

Lysis Buffer Composition:

50 mmol/l TrisHCl, pH 8.0, 1 mmol/l EDTA, 0.5% Tween (volume %)

Proteinase K, Roth

Prepare a 30 mg/ml stock solution in H₂O. The size of the stock solutionshould be adjusted to the number of samples to be processed. Forexample, 300 mg proteinase K dissolved in 10 ml H₂O will be sufficientfor ˜400 samples. Proteinase K can be stored at 4° C. for up to one weeksafely. If more samples will be processed it is recommended to preparefresh solutions repeatedly.

Procedure:

-   -   1. Add 190 μl of the prepared lysis buffer to each sample. It is        important to ensure that all sample material is covered by lysis        buffer.    -   2. Add 20 μl of the prepared proteinase K solution.    -   3. Vortex the tube rigorously to ensure proper mixing of sample        with lysis buffer and proteinase K. Make sure the tube caps are        tightly closed—otherwise loss of liquid will happen!    -   4. Incubate at 50° C., shaking 1,000 rpm (thermoshaker).    -   5. Incubate for 40 to 48 h, no further additions of proteinase K        necessary.    -   6. Spin in the morning and the evening of each day to remove        droplets from the cap, vortex vigorously.

Quality Check of Lysis (During Lysis):

-   -   After these lysis steps, there should be a homogeneous, maybe        turbid solution in the tube with no visible pieces of tissue        left. However, should there be visible pieces of tissues in MANY        of the samples left after the first over night incubation        additional proteinase K step and increase of lysis volume should        be considered. If only individual samples have some undigested        material left this may be neglected. Have a careful look!    -   7. Incubate samples at >95° C. for 10 min in to order to        inactive proteinase K. For this set the temperature of the        thermomixer at 99° C., since the real temperature at the highest        setting is some degrees below the indicated temperature. (Active        proteinase K in the lysate will reduce PCR performance,        especially if lysate is used directly for quantitation of        genomic DNA by RT-PCR.)    -   8. Lysed samples may be stored at either −20° C. or −80° C.        (depending on storage time) or be used immediately for        downstream processing

Example 4

All steps will be done in the tubes in which the samples are provided.The tubes can be both 1.5 and 2.0 ml tubes. Please double check thattube formats fit into the centrifuge.

The solvents and buffers can be delivered with either single channelpipettes or multipettes.

a) Removal of Paraffin

Chemical Needed:

Limonenel45, Fluka Chemika, Art Nr. 89188

Procedure:

-   -   1. Add 1 ml limonene to each tube (containing 1-6 sections of a        paraffin-embedded formalin-fixed surgery sample or an equal        amount of a biopsy). In some cases sample material is already        very brittle with small pieces of paraffin/tissue in tube—make        sure that material sticking to the tube cap goes back into the        tube.    -   2. 10 min incubation at room temperature, during incubation        vortex rigorously several times (2-4×5 sec) such that the sample        disintegrates as much as possible. This may vary from sample to        sample.    -   3. Place tubes into centrifuge and spin at 16,000 rcf        (=16,000×g) for 5 min. The tissue will pellet at the tube        bottom.    -   4. Use a 1 ml pipet to suck up the limonene from each sample.        Great care should be taken not to disturb the pellet! Place        pipet tip opposite the pellet onto the tube and gently allow        limonene to enter the pipet tip. In some cases it can be easier        to remove the entire volume in two rather than one pipetting        steps. It is o.k. if small amounts (few μl) of limonene remain        in tube.    -   5. If the tissue settles only weakly at the bottom (i.e. not        forming a nice pellet) do the following:        -   repeat centrifugation again for 5 min on Eppendorf 5417            centrifuge at max speed (>20,000 rcf)        -   then repeat the removal of limonene: make sure the pipet tip            is pressed against the bottom of the tube and limonene is            removed very slowly such as not to suck in the tissue.            Remove as much limonene as possible.    -   6. Add 1 ml of Ethanol (purity>99%).    -   7. 10 min incubation at room temperature. During incubation        vortex tubes 2-3 times such that the pellet loosens and all        tissue is soaked in ethanol.    -   8. Place tubes into centrifuge and spin at 16,000 rcf for 5 min,        the tissue will pellet again at the tube bottom.    -   9. Use pipet to suck up the ethanol, great care should be taken        not to disturb the pellet! Place pipet tip opposite the pellet        onto the tube wall and gently allow ethanol to enter the pipet        tip. Remove as much of ethanol as possible with the pipet.    -   10. Residual ethanol not removed by pipetting must be evaporated        by incubation in a thermomixer at 50° C. This may take between        10 to 30 min, but take care not to overdry the samples.        b) Lysis Step

Prepare a larger volume of the lysis buffer (0.5 or 1 l), depending onthe number of samples to be processed for a project. This buffer can bestored at room temperature for 3 months. After this time it is prudentto prepare a fresh buffer.

Chemicals:

TRIS (tris-hydroxymethyl-amino-methan), Merck, Art. Nr. 1.01549.0500;MW=121.14 g/ml; Prepare a 1 mol/l stock solution: Dissolve 121.14 g in800 ml H₂O and adjust to pH 8.0 with HCl and fill up to 1 l. A 50 mmol/lTris solution should be preared from this stock by dilution.

EDTA (ethylendiaminetetraacetic acid); sodium EDTA (Titriplex III) fromMerck, Art. Nr. 159294; MW=372.24 g/mol; prepare a 0.5 mol/l stocksolution: Dissolve 186.1 g in 800 ml H₂O and adjust to pH 8.0 with NaOH,fill up to 1 l.

Tween (Tween 20), Fluka, Chemika Art Nr. 93773; this detergent is addedto the buffer in volume percent. To add Tween to the buffer take 1 ml ofTween (in 2 ml tube), warm it at 50° C. and add desired volume to bufferwith a widened pipet tip.

Lysis Buffer Composition:

50 mmol/l TrisHCl, pH 8.0, 1 mmol/l EDTA, 0.5% Tween (volume %).

Proteinase K, Roth

Prepare a 10 mg/ml stock solution in H₂O. The size of the stock solutionshould be adjusted to the number of samples to be processed. Forexample, 100 mg proteinase K dissolved in 10 ml H₂O will be sufficientfor ˜160 samples. Proteinase K can be stored at 4° C. for up to twoweeks safely. If more samples will be processed it is recommended toprepare fresh solutions repeatedly.

Procedure:

-   -   1. Add 150 μl of the prepared lysis buffer to each sample. It is        important to ensure that all sample material is covered by lysis        buffer.    -   2. Add 20 μl of the prepared proteinase K solution. Vortex the        tube rigorously to ensure proper mixing of sample with lysis        buffer and proteinase K. Very briefly spin to bring down        droplets. Make sure the tube caps are tightly closed—otherwise        loss of liquid will happen!    -   3. Incubate at 50° C., shaking 1,000 rpm (thermoshaker).    -   4. Incubate for 40 h, with a total of 3× proteinase K injections        (always 20 μl).    -   5. After each incubation period the tubes should be briefly        spinned to remove any liquid from the cap to prevent        contamination risk (via gloves). After the proteinase K        injection, samples should be vortexed to ensure proper mixing.        Spin down and continue with incubation.    -   Incubation scheme: 1 overnight, 1 day, 1 overnight

Suggested Workschedule:

-   -   a. Per person not more than 24 samples should be processed in        parallel.    -   b. Sample deparaffination of 24 samples will take approximately        2 h.    -   c. First proteinase K step at 16:00.    -   d. Second proteinase K step next day 8:00.    -   e. Third proteinase K step this day at 16:00.    -   f. Lysis complete overnext day at 8:00.        Quality Check of Lysis (after End of Lysis):

After these lysis steps, there should be a clear solution in the tubewith no visible pieces of tissue left. However, should there be visiblepieces of tissues in MANY of the samples left additional proteinase Ksteps should be considered. If only individual samples have someundigested material left this may be neglected.

-   -   6. Incubate samples at >95° C. for 10 min in to order to        inactive proteinase K. For this the temperature of the        thermomixer is set to 99° C., since the real temperature at the        highest setting is some degrees below the indicated temperature.        (Active proteinase K in the lysate will reduce PCR performance,        especially if lysate is used directly for quantitation of        genomic DNA by RT-PCR)    -   7. Lysed samples may be stored at either −20° C. or −80° C.        (depending on storage time) or be used immediately for        downstream processing.        c. DNA extraction with QIAGEN DNA-Mini-Kit        Time Exposure for 30 Samples:

Provision of devices and materials (15 min); Preparation (0.5 h);Implementation (1.5 h).

Provision of Devices and Materials:

The Following Devices/Means of Labour are Needed:

-   -   centrifuge Eppendorf 5417R, Eppendorf pipettes, 1.5 ml        reaction-tubes, 2 ml reaction-tubes, thermomixer or waterbath.        The Following Reagents are Needed:    -   Sample units (liquid or tissue)    -   Phosphate buffered saline (PBS)    -   Ethanol (96-100%)    -   Water for molecular biology (0.2 μm-filtered, DEPC-treated,        autoclaved, and free of DNases, RNases, proteases, and        phosphatases)    -   QIAamp DNA-Mini-Kit        Preparation of Solutions:    -   1. Mix buffer AL thoroughly by shaking before use. Buffer AL is        stable for 1 year when stored at room temperature. If a        precipitate has formed in buffer AL, dissolve by incubating at        70° C.    -   2. Buffer AW 1 is supplied as a concentrate. Add 125 ml ethanol        (96-100%) before first use. Buffer AW 1 is stable for 1 year        when stored closed at room temperature.    -   3. Buffer AW 2 is supplied as a concentrate. Add 160 ml ethanol        (96-100%) before first use. Buffer AW 2 is stable for 1 year        when stored closed at room temperature.    -   4. Equilibrate samples to room temperature.    -   5. Heat a waterbath or thermomixer to 56° C.    -   6. Equilibrate the desired elution buffer (buffer AE or water)        to room temperature.    -   7. All centrifugation steps should be carried out at room        temperature.        Procedure:    -   1. Add 200 μl Buffer AL to the sample. Mix by pulse-vortexing        for 15 sec.    -   2. Incubate at 56° C. for 10 min. A longer incubation may lead        to DNA degradation!    -   3. Add 200 μl ethanol (96-100%) to the sample, and mix by        pulse-vortexing for 15 sec. After mixing, briefly centrifuge the        1.5 ml reaction tube to remove drops from the inside of the lid.    -   4. Carefully apply the mixture from step 3 on a QIAamp spin        column previously placed in a 2 ml collection tube without        wetting the rim. Close the cap and centrifuge at 6,000×g (8,000        rpm) for 1 min. Place the QIAamp spin column in a clean 2 ml        collection tube (provided), and discard the tube containing the        filtrate.    -   5. Carefully open the QIAamp spin column and add 500 μl buffer        AW 1 without wetting the rim. Close the cap and centrifuge at        6,000×g (8,000 rpm) for 1 min. Place the QIAamp spin column in a        clean 2 ml collection tube (provided), and discard the        collection tube containing the filtrate.    -   6. Carefully open the QIAamp spin column and add 500 μl buffer        AW 2 without wetting the rim. Close the cap and centrifuge at        full speed 20,000×g (14,000 rpm) for 3 min.    -   7. Discard the filtrate, dry the collection tubes by beating        them on a kleenex tissue on the bench, insert the column and        spin again for 1 min at 8,000 rpm to remove residual ethanol        present in AW2.    -   8. Place the QIAamp spin column in a clean 1.5 ml reaction-tube,        and discard the collection tube containing the filtrate.        Carefully open the QIAamp spin column and add an adequate volume        (50-150 μl) of warm (˜40° C.) buffer AE or water.    -   9. Incubate at room temperature for 1 min, and then centrifuge        at 6,000×g (8,000 rpm) for 1 min.    -   10. Take the eluate and pipet it a second time on the QIAamp        spin column. Incubate at room temperature for 1 min, and then        centrifuge at 6,000×g (8,000 rpm) for 1 min. Incubation of the        QIAamp spin column loaded with buffer for 5 min at room        temperature before centrifugation generally increases DNA yield.    -   11. For immediate use, a storage at +4° C. in the fridge is        acceptable, while for long term, storage at −20° C. is        recommended.    -   12. Optional, the quality and the quantity should be checked by        measurement with the photometer. A sample of 200 μl whole human        blood typically yields 6 μg of DNA in 200 μl water (30 ng/μl)        with an A260/A280 ratio of 1.7-1.9. A further quality control of        the DNA status would be to load around 5 μl (1 μl sample+4 μl        water) on an 0.8% agarose gel. By this check, the level of DNA        degradation and the average fragment size as well as the rough        concentration can be determined.

Example 5 a) Bisulfite treatment and b) DNA Purification with Microron™Device and Using Dioxane

Equipment Needed:

-   -   thermo cycler (e.g. Eppendorf, Tetrad)    -   centrifuge (capable of up to 14,000×g)    -   pipettors for volumes of 100 μl and 1,000 μl        Material Needed:    -   Microcon Centrifugal Filter devices, Microcon® YM-30,        Millipore/Amicon    -   Pipet tips (100 μl, 1,000 μl)    -   200 ul PCR tubes, thin wall    -   1.5 ml reaction-tubes    -   15 ml and 50 ml Falcon tubes        Chemicals Needed:    -   sodium bisulfite (Na₂S₂O₅, MW=190.1 g/mol), Merck 1.06528.0500    -   sodium sulfite, anhydrous (Na₂SO₃, MW=126.04 g/mol), Fluka 71988    -   ddH₂O molecular biology grade (0.2 μm filtered, DEPC-treated,        autoclaved, free of DNases and RNases)    -   1,4-dioxane, stabilized (MW=88.11 g/mol), Riedel de Haën 33147    -   6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid        (MW=250.29 g/mol), Aldrich 23,881-3    -   Tris-hydroxymethyl-aminomethan (M=121.14 g/mol), Merck        1.01549.0500    -   sodium hydroxide pellets (MW=40 g/mol), Merck 1.06482.1000    -   EDTA (Titriplex® III, MW=372.24 g/mol), Merck 1.08418.0250        Preparation of Solutions:    -   Bisulfite solution: Sodium disulfite (4.708 g) and sodium        sulfite (1.128 g) are dissolved by adding 10 ml ddH₂O (the        solution is 4.9 M). Check pH of the solution—if it is not        between 5.45 and 5.5, discard solution and repeat preparation.        Shake rigorously and if needed, heat the solution to 50° C. in a        waterbath than vortex at max speed for 30 sec. Repeat this        procedure as often until the salt is completely dissolved.    -   Dioxane-radical scavenger solution: Dissolve 197.2 mg of        6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid by        adding 5 ml 1,4-dioxane. Vortex rigorously in order to ensure        that no undissolved particles remain. Dioxane is hazardous.        Therefore take appropriate precautions when handling this        chemical. If only few samples are to be bisulfite treated,        prepare smaller volumes.    -   NaOH 0.2 M: Dissolve 0.32 g sodium hydroxide in 40 ml ddH₂O.    -   TE buffer: 10 mmol/l Tris, 0.1 mmol/l EDTA, pH 8.        General:    -   This procedure can be applied to a single sample or many samples        in parallel.    -   The working solutions should not be stored over prolonged        periods of time. It is best to prepare them fresh and scale the        solutions according to the number of samples to be processed.    -   All solutions collected as waste in this procedure should be        collected e.g. in a glass bottle and finally discarded as        halogen-free organic solvents.        Procedure:

Pipet the following solutions into a 200 ul PCR tube in the order shown:

-   -   1. 20 μl buffer/water containing the DNA to be bisulfite        treated.    -   2. 85 μl bisulfite solution.    -   3. 35 μl dioxane solution, containing the radical scavenger        (total volume of the reaction mixture is 140 μl)        Temperature Program:    -   5:00 min denaturation of DNA at 99° C.    -   25 min incubation at 60° C.    -   5:00 min denaturation of DNA at 95° C.    -   1:25 hours incubation at 60° C.    -   5:00 min denaturation of DNA at 95° C.    -   2:55 hours incubation at 60° C.    -   cooling at 20° C. forever

Due to the high molarity of the bisulfite salts some of the salt mayprecipitate. These precipitates will not affect the bisulfite reaction.

DNA Purification:

-   -   1. After incubation is over, transfer reaction solution (140 μl)        into 1.5 ml collection tube, add 260 μl ddH₂O into the        collection tube.    -   2. Mix by vortexing.    -   3. Take all of this solution (400 μl) and pipet it into the        sample reservoir of an assembled Microcon filter device. (Do not        touch the membrane with the pipet tip!)    -   4. Seal with the attached cap.    -   5. Place the assembly into the centrifuge, align the cap strap        towards the center of the rotor and spin 15 min at 14,000×g        (=rcf).    -   6. After the spin take out assembly and discard flowthrough.    -   PLEASE NOTE: the centrifugation efficacies may vary depending on        the particular centrifuge model and instrument used. Therefore        for all centrifugation steps always check whether the sample        volume passed through the membrane! If needed, increase the spin        times in 2 min steps.    -   7. Take filter assembly out of centrifuge.    -   8. Add 400 μl 0.2 mol/l NaOH to the membrane.    -   9. Place assembly back to centrifuge and spin 12 min at        14,000×g, discard flowthrough.    -   10. Wash the membrane with by adding 400 μl water and spin for        12 min, discard flowthrough.    -   11. Repeat washing-step two more times.    -   12. The membrane should look moist, but should not be covered by        a visible volume of liquid.    -   13. For elution, take filter assembly out of centrifuge.    -   14. Add 75 μl of prewarmed (50° C.) TE buffer (Tris/HCl 10        mmol/l; EDTA 0.1 mmol/l) into the sample reservoir.    -   15. Incubate for 10 min while shaking on a thermomixer with        1,000 rpm (50° C.).    -   16. Invert the filter device and place it into a new Microcon        1.5 ml tube.    -   17. Spin 5 min at 1,000×g.    -   18. Store DNA at −20° C. for long term storage or at +4° C. for        immediate use.

Example 6 DNA Purification by Means of a QIAamp Viral RNA Mini Kit

Equipment Needed:

-   -   Tube centrifuge    -   Pipettors for volumes of from 10 μl to 1,000 μl        Material Needed:    -   QIAamp Viral RNA Mini Kit (50) (Qiagen cat#52904)    -   Pipet tips (100 μl, 1,000 μl)        Chemicals Needed:    -   Ethanol, molecular biology grade    -   Sodium hydroxide pellets (NaOH, MW=40.0 g/mol), Merck        1.06482.1000        Preparation of Solutions:    -   Desulfonation buffer: Dissolve 0.8 g sodium hydroxide in 10 ml        ddH₂O to prepare a 2 mol/l stock solution. For the desulfonation        buffer mix 1.0 ml 2 mol/l sodium hydroxide and 9.0 ml ethanol.        The solution has to prepared freshly before each purification!    -   AVL-buffer: Add 1 μl of buffer AVL to one tube of lyophilized        carrier RNA. Dissolve thoroughly. Transfer to the buffer AVL        bottle, and mix thoroughly before using buffer AVL for the first        time. This buffer can be stored at 2-8° C. for future use.        However, if a precipitate develops, then redissolve by heating        at 80° C. This should be done no more than a total of 6 times.        Cool to room temperature before use. A small aliquot can be kept        at room temperature for up to 2 weeks.        Procedure:

-   1. For binding of bisulfite treated DNA, pipet 560 μl of prepared    buffer AVL/carrier RNA into the tubes containing 140 μl bisulfite    treated DNA solution. Add 560 μl ethanol to the samples.    Pulse-vortex for 15 sec. Centrifuge briefly.

-   2. Incubate at room temperature for 10 min.

-   3. Load 630 μl of the mixture from step 2 to the QIAamp spin column,    which is placed in a collection tube (pre-labeled). Close the cap    and centrifuge at full speed for 1 min.

-   4. Place the spin column in a clean 2 ml collection tube and load    the rest of the mixture from step 2. Close the cap and centrifuge at    full speed for 1 minute.

-   5. For washing, add 500 μl buffer AW1 to the spin column in a clean    2 ml collection tube. Centrifuge at full speed for 1 min. Discard    the filtrate.

-   6. For desulfonation, add 500 μl 0.2 mol/l NaOH/ethanol to the spin    column in a clean 2 ml collection tube. Incubation for 15 min at    room temperature. Centrifuge at full speed for 1 min.

-   7. Add 500 μl buffer AW2 spin column in a clean 2 ml collection    tube. Centrifuge at 14,000 rpm for 3 min. Discard the filtrate.

-   8. Place the QIAamp spin column in a new 2 ml collection tube.    Centrifuge at 14,000 rpm for 1 min to eliminate possible buffer AW2    carryover. Discard the filtrate.

-   9. Place the QIAamp spin column in a 1.5 ml pre-labeled    micro-centrifuge tube. Add 75 μl buffer AVE to the QIAamp spin    columns. Incubate for 5 min at room temperature. Centrifuge at 9.000    rpm for 1 min.

Example 7 Lysis Step by Means of Heating

-   -   1. Centrifuge 1-6 paraffin-embedded formalin-fixed tissue        sections in a 1.5 ml reaction tube for 5 min at 16,000×g.    -   2. Add 100 μl lysis buffer (50 mmol/l TrisHCl, pH 8.0, 1 mmol/l        EDTA, 0.5 v/v % Tween 20, 5 ng/μl polydA)    -   3. Incubate 10 min at 65° C. with agitation at 1,000 rpm in a        thermomixer.    -   4. Set thermomixer to 50° C. and 1, 400 rpm, leave samples in        thermomixer and allow them to cool down.    -   5. Add 10 μl proteinase K (30 mg/ml).    -   6. Spin down to remove all droplets from the tube wall. Make        sure the tube caps are tightly closed—otherwise loss of liquid        will happen.    -   7. Incubate 40-48 h at 60° C. in a thermomixer with agitation at        1,000 rpm.    -   8. Incubate samples at >95° C. for 10 min in to order to        inactive proteinase K. For this, set the thermomixer temperature        to 99° C. Transfer tubes IMMEDIATELY to another thermomixer        temperated to 50° C., agitate at 1,400 rpm and incubate for 5        min. This avoids the formation of a paraffin film.    -   9. Apply 44 μl of this lysate directly (without further        extraction) to example 8.

Example 8 a) Bisfulfite Treatment and b) DNA Purification by Means ofMicroron™ Device and Using DME

Equipment Needed:

-   -   thermo cycler (e.g. Eppendorf, Tetrad)    -   centrifuge (capable of up to 14,000×g)    -   pipettors for volumes of 100 μl and 1,000 μl        Material Needed:    -   Microcon Centrifugal Filter devices, Microcon® YM-30        (Millipore/Amicon 42410)    -   pipet tips (100 μl, 1,000 μl)    -   200 μl PCR-tubes (e.g. Eppendorf 0030 124.359)    -   1.5 ml tubes (e.g. Eppendorf 0030 120.086)    -   15 ml and 50 ml Falcon tubes        Chemicals Needed:    -   sodium bisulfite (Na₂S₂O₅, MW=190.1 g/mol), Merck 1.06528.0500    -   sodium sulfite, anhydrous (Na₂SO₃, MW=126.04 g/mol), Fluka 71988    -   ddH₂O molecular biology grade (0.2 μm filtered, DEPC-treated,        autoclaved, free of DNases- and RNases)    -   diethyleneglycoldimethylether (DME), Merck 8.02934.0250    -   6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid        (MW=250.29 g/mol), Aldrich 23,881-3    -   Tris-hydroxymethyl-aminomethan (C₄H₈O₂, MW=121.14 g/mol), Merck        1.01549.0500    -   sodium hydroxide pellets (NaOH, MW=40.0 g/mol), Merck        1.06482.1000    -   EDTA (Titriplex® III, C₁₀H₁₄N₂O₈Na₂*2H₂O, MW=372.24 g/mol),        Merck 1.08418.0250        Preparation of Solutions (Sufficient for 80 Reactions):    -   Bisulfite solution: Sodium disulfite (4.708 g) and sodium        sulfite (1.128 g) are dissolved by adding 10 ml ddH₂O (the        solution is 4.9 M). The final volume is around 12 ml. Check pH        of the solution—if it is not between 5.45 and 5.5, discard        solution and repeat preparation. Shake rigorously and if needed,        heat the solution to 50° C. in a waterbath than vortex at        maximum speed for 30 sec. Repeat this procedure as often until        the salt is completely dissolved.    -   DME-radical scavenger solution: Dissolve 125.3 mg of        6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid by        adding 1.0 ml DME. Vortex rigorously in order to ensure that no        undissolved particles remain. If only few samples are to be        bisulfite treated, prepare smaller volumes.    -   NaOH 0.2 M: dissolve 0.32 g sodium hydroxide in 40 ml ddH₂O.    -   TE buffer: 10 mmol/l Tris, 0.1 mmol/l EDTA, pH 8.        General:    -   This procedure is designed to be applied in 200 μl PCR-tubes.        The total number of samples is limited by the number of tubes        that can be handled in the thermocyclers, centrifuges, etc.    -   The working solutions should not be stored over prolonged        periods of time. It is best to prepare them fresh and scare the        solutions according to the number of samples to be processed.    -   All solutions collected as waste in this procedure should be        collected e.g. in a glass bottle and finally discarded as        halogen-free organic solvents        Procedure Bisulfite Treatment:

Pipet the following solutions into PCR-tubes in the order shown.

-   -   1. 45 μl buffer/water containing the DNA to be bisulfite        treated.    -   2. 83 μl bisulfite solution.    -   3. 13 μl DME solution, containing the radical scavenger.    -   4. Mix thoroughly.    -   5. Place in 0.2 ml wells of thermocycler.

The total volume of the reaction mixture is 141 μl! Tightly close thecaps of PCR-tubes!

Temperature Protocol:

-   -   5:00 min denaturation of DNA at 99° C.    -   22:00 min incubation at 60° C.    -   3:00 min denaturation of DNA at 99° C.    -   1:27:00 hours incubation at 60° C.    -   3:00 min denaturation of DNA at 99° C.    -   2:57:00 hours incubation at 60° C.    -   Cooling at 20° C.

Due to the high molarity of the bisulfite salts some of the salt mayprecipitate. These precipitates will not affect the bisulfite reaction.

Procedure DNA Purification:

-   -   After incubation is over, transfer reaction solution (141 μl)        into 1.5 ml collection tube.    -   Add 260 μl ddH₂O to the collection tube.    -   Close caps, vortex intensively and spin shortly to remove drops        from lid.    -   Take all of this solution (400 μl) and pipet it into the sample        reservoir of an assembled Microcon filter device—do not touch        the membrane with the pipet tip!    -   Seal with the attached cap.    -   Place the assembly into the centrifuge, align the cap strap        towards the center of the rotor and spin 15 min at 14,000×g        (=rcf).    -   After the spin take out assembly and discard flowthrough.    -   PLEASE NOTE: the centrifugation efficacies may vary depending on        the particular centrifuge model and instrument used. Therefore        for all centrifugation steps always check whether the sample        volume passed through the membrane! If needed, increase the spin        times in 2 min steps.    -   For desulfonation, add 400 μl 0.2 mol/l NaOH to the membrane.    -   Place assembly back to centrifuge and spin 12 min at 14,000×g.        Take out assembly and discard flowthrough.    -   Add 400 μl ddH₂O.    -   Place assembly back to centrifuge and spin 12 min at 14,000×g.        Take out assembly and discard flowthrough.    -   Repeat this step two additional times!    -   PLEASE NOTE: after this the membrane should look moist, but        should not be covered by a visible volume of liquid.    -   For elution of the DNA, take filter assembly out of centrifuge.    -   Add 75 μl of prewarmed TE buffer (50° C.) into the sample        reservoir. (Note: If the total amount of is critical, elution        should be performed by 2 subsequent elution steps, e.g. 2×37.5        μl—should be defined prior to each study)    -   Incubate for 10 min at 50° C. while shaking in a thermomixer at        1,000 rpm.    -   Invert the filter device and place it into a new Microcon 1.5 ml        tube.    -   Elute DNA from membrane by spinning 5 min at 1,000 g.    -   (if desired transfer DNA to a new tube—the lid of Microcon tubes        tends to open quickly)    -   store DNA at −80° C. for long term storage or at +4° C. for        immediate use.

Example 9 9.1. Sample Sets

9.1.1. Estrogen Receptor Positive (ER+) Nodal Status Negative (N0)Untreated Population

ER+ N0 tumor samples from patients not treated with any adjuvant therapywere analyzed. Markers that are able to show a significant survivaldifference in this population are considered to be prognostic. Sinceadjuvant therapy has become the routine regiment for breast cancerpatients for many years, the collected sample set is a historical onefrom the Eighties of the last century.

All 508 samples of this set were obtained from the Erasmus MedicalCenter in Rotterdam as cell nuclei pellets (fresh frozen samples).

9.1.2. ER+ N0 Tamoxifen (TAM) Treated Population

The target population of the final test is supposed to be patients withER+ N0 tumors that are treated with hormone therapy. To check theperformance of the marker candidates in this population, 589 samplesfrom ER+ N0 tumors from patients treated with Tamoxifen were analyzed.All samples were received as paraffin-embedded formalin-fixed tissues(PET). Three to ten 10 μm sections were provided.

-   -   In addition, for 89 PET patient samples matching fresh frozen        samples from the same tumor were included into the study as        controls.

9.2. DNA Extraction

9.2.1. DNA extraction from Fresh Frozen Samples

From a total of 508 fresh frozen samples available as cell nucleipellets, genomic DNA was isolated using the DNeasy Tissue Kit (Qiagen,Hilden, Germany). The extraction was done according to the Cell Cultureprotocol using Proteinase K with few modifications.

20 μl of Proteinase K (Qiagen, Hilden, Germany) were pipetted into a 2ml reaction tube (Eppendorf, Hamburg, Germany) containing the pellets.200 μl PBS buffer was added and pulse-vortexed overnight at 37° C.Another 200 μl of AL buffer were added and subsequently pulse-vortexedagain at 56° C. for 10 minutes. After incubation at 70° C. for 10minutes, 200 μl ethanol (96%) was added and incubated for 15 seconds.The mixture was applied to a column and centrifuged at 6,000×g for 1min. The column was placed into a provided 2 ml collection tube and 500μl buffer AW 1 was added. After centrifugation at 6,000×g for 1 minute,500 μl AW 2 buffer was added to the column placed in another provided 2ml collection tube followed by centrifugation at 20,000×g for 3 min. Thecollection tube was kept open to dry the DNA pellet for several minutesand spin again at 6,000×g to remove residual ethanol present in bufferAW 2. The column was placed into an clean 1.5 ml reaction tube(Eppendorf, Hamburg, Germany) and 60 μl of prewarmed (˜40° C.) buffer AEwas added. After incubation at room temperature for 1 min, samples werecentrifuged at 6,000×g for 1 min. The eluate was pipetted a second timeon the column incubated again at room temperature for 1 min with thefollowing step of centrifugation under same conditions. The quality andquantity of the extracted genomic DNA was checked by photometricalmeasurement (A260 and A280). Extracted DNA was stored at −20° C. untilfurther processing.

9.2.2. Deparaffination, Lysis, and DNA Extraction from Paraffin-EmbeddedFormalin-Fixed (PET) Samples

For deparaffination, 589 provided paraffin-embedded formalin-fixed (PET)samples were processed directly in the tube in which they were deliveredby the providers. 1 ml of limonene was added to each tube whichcontained 3 to 10 sections, each about 10 μm thick and incubated at roomtemperature for 10 minutes. During incubation they were vortexedrigorously several times (2-4×5 seconds). The paraffin samples werecentrifuged at 16,000×g for 5 minutes. The limonene supernatant wasremoved very carefully by placing a pipet onto the opposite side of thepellet. If no pellet was received, centrifugation was repeated at higherspeed (20,000×g) for the same time and the remaining limonene wasremoved. Afterwards 1 ml of EtOH (purity>99%) was added and incubated atroom temperature for 10 minutes while vortexing 2-3 times. Then thetubes were centrifuged at 16,000×g for 5 min. As much ethanol aspossible without disturbing the pellet was removed by pipetting.Residual ethanol not removed by pipetting was evaporated by incubationin a thermomixer at 50° C. for 10 up to 30 minutes.

For lysis of the tissue, 150 μl lysis buffer (50 mmol/l TrisHCl, pH 8.0,1 mmol/l EDTA, 0.5% Tween (volume %), TRIS(tris-hydroxymethyl-amino-methan), Merck, no 1.01549.0500, Sodium EDTA(Titriplex III) from Merck, no. 159294, Tween (Tween20), Fluka, no.93773) as well as 20 μl proteinase K (10 mg/ml stock solution in H₂O,Roth, Karlsruhe) was added to each deparaffinated sample. Aftervortexing rigorously, samples were shortly centrifuged and incubated ona thermoshaker at 50° C. During the incubation period of about 40 hours,proteinase K was added every 8-12 hours (altogether three times). Thetubes were always briefly centrifugated before opening to avoidcontamination. After the lysis step, samples were checked to be clear,containing no debris anymore. Subsequently the inactivation ofproteinase K was done by incubation the lysed samples at 95° C. for 10minutes. If lysed samples were not directly used for DNA extraction,they were stored at −20° C.

The DNA-Isolation from lysates of paraffin-embedded formalin-fixedtissue (PET) samples was done with the DNeasy Tissue kit (Qiagen cat no.69504 [50 columns] or 69506 [250 columns]) with few modifications. 200μl buffer AL was added to 210 μl room temperature equilibrated lysateand mixed thoroughly by vortexing. This mixture was placed into athermomixer and incubated at 70° C. while shaking for 10 minutes. Then200 μl 96% ethanol was added and mixed by pulse-vortexing for 15 sec.After a brief centrifugation, the whole mixture was applied onto acolumn which was placed into a 2 ml collection tube (Qiagen provided).This was followed by centrifugation at 6,000×g for 1 minute. Afterwardsthe column was placed into a 2 ml collection tube (Qiagen provided) and500 μl of AW 1 buffer was added. Recentrifugation under same conditionswas applied. The column was placed into an additional providedcollection tube and AW 2 buffer was added followed by centrifugation at20,000×g for 3 min. After some minutes of drying, the centrifugationstep was repeated at 20,000×g for 1 minute. To eluate the DNA, thecolumn was placed into a 1.5 ml reaction-tube (Eppendorf, Hamburg,Germany) and 35 μl of elution buffer AE (adjusted to room temperature)was pipetted onto the center of the column. After incubation at roomtemperature for 1 minute, the column was centrifuged at 6,000×g for 1minute. Another 35 μl elution buffer was added to the column and thecentrifugation repeated. Therefore, the final volume of extracted DNAwas appr. 70 μl. DNA was stored −20° C.

9.3. Bisulfite Treatment

9.3.1. Bisulfite Treatment of Fresh Frozen Samples

Extracted genomic DNA was modified by bisulfite treatment. During thebisulfite reaction, unmethylated cytosines are first sulfonated, duringa next step deaminated, and finally desulfonated converting them touracil while 5′-methylcytosin remains unaffected.

In order to avoid potential process biases, all samples were randomizedin batches of about 30 samples regarding their clinical follow-up. Thisrandomization was transferred to the 384 well plate layout of the assayplates resulting in a satisfactorily randomization for these plates aswell. The bisulfite treatment of genomic DNA derived from fresh frozenmaterial was carried out as described in the following. 15 μl of lysedgenomic DNAs was pipetted into a 96 well plate for each bisulfite batchaccording the randomization. Afterwards 60 μl bisulfite solution (4.9 M,pH 5.5; sodium bisulfite, Merck 1.06528.0500, sodium sulfite, anhydrous,Fluka 71988, ddH₂O molecular biology grade) and 25 μl dioxane solutioncontaining the radical scavenger (dioxane-radical scavenger solution:98.6 mg of 6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid,Aldrich 23, 881-3 with 2.5 ml 1,4-dioxane, Riedel de Haën 33147) wereadded to each well. The total volume of 100 μl per well were sealed bycap-strips.

The reaction mixture was thermocycled by the following protocol:

5:00 min denaturation of DNA at 99° C.

1:30 min cooling down to 4° C.

23:30 min incubation at 50° C.

3:00 min denaturation of DNA at 99° C.

1:30 min cooling at 4° C.

1:25:30 hours incubation at 50° C.

3:00 min denaturation of DNA at 99° C.

1:30 min cooling at 4° C.

2:55:30 hours incubation at 50° C.

cooling down to 4° C.

After incubation, the reaction was transferred into a 500 μl collectiontube (Eppendorf no. 124.502, Hamburg, Germany) and 300 μl ddH₂O wasadded to increase the solubility of the bisulfite salts.

The whole mixture of 400 μl was pipetted into a sample reservoir of anassembled Microcon™ filter device (Microcon™ YM-30, 42410, Millipore,USA) and sealed with the attached cap. The assembly was centrifuged at14,000×g for 15 minutes. After discarding the flowthrough, 400 μl TEbuffer was added and centrifuged again at same speed for 12 minutes. Thewashing step was repeated once. For the desulfonation, 100 μl NaOH 0.2mol/l (Merck no. 1.06482.1000) was added to the filter assembly withouttouching the membrane and incubated at room temperature for 10 minutes.The assembly was centrifuged again at same speed for 10 minutes. Theresidual sodium hydroxide solution was removed by washing the membranewith 400 μl TE buffer and centrifugation at same speed for 12 minutes.For elution of the bisulfite converted DNA (bisDNA), 50 μl of prewarmedTE buffer (50° C.) (10 mmol/l Tris, Merck no. 1.01549.0500; 0.1 mmol/lEDTA, pH 8, Merck no. 1.08418.0250) were pipetted into each samplereservoir and incubated at room temperature for 10 minutes. Subsequentlythe filter device was inverted and placed into a new Microcon 1.5 mltube and centrifuged at 1,000×g for 5 minutes. The bisulfite treated DNAsamples were transferred into a new 96 well plate according to theirspecified sample order. The bisulfite treated DNA samples were stored at−20° C.

9.3.2. Bisulfite Treatment of Paraffin-Embedded Formalin-Fixed Tissue(PET) Samples

The bisulfite treatment of genomic DNA derived from paraffin-embeddedformalin-fixed tissue was done according to example 5. For this process,the samples were randomized not only regarding to their clinicalfollow-up but also regarding to their providers. For paraffin-embeddedformalin-fixed (PET) samples, half of the volume obtained from DNAextraction was used for subsequent bisulfite reaction.

The procedure was especially designed for bisulfite-treatment ofparaffin embedded formalin-fixed tissue samples (PET-samples) toincrease the resulting bisDNA amount. Therefore, two bisulfite reactionsof the same DNA sample were performed and purified on one Microconspin-column. The following modifications compared to the fresh frozenprotocol (see above) were conducted. The first step of pipetting 15 μlof lysed genomic DNAs into a 96 well plate with 60 μl bisulfite solution(for ingredients see above) and 25 μl dioxane solution (for ingredientssee above) containing the radical scavenger was done twice for each DNAsample. The incubation step was performed with the same thermocyclerprogram as for the fresh frozen samples. After incubation, bothreactions (200 μl in total) originating from the same sample DNA weretransferred into one 500 μl collection tube (Eppendorf no. 124.502,Hamburg, Germany) while each well was washed with 100 μl ddH₂O and alsotransferred to the collection tube containing finally 400 μl reactionsolution. After mixing briefly, the solution was pipetted into thesample reservoir of an assembled Microcon™ filter device and purified,desulfonated and eluted as the fresh frozen sample DNA. The bisulfitetreated DNA samples were stored at −20° C.

9.4. Preparation of DNA Standards for QM Assays

9.4.1. Preparation of Quantification Standards

2,000 ng batches of human genomic DNA (Promega) were treated withbisulfite. For this 100 μl DNA (2,000 ng) are mixed with 354 μlbisulfite solution and 146 μl dioxane solution. Therefore the followingtemperature program was applied for bisulfite reaction: 1. Water bath at95° C. for 3 min; 2. Thermomixer at 50° C. for 30 min, shaking at 1,000rpm; 3. Water bath at 95° C. for 3 min.; 4. Thermomixer 50° C., 1.5hours, shaking at 1,000 rpm; 5. Waterbath 95° C., 3 min; 6. Thermomixer50° C. for 3 hours, shaking 1,000 rpm). The desalting, washing anddesulfonation was done via Microcon™ YM-30 columns (Millipore/Amicon)following the working instructions. Quantification of the standard DNAwas done with UV spectrometer.

9.4.2. Preparation of Calibration Standards

Molecular-Displacement (MDA) DNA

Molecular-displacement (MDA) DNA is generated according to theGenomiPhi™ DNA amplification kit (Amersham Bioscience). In brief,genomic DNA is applied to Phi-DNA-polymerase in the presence of randomprimers. This leads to a whole genome amplification of DNA fragmentswhich are unmethylated.

Sss1 Treatment

To generate methylated MDA DNA, 13 tubes of 4.5 μg MDA-DNA (700 ng/μl)was treated with Sss1 in the following reaction with a total volume of75 μl (keep reaction-solutions on ice)

-   -   4.5 μg MDA-DNA (6.3 μl)    -   57.3 μl H₂0    -   0.375 μl 200×SAM    -   3 μl (12 U) Sss1    -   7.5 μl NE-buffer2

Incubation was performed at 37° C. in a water bath. After appr. 3 h,0.375 μl SAM was added and after another 5 h, 3 μl Sss1 were added (2times). Incubate over night and subsequently inactivate at 65° C. for 10min. Pool all 13 tubes (975 μl) take 967 μl and place DNA in a new 10 mlFalcon tube. Add 2 times 967 μl water (20 ng/μl) and aliquotate the DNAin 25×1.5 ml Eppendorf tubes containing 100 μl each (2 μg).

Bisulfite Treatment of MDA-DNA Sss1 Treated

24 tubes each 2 μg were bisulfite treated. This was done by mixing 100μl DNA with 354 μl bisulfite solution and 146 μl dioxane solution.Thereafter the following temperature program was applied for bisulfitereaction: 1. Waterbath at 95° C., 3 min.; 2. Thermomixer at 50° C., 30min, shaking at 1,000 rpm; 3. Waterbath at 95° C. 3 min.; 4. Thermomixer50° C., 1.5 hours, shaking at 1,000 rpm; 5. Waterbath 95° C. for 3 min.;6. Thermomixer 50° C., shaking 1,000 rpm, 3 hours. The desalting,washing and desulfonation was done via Microcon™ YM-30 columns(Millipore/Amicon).

Bisulfite Treatment of MDA-DNA Not Sss1 Treated

For bisulfite treatment of MDA-DNA, take 82.9 μl MDA-DNA (700 ng/μl) andplace in a new 10 ml Falcon tube. Add 3 times 939 μl water (20 ng/μl),aliquotate the DNA in 25 1.5 ml Eppendorf tubes containing 100 μl each(2 μg), perform 24 times the following: Mix 100 μl DNA with 354 μlbisulfite solution and 146 μl dioxane solution and apply thereafter thefollowing temperature program for bisulfite reaction: 1. Waterbath at95° C., 3 min.; 2. Thermomixer at 50° C., 30 min, shaking at 1,000 rpm;3. Waterbath at 95° C. 3 min.; 4. Thermomixer 50° C., 1.5 hours, shakingat 1,000 rpm; 5. Waterbath 95° C. for 3 min.; 6. Thermomixer 50° C.,shaking 1,000 rpm, 3 hours. The desalting, washing and desulfonation wasdone via Microcon™ YM-30 columns (Millipore/Amicon).

Quantification of Bisulfite Converted MDA-DNA Sss1 Treated—and MDA-DNAnot Sss1 Treated

MDA-DNA Sss1 treated and MDA-DNA not Sss1 treated was diluted 1 to 2 and1 to 10 each sample, and DNA concentration was determined in duplicatesusing the C3 assay and the quantification standard prepared according to9.4.1. Both standards were diluted 1 to 10 and 1 to 100. Afterwards, 10μl were used for UV quantification.

Determination of Sulfite Concentration in MDA-DNA Sss1 Treated—andMDA-DNA not Sss1 Treated

Determination of residual sulfite was performed using the MerckSulfit-Küvettentest 1.1 (Merck, Darmstadt) according to the proceduredescribed for sample measurement. The sulfite concentrations were below100 mg/l resulting in values further below the critical value of 50 mg/lsulfite in the PCR via dilution of the stock solution.

Preparation of Calibration Standard Mixtures

Calibration standards were prepared using the stock solutions of MDA-DNASss1 treated—and of MDA-DNA not Sss1 treated separately for the samplessets of the ER+ N0 untreated population and ER+ N0 TAM treatedpopulation according to Table 1a. For that, we prepared DNA solutions of14 different methylation level (logarithmical series) with theconcentration of 1 ng/μl and distributed 40 μl of each level to several96 well plates (plate 05) for automatic pipetting into 384 well assayplates. TABLE 1a Preparation of calibration standards. MDA-DNA Sss1treated - and MDA-DNA not Sss1 treated were mixed in the indicatedratios. STARNDARD DNAs MDA DNA 22.0 ng/μl Sss1 treatedMDA- 28 μg/μl DNA% +μl H2O -> methylation up down ng needed ng up ng down μl up μl down10 ng/μl  0 0 1.00 1500 0 1500 0 75 90  4 0.04 0.98 1500 60 1440 2.36 7290.64 10 0.1 0.90 1500 150 1350 5.89 67.5 91.61 17 0.17 0.83 1500 2551245 10.02 62.25 92.73 25 0.25 0.75 1500 375 1125 14.73 56.25 94.02 340.34 0.66 1500 510 990 20.04 49.5 95.46 44 0.44 0.56 1500 660 840 25.9342 97.07 50 0.5 0.50 1500 750 750 29.46 37.5 98.04 56 0.56 0.44 1500 840660 33 33 99 66 0.66 0.34 1500 990 510 38.89 25.5 100.61 75 0.75 0.251500 1125 375 44.2 18.75 102.05 83 0.83 0.17 1500 1245 255 48.91 12.75103.34 90 0.9 0.10 1500 1350 150 53.04 7.5 104.46 96 0.96 0.04 1500 144060 56.57 3 105.43 100  1 0.00 1500 1500 0 58.93 0 106.07 441.96 562.5Verification of Methylation Status of Bisulfite Treated DNA

To check the methylation status of the MDA-DNA Sss1 treated—and MDA-DNAnot Sss1 treated, a bisulfite sequencing was performed. Both types ofDNA were amplified using the following primer pairs producing fragmentscovering the regions that were amplified by the QM assays. The length ofthe PCT products for sequencing is between 200 and 500 bp. Primer2064:300P22 Primer 2064:514O22 Seq ID NO 1: Seq ID NO 2:GGAGGGGGTAGAGTTATTAGTT TATACTTCCTCAAACAACCCTC Primer 4063:1431P22 Primer4063:1868O20 Seq ID NO 3: Seq ID NO 4: GTGATATTTGGGGATTGTTATTACTCCCTCCCCTATCTTACA Primer 15665:699P21 Primer 15665:1124O22 Seq ID NO5: Seq ID NO 6: TTTGTTGGGATTTGTTAGGAT AAACATTTTACCCCTCTAAACC Primer15947:907P24 Primer 15947:1360O23 Seq ID NO 7: Seq ID NO 8:TGATTGTGTAGATTATTTTTGGTT CAAACTCTCTAAACCTCAATCTC Primer 2265:176P22Primer 2265:582O22 Seq ID NO 9: Seq ID NO 10: TTGGTGATGTTGATTAGAGTTTTAAAACACCTTACATTTTCCCT Primer 15908:782P22 Primer 15908:1228O23 Seq IDNO 11: Seq ID NO 12: GGTAGAGGAAGTAGTTGGTTTG CTTTTATATTTCTCCCAATCTCCPrimer 0003522:2102Q21 Primer 0003522:1738R23 Seq ID NO 13: Seq ID NO14: GTAGGGGAGGGAAGTAGATGT TCCTCAACTCTACAAACCTAAAA

Bisulfite sequencing was done according to standard protocols and wasperformed on a ABI 3770 sequencer (96 well plate). The expectedsequences and methylation ratios could be confirmed for the usedfragments (data not shown).

9.5. Quantification and Adjustment of Bisulfite DNA Concentration

9.5.1. Determination of Sulfite Concentration in Bisulfite DNA

Increased concentrations of residual sulfite influence the QM-assay.Therefore, we decided to determine the sulfite concentration for each ofthe bisulfite treated samples of both sample sets. Increased sulfite(higher 50 mg/l in the PCR reaction) affects the PCR amplification ofthe bisulfite DNA resulting in higher CT-values compared to sulfiteconcentrations below this range. CT-values represent the threshold cycleor the crossing point of a real time PCR.

Sodium sulfite was used to prepare a sulfite standard stock solutionwith 1 g/l SO₃ ²⁻ in 1×TE buffer. We produced standard solutions from100 mg/l to 1.56 mg/l sulfite via stepwise dilution and intensivevortexing between 2 dilution steps to produce the standard curve. TABLE2 Sulfite-standards for sulfite test. Sulfite-standards for sulfite testin 384 MTP addition of standard solution addition TE conzentrationnumber in μl number μl SO₃ ²⁻ [mg/l] 1 100 Stock 900 100 2 500 1 500 503 500 2 500 25 4 500 3 500 12.5 5 500 4 500 6.25 6 500 5 500 3.13 7 5006 500 1.56sample stock and 27 μl of ddH₂O were mixed. 10 μl of the pre-dilutedsample and 10 μl sulfite reagent (Sulfit-Kuvettentest—Merck,1.14394.0001) was placed in a 384 well plate and vortexed. After 2minutes of waiting time the absorbance of the solution was measured witha Photometer-Plate reader at 412 nm. The sulfite concentration wasdetermined according to the calibration curve in mg/l sulfite.Results

The amount of sulfite determined for the stock solution of all samplesof the ER+ N0 untreated population were between 0-390 mg/l. The sulfiteamount was reduced up to 0-30 mg/l for the entire sample set afteradjustment of the sample concentration to 1 ng/μl, except for 1 sample.Here we measured exactly the limit value of 100 mg/l.

The sulfite concentration of the sample set ER+ N0 TAM treatedPopulation was determined with 0-1195 mg/l sulfite. The sulfiteconcentration for 7 samples was in a critical, but still acceptablerange (between 50 und 100 mg/l) and for 2 samples over 100 mg/l (120mg/l).

In conclusion, residual sulfite in bisulfite treated DNA was no majorissue.

9.5.2. Real-Time PCR Based Quantification of Bisulfite DNA

The GSTP1-C3 assay design makes it suitable for quantitating DNAs fromdifferent sources, including fresh/frozen samples, remote samples suchas plasma or serum, and DNA obtained from archival specimen such asparaffin-embedded formalin-fixed material. Table 3 provides an overviewof fragment and oligonucleotide sequences. TABLE 3 Sequence informationof C3 fragment and oligos GSTP1 gene - Genbank number for genomicsequence: AY324387 GSTP1-C3 130 bp bis-sequence Seq ID No 15:GGAGTGGAGGAAAtTGAGAtttAtTGAGGTTACGTAGTTTGtttAAGGTtAAGttTGGGTGttTGtAATttTTGtttTGTGttAGGtTGttTtttAGGTGTtAGGTGAGtTtTGAGtAttTGtTGTGTGG Primer 2111.C3F Seq ID NO 16:GGAGTGGAGGAAAtTGAGAt Primer 2111.C3R Seq ID NO 17:CCACACAaCAaaTaCTCAaAaC TaqMan probe C3-TAQ2 Seq ID NO 18:FAM-TGGGTGTTTGTAATTTTTGTTTTGTGTTA GGTT-TAMRA

The preparation of the quantification standard DNA was described in9.4.1. The DNA concentration was adjusted between 4-0.0312 ng/μl andplaced into a 96 well format for automatic pipetting into a 384 well PCRassay plate. Each calibration standard DNA was amplified up to 3× (lightgreen on the 96 well plate and 384 PCR plate). TABLE 4 DNA amounts andserial dilution steps for quantification of bisulfite treated DNAsamples. Step  and ng DNA per PCR dilution of stock 40.000 ng  1  120.000 ng  2  1:2 10.000 ng  3  1:4 5.000 ng 4  1:8 2.500 ng 5  1:161.250 ng 6  1:32 0.625 ng 7  1:64

TABLE 5 96 well plate with calibration standard DNA, plate 05. 96 wellplate with quantification standard, plate 05 1 2 3 4 5 6 7 8 9 10 11 12A 40 ng Ntc B 20 ng Ntc C 10 ng Ntc D 5 ng Ntc E 2.5 ng F 1.25 ng G0.625 ng H 0.312 ng(Ntc. = No template control)

The Mastermix for the entire 384 PCR plate was pipetted according toTable 6, mixed in a 15 ml falcon tube and distributed to 8×500 μl screwcap vials for automatic pipetting with TECAN workstation. TABLE 6 PCRmastermix preparation for C3 assay quantification. final solutionConcentration volume concentration provider PCR buffer 10x 2 μl 1xEurogentec dNTP mix 25 mmol/l 0.2 μl 250 μmol/l Fermentas (each) (each)MgCl₂ 25 mmol/l 2.4 μl 3 mmol/l Eurogentec DNA 5 U/μl 0.2 μl 1 unitEurogentec polymerase Primer 5 μmol/l 1.25 μl 0.313 MWG mixture (each)μmol/l TaqMan 10 μmol/l 0.6 μl 0.3 μmol/l TibMolBiol probe water — 3.35μl — Fluka diluted DNA — 10 μl — — Total react. 20 μl volume

TABLE 7 PCR cycling conditions for C3 assay at ABI 7700 or 7900instrument. 1 Initial 95° C. 10 min denaturation 2 Denaturation 95° C.15 sec 3 Annealing/extension 58° C. 60 sec 4 Cycling Repeat steps (2 +3) 45x

The bisulfite treated DNA samples of the ER+ N0 untreated populationwere stored in 7×96 well plates (plate 01-07) and of the ER+ N0untreated population in 8×96 well plates (plate 01-08). To quantify allsamples, 3 μl of the sample was taken and 27 μl water were added. Thisresults in a 1:10 dilution of the DNA stock concentration. Furthermoreadditional 3 μl of the first dilution (1:10) were diluted again with 27μl of water to obtain a 1:100 dilution of the stock DNA. This processresults in 2 dilution plates (1:10 and 1:100) for each sample DNA inseparate 96 well plates. The 384 PCR plates for quantification werepipetted with the TECAN workstation using always 4 (2×1:10 dilution and2×1:100 dilution)×96 well plates. So each quantification PCR runquantified 2 of the DNA stock plates in 2 replicates next to each otherfor each DNA sample. The pipetting program of the TECAN workstationtransferred first 10 μl of the Mastermix and afterwards 10 μl of therespective DNA into the designed well. So DNAs from plate 01 and 02 (oneDNA stock plate) result in orange colors and from plate 03 and 04 inblue colors on the 384 well PCR plate. Standard DNA wells are marked inlight green and negative control PCR reactions in dark green on thefinal plate. TABLE 8 96 well plate with bisulfite treated samples (1:10and 1:100 dilution). 1 2 3 4 5 6 7 8 9 10 11 12 A 01A1 01A2 01A3 01A401A5 01A6 01A7 01A8 01A9 01A10 01A11 B 01B1 01B2 01B3 01B4 01B5 01B601B7 01B8 01B9 01B10 01B11 C 01C1 01C2 01C3 01C4 01C5 01C6 01C7 01C801C9 01C10 01C11 D 01D1 01D2 01D3 01D4 01D5 01D6 01D7 01D8 01D9 01D1001D11 E 01E1 01E2 01E3 01E4 01E5 01E6 01E7 01E8 01E9 01E10 01E11 F 01F101F2 01F3 01F4 01F5 01F6 01F7 01F8 01F9 01F10 01F11 G 01G1 01G2 01G301G4 01G5 01G6 01G7 01G8 01G9 01G10 01G11 H 01H1 01H2 01H3 01H4 01H501H6 01H7 01H8 01H9 01H10 01H11

Results of Quantification TABLE 10 Results of C3 quantification on freshfrozen samples (ER+ N0 untreated population). ER+ N0 untreatedpopulation Concentration Number of Amount of DNA quantified with C3, ngof DNA, ng/μl samples 1807-9992  40-222 57  900-1732 20-40 112 454-89810-20 181 225-442  5-10 90 87.3-221  2-5 36 41.5-81.5 1-2 10 11.7-41.00.25-1   10 0 0.0 12

TABLE 11 Results of C3 quantification on paraffin-embeddedformalin-fixed (PET) samples (ER+ N0 TAM treated population). ER+ N0 TAMtreated Population Amount of DNA quantified Concentration Number of withC3 assay, ng of DNA, ng/μl samples  1813-24500  40-545 75  905-179520-40 52 452-886 10-20 74 225-447  5.0-10.0 72 90.4-225  2.0-5.0 9845.4-88.4 1.0-2.0 69  4.7-45.2 0.1-1   96 0.24-4.5  0.01-0.1  33 0.0 0.0209.5.3. Adjustment of DNA Concentration

According to the resulting concentration determined via quantification,we adjusted each sample to a concentration of 1 ng/μl if possible. Thisconcentration results in up to 10 ng DNA in the QM assay reaction. Forthe adjustment, the DNA samples of one 96 well DNA stock plate werepipetted into a deep well plate using maximal 390 ng, producing aconcentration adjusted copy plate (96 wells). The adjustment step wasalso done with the TECAN workstation pipetting between 4 μl and 32 μl ofDNA and adding the respective amount of water (up to 900 μl) to achieve1 ng/μl. The adjusted DNA solution was afterwards transferred from deepwell plates into several identical 96 well plates for final QM assaypipetting.

Note that not all samples could be adjusted to the desired concentrationof 1 ng/μl due to limited material. Table 12 and Table 13 shows thedistribution of actual amounts of DNA that was used in the QM assays.TABLE 12 Final amount of DNA in QM assay for fresh frozen samples (ER+N0 untreated population) after adjustment. ER+ N0 untreated PopulationAmount of DNA (adjusted) in QM assay Number of samples 10 ng 357 5-10 ng85 2-5 ng 34 1-2 ng 10 0-1 ng 10 0 ng 12

TABLE 13 Final amount of DNA in QM assay for paraffin- embeddedformalin-fixed (PET) samples (ER+ N0 TAM treated population) afteradjustment. ER+ N0 TAM treated Population Amount of DNA (adjusted) in QMassay Number of samples 10-24 ng 9 10 ng 263 5-10 ng 72 2-5 ng 96 1-2 ng41 0-1 ng 88 0 ng 20

9.6. QM Assay Runs

The bisulfite treated DNA and concentration adjusted samples of the ER+N0 untreated population were stored in 7×96 well plates (plate 01-07)and of the ER+ N0 untreated population in 8×96 well plates (plate01-08). To measure the entire sample set of both populations we run2×384 PCR reaction plates for each QM assay and population. Each QMassay plate contains the samples of 3 or 4×96 well plates (88 wellsactually used per plate) and 1×946 well plate with standard DNA (14mixtures of the calibration DNA and water for the no template controlPCR reaction, see Table 15 below). Repetitions of sample measurementswere done by repeating the QM assay run 3 times.

The 384 PCR plates were also pipetted with the TECAN workstation. Thepipetting program transferred at first 10 μl of the mastermix andafterwards 10 μl of the respective DNA into the designed well. Asdescribed for the quantification step, DNAs from plate 01 and 02 resultin orange colors and from plate 03 and 04 in blue colors on the 384 wellPCR plate (see 9.5.2.). Standard DNA wells are signed in light green andnegative control PCR reactions in dark green on the final plate. Thecomponents of the mastermix for each QM assay were adapted according thetable 14. The mixture was pipetted in a falcon tube and distributed to8×500 μl screw cap vials for automatic pipetting with TECAN workstation.TABLE 14 PCR components for 384 well PCR plate (e.g. for QMassay3522-II). number of reactions: 384 Factor: 1.1 384 component stockconc. μl/reaction μl in MM final conc. Ampli reaction 10x 2 844.8 1xbuffer Ampli MgCl2 25 mmol/l 2 844.8  2.5 mmol/l dNTPs 25 mmol/l 0.284.48 250 μmol/l each primer mix 6.25 μmol/l 2 844.8 625 nmol/l cg-probe4 μmol/l 1 422.4 200 nmol/l Tg-probe 4 μmol/l 1 422.4 200 nmol/lAmpliTaqGold 5 U/μl 0.2 84.48 1 U water 1.6 675.84 Ad 10 10 4224

TABLE 15 Calibration standard DNA mixtures and no template control(plate 05). 96 well plate 1 2 3 4 5 6 7 8 9 10 11 12 A 0% 66% Ntc B 4%75% Ntc C 10% 83% Ntc D 17% 90% Ntc E 25% 96% F 34% 100% G 44% H 56%(Ntc = No template control)

All QM assays were run on a ABI TAQMAN 7900HT real-time device (SDS 2.2.software) with a reaction volume of 20 ul and 9600 emulation (emulationof ABI TAQMAN 7700). An automatic sample setup was used to transfer thecorrect sample names and detector/reporter dyes to the TAQMAN software.The cycling conditions were manually adjusted (Table 16) and ROX wasused as passive reference dye. TABLE 16 Optimized MgCl₂ concentrationsand annealing temperatures of QM assays. Annealing Assay Gene MgCl₂conc. Temp. 3522 I PITX2 3 mM 62° C. 3522 II PITX2 2.5 mM 60° C. 2395PLAU 2.5 mM 60° C. 2064 ERBB2 2.5 mM 62° C. 15908 II TBC1D3 4.5 mM 60°C. 15665 ONECUT2 3 mM 60° C. 15947 ABCA8/9 3 mM 62° C. 2265 TFF1 2.5 mM60° C.

All 384 well PCR plates we re-analyzed by the SDS2.2 software using themanual analysis settings (baseline setting with start and stop valuesand manual threshold) to produce results files for each runindividually.

Example 10 DNA Quantification Methods

a) UV Determination of Physical DNA Concentration.

UV quantification was performed to determine the total amount of DNApresent including DNA which cannot be amplified using a real time PCRbased approach. UV quantification was done by using a standardspectrophotometer for example the UV mini 1240 UV-VIS spectrophotometer(Shimadzu).

b) Real Time PCR Determination of Bisulfite Converted DNA (HB14 Assay)by Means of a Lightcycler Instrument (Roche).

Real time PCR quantification specifically detects bisulfite convertedDNA. Only DNA which is not affected by degradation due to formalinfixation, paraffin embedding and storage is quantified using a real timePCR approach. The quantification was performed in a total volume of 20μl containing 10 μl template DNA or a dilution thereof, 1 U or 3 UFastStart Taq DNA polymerase (Roche), respectively, 4 mmol/l MgCl₂, 500nmol/l (each) forward and reverse primers (forward primer Seq ID NO 19:TGGTGATGGAGGAGGTTTAGTAAGT, reverse primer Seq ID No 20:AACCAATAAAACCTACTCCTCCCTTAA), 1×PCR buffer (Roche), 0.25 mmol/l or 0.5mmol/l of each dNTP (Fermentas), respectively, 0.25 mg/ml BSA (SigmaAldrich) and 250 nmol/l of each detection probe (Seq ID NO 21:TTGTGAATTTGTGTTTGTTATTGTGTGTTG-Fluo and Seq ID NO 22:Red640-TGGTGGTTATTTTTTTTATTAGGTTGTGGT-Phosphate). Cycling was done usinga LightCycler detection System (Roche) with the following conditions: 10min at 95° C. and 40 cycles at 95° C. for 10 s, 58° C. for 20 s, 72° C.for 10 s or 72° C. for 70 s, detection at 58° C., and ramping rates 20°C./s. The amplification results in 133 bp fragments.

c) Real Time PCR Determination of Bisulfite Converted DNA (C3 Assay) byMeans of a 7900HT Fast Real-Time PCR System (Applied Biosystems).

The C3 assay specifically detects bisulfite converted DNA. Real time PCRquantification (C3 assay) was performed in a total volume of 20 μlcontaining 10 μl template DNA or a dilution thereof, 1 U HotGoldStarpolymerase (Eurogentec), 3 mmol/l MgCl₂, 625 nmol/l (each) forward andreverse primers (forward primer Seq ID NO 23: GGAGTGGAGGAAATTGAGAT,reverse primer Seq ID NO 24: CCACACAACAAATACTCAAAAC), 1× reaction buffercontaining ROX passive reference (Eurogentec), 0.25 mmol/l of each dNTP(Fermentas) and 200 nmol/l detection probe (Seq ID NO 25:FAM-TGGGTGTTTGTAATTTTTGTTTTGTGTTAGGTT-EclipseDQ or BNQ1). Cycling wasdone using a Applied Biosystems 7900HT Fast Real-Time PCR System withthe following conditions: 10 min at 95° C. and 40 cycles at 95° C. for15 s, 58° C. for 60 s, detection at 72° C., and ramping rates 3° C./s.

d) Real Time PCR Based Simultaneous Determination of Bisulfite Convertedand Unconverted DNA (CFF1 Assay) by Means of a 7900HT Fast Real-Time PCRSystem (Applied Biosystems).

The CFF1 assay is located in a region without any cytosines andtherefore this region is not affected by the bisulfite conversion.Accordingly, this assay enables the determination of both, genomic andbisulfite converted DNA simultaneously. Real time PCR quantification(CFF1 assay) was performed in a total volume of 20 μl containing 10 μltemplate DNA, 1 U HotGoldStar polymerase (Eurogentec), 2.5 mmol/l MgCl₂,625 nmol/l (each) of forward and reverse primers (forward primer Seq IDNO 26: TAAGAGTAATAATGGATGGATGATG, reverse primer Seq ID NO 27:CCTCCCATCTCCCTTCC), 1× reaction buffer containing ROX passive reference(Eurogentec), 0.25 mmol/l of each dNTP (Fermentas) and 200 nmol/ldetection probe (Seq ID NO 28: FAM-ATGGATGAAGAAAGAAAGGATGAGT-EclipseDQor BHQ1). Cycling was done using a Applied Biosystems 7900HT FastReal-Time PCR System with the following conditions: 10 min at 95° C. and40 cycles at 95° C. for 15 s, 58° C. for 60 s, detection at 72° C., andramping rates 3° C./s.

Example 11 Bisulfite Treated DNA Derived from Paraffin-EmbeddedFormalin-Fixed Tissues (PET) in Real Time PCR

Several different paraffin-embedded formalin-fixed tissue (PET)specimens (4 breast, 12 gallbladder, 12 tonsil samples) were processedaccording to example 2. Bisulfite treated and purified DNA of thesespecimens was pooled and subsequently subjected to the quantitative realtime PCR of example 10b (HB14 assay). FIG. 2 shows that the effectiveDNA input in the real time PCR quantification assay (HB14 assay) is instrong concordance to the quantified DNA amount over a wide range of DNAinput amounts. The use of dNTPs each 250 μmol/l in the quantificationassay leads to a reliable amplification and therefore quantification ofup to 25 ng input DNA. Higher DNA inputs results in a relative decreaseof amplified DNA in comparison to the effective input indicating aninhibition of the PCR. Increasing the dNTP concentration to 500 μmol/lfor each nucleotide enables a proper amplification and thereforequantification of up to 100 ng of input DNA.

A increase in the extension time within each PCR cycle also leads to ahigher amplifiablity of bisulfite treated DNA derived from archivedsamples in case high DNA amounts are used. FIG. 3 shows theamplification and quantification of up to 130 ng input DNA using aprolonged extension time of 90 s compared to a extension time of 30 s.For this experiment, it is taken into account that the polymeraseactivity already starts during the annealing step at 58° C. which istherefore also regarded as extension time.

In case of the use of higher levels of DNA input amounts, the real timePCR performance at is also affected by the amount of polymerase. FIG. 4shows the positive influence of the three fold increase of thepolymerase activity. This increase enables the proper amplification andquantification of up to 200 ng of bisulfite DNA in a single PCRreaction.

Example 12 Processing of Tissue Sections Derived from Paraffin-EmbeddedFormalin-Fixed Prostate Biopsies (Processing of 2×24 Samples)

Sections from 24 different paraffin-embedded formalin-fixed prostatebiopsy specimens (1-3 biopsy cores per paraffin block) were analyzed.Two samples (a and b) of each specimen each consisting of 5 sections (10μm) were processed resulting in 48 samples in total. Samples wereprocessed according to example 7 followed by a bisulfite treatment andDNA purification by means of Microcon™ device as described in example 8.The DNA yield after bisulfite treatment and subsequent purification wasdetermined according to example 10c. FIG. 5 shows that the yield ofbisulfite treated and purified DNA is more than 100 ng for at least oneof the two samples per specimen except specimen and 6. Samples of 6specimen resulted in more than 500 ng bisulfite DNA. DNA yields fromboth samples of each specimens show a strong concordance. Thisillustrates the high reproducebility and reliability of the methodaccording to the invention. Most samples comprise 20%-50% amplifiableDNA (FIG. 6) which is characterized by the ratio of DNA amounts resultedfrom the quantification by means of example 10c and of the UV value (seeexample 10a).

Example 13 Amplification of PCR Amplicons of Different Lengths fromParaffin-Embedded Formalin-Fixed Tissues (PET)

Several different paraffin-embedded formalin-fixed tissue (PET)specimens (4 breast, 12 gallbladder, 12 tonsil samples) were processedaccording to example 2. The purified DNA after bisulfite treatment waspooled and subsequently subjected to PCR in which amplicons of differentlengths (185 bp-711 bp) should be amplified. PCR was performed in atotal volume of 25 μl containing 1 U and 3 U Hotstar Taq polymerase(Qiagen), respectively, 12.5 pmol of forward and reverse primers (primersequences are shown in table 17a), 1×PCR buffer (Qiagen), 0.2 mmol/l ofeach dNTP (Fermentas). Cycling was done using a Mastercycler (Eppendorf)with the following conditions: 15 min at 95° C. and 40 cycles at 95° C.for 30 s, 55° C. for 45 s and 72° C. for 1:30 min. Each PCR contained 30ng template DNA. This amount is based on a prior real time PCRquantification as exemplified by example 10b (HB14 assay) and thereforereflecting the amplifyable partition of the physically present total DNAamount. TABLE 17a Amplicon sizes and the respective primer sequences.Bisulfite treated high molecular weight (HMW) DNA (human genomic DNA,Promega, USA) was used as positive control for each PCR amplicon.amplicon size forward primer reverse primer [bp] (5′->3′) (5′->3′) 185Seq ID No 29: Seq ID No 30: TTTTTGTAGTTTAGAAGGAGGTTAGACACAATAAATTCAACCACCAA 210 Seq ID No 31: Seq ID No 32:GGGAGATTTAATTTGGGG CACCCTCTAATAACCAACCA 235 Seq ID No 33: Seq ID No 34:TTAGGTATAAGTTGGTGGTGG CCCATAAACAACCCCTAAAA 260 Seq ID No 35: Seq ID No36: AGGTATAGGATGGGGAATTAGT AACCCAAACCCTTATACAAAC 285 Seq ID No 37: SeqID No 38: GTTTTTGGAGTTAATTGGGAG CACCCCCATCATTACTATTC 310 Seq ID No 39:Seq ID No 40: AGGGTAGAGGGTGTTGGT CCAAAACTATAAACCTTCCCA 335 Seq ID No 41:Seq ID No 42: TTTAGTATGGGTTGAGAGGAGT CCTCTTTCCTAAAACTACACATTC 360 Seq IDNo 43: Seq ID No 44: GGATTATTGTTGGGTATTTGTT ACACTTCCCTAAAATCTTCAAA 385Seq ID No 45: Seq ID No 46: GTTGGATTTGTTTAGAGAGAGGACATTTAACTCTTTATCCCAAAA 410 Seq ID No 47: Seq ID No 48:TTATTTGATGGGGATAGAGATT ACAAACAACACACCCTCATAC 435 Seq ID No 49: Seq ID No50: TGTAATGAAAGAAGGTGTTGAG TTAACTAAACCATCCATAACCC 460 Seq ID No 51: SeqID No 52: GGATTATAGGAATTAGAATGGGT TCTTTCCAACTCAACATCTTACT 485 Seq ID No53: Seq ID No 54: TGGTGGTATGGATTGGATAA TCCCCCAAATAACACAATATAC 511 Seq IDNo 55: Seq ID No 56: AGAGGAAAGAGTAAGGAATTTTT CTTATCCCCCACAAAACC 535 SeqID No 57: Seq ID No 58: GGTGGAGGGAGAGTTAAGG CCAACAAAACGCCCTCTCC 561 SeqID No 59: Seq ID No 60: GATTGAGATTATTTTGGGTTTT ACTTAAACCTTCCCTCTCCAC 586Seq ID No 61: Seq ID No 62: TTAAGTATTGGATTTGGGGTTAACCTACCCTCTAACTCTACAAAAA 606 Seq ID No 63: Seq ID No 64:AGTAAATAGTGGGTGAGTTATGAA AAAAACCTCTAAAAACTACTCTCC 636 Seq ID No 65: SeqID No 66: AAGGTTTTAGGGAAGAGTGTTT CCTTTTCCTATCACAAAAATAA 660 Seq ID No67: Seq ID No 68: AGGGGGAATTAAATAGAAAGAG CAATAAAACCATCCCAAATACT 678 SeqID No 69: Seq ID No 70: TATGGGAGGAGGTTAGTAAGTG CCCCAAATCCTACATATAAAAA711 Seq ID No 71: Seq ID No 72: GTATTATGTGGTTTAAGGAGGGACTCCAAACAAATTCAACAACT

FIG. 7 shows the results of the PCR amplifications. The use of 1 U ofTaq polymerase per reaction resulted in the successful amplification ofamplicons up to 335 bp. To the contrary, it was possible to successfullyamplify amplicons of up to 511 bp by means of 3 U Taq polymerase perreaction.

Example 14 Paraffin Removal, Lysis and DNA Extraction Plate Scale

Samples from 18 different paraffin-embedded formalin-fixed prostatespecimens (P1, P2, P4, P5, P6, P7, P8, P9, P10, ST-268, ST-269, ST-270,ST-271, ST-272, ST-273, ST-274, ST-275, ST-276) were processed accordingto example 1a) (paraffin removal step), example 1b) (lysis step) andexample 1c) (DNA extraction step). Four samples per specimen wereprocessed independently. Each sample consisted of 3 sections (10 μm).The concentration of amplifiable DNA after lysis and DNA extraction wasdetermined according to example 10d (CFF1 assay), respectively. Theratio of the quantified amplifiable DNA concentration after the DNAextraction step and of the quantified amplifiable DNA concentrationafter the lysis step reflects the yield of the extraction procedure. Thetotal amount of DNA physically present in the extract was determined byUV spectrophotometry (example 10a). The content of amplifiable DNA inthe extracts is reflected by the ratio of quantified DNA according toexample 10d and of the total amount of DNA determined by means of UVspectrophotometry (example 10a). Results are shown in Table 17b andFIGS. 8-12. TABLE 17b Processing of 18 paraffin-embedded formal in-fixedtissue specimens. Results of real time PCR based (example 10d) and UVspectrophotometry based (example 10a) quantification. All datas aremeans of four independently processed samples per specimen includingstandard deviation. Total Total Total DNA DNA in DNA in in lysate -extract - extract - CFF1 CFF1 UV assay Standard assay Standard YieldStandard quantification Standard Amplifiablility Standard sample [ng]deviation [ng] deviation [%] deviation [ng] deviation [%] deviation P1769.37 212.86 463.42 62.10 67.30 34.96 8490 1056.98 5.49 0.68 P2 4108.873810.73 2697.79 406.28 185.17 184.96 23580 8277.25 12.02 2.59 P4 1735.07878.86 1181.97 23.15 98.68 84.95 18660 6092.29 6.76 1.75 P5 1235.85361.47 916.91 134.47 81.92 35.32 19560 3191.49 4.83 1.30 P6 1389.80438.28 951.95 71.40 73.78 22.61 18240 4313.88 5.46 1.45 P7 3245.582235.31 2126.81 53.40 87.89 46.38 21090 1992.69 10.14 0.79 P8 2620.081791.35 1687.70 144.38 99.66 69.38 21765 367.83 7.76 0.75 P9 1808.96549.44 1032.30 686.75 69.39 55.39 21240 10360.27 5.34 4.39 P10 1031.69326.70 696.47 62.02 71.48 17.29 14865 1818.16 4.76 0.90 ST-268 18906.181697.40 4354.72 299.62 23.10 1.54 45195 4658.51 9.67 0.62 ST-26922888.11 201.42 3736.64 415.22 16.32 1.69 55545 4707.71 6.73 0.46 ST-27041912.14 14525.27 10316.21 828.41 27.36 10.65 45495 6065.72 22.82 1.56ST-271 39288.96 21812.73 7842.60 975.43 25.91 14.93 37185 4089.22 21.283.53 ST-272 30026.72 6636.77 6578.06 1035.90 23.29 8.43 49725 9499.1413.31 0.86 ST-273 69900.08 36062.28 15876.32 2394.68 26.92 11.00 704706251.05 22.60 3.40 ST-274 19929.85 1098.59 2758.56 754.86 13.78 3.2750085 8262.94 5.52 1.11 ST-275 46583.92 25018.63 14482.29 1766.26 38.0017.48 62640 22706.76 25.80 10.11 ST-276 21562.06 701.41 4785.23 430.7522.25 2.65 40200 4213.41 11.98 1.40

Example 15 Paraffin Removal, Lysis and DNA Extraction Tube Scale

Sections from 17 different paraffin-embedded formalin-fixed prostatespecimens (P1, P2, P4, P5, P6, P7, P8, P9, P10, ST-268, ST-269, ST-270,ST-271, ST-272, ST-274, ST-275, ST-276) were processed according toexample 1a) (paraffin removal step), example 1b) (lysis step) andexample 2c) (DNA extraction with QIAGEN DNeasy tissue kit). Each sampleconsisted of 3 sections (10 μm). The concentration of amplifiable DNAafter lysis and DNA extraction was determined according to example 10d(CFF1 assay) respectively. The ratio of the quantified amplifiable DNAconcentration after the DNA extraction step and of the quantifiedamplifiable DNA concentration after the lysis step reflects the yield ofthe extraction procedure. The total amount of DNA physically present inthe extract was determined by UV spectrophotometry (example 10a). Thecontent of amplifiable DNA in the extracts is reflected by the ratio ofquantified DNA according to example 10d and of the total amount of DNAdetermined by means of UV spectrophotometry (example 10a). Results areshown in Table 18 and FIGS. 13-17. TABLE 18 Processing of 17paraffin-embedded formalin-fixed tissue specimens. Results of real timePCR based (example 10d) and UV spectrophotometry based (example 10a)quantification. Total Total DNA in DNA in lysate - extract - Total DNAin CFF1 CFF1 extract - UV Content of assay assay Yield quantificationamplifiable sample [ng] [ng] [%] [ng] DNA [%] P1 179.73 77.29 43.00 47041.64 P2 4884.12 1961.33 40.16 9240 21.23 P4 2036.82 732.73 35.97 114606.39 P5 903.14 400.61 44.36 5520 7.26 P6 1750.69 491.23 28.06 6480 7.58P7 3863.33 1176.92 30.46 12240 9.62 P8 957.18 542.60 56.69 9900 5.48 P9715.74 561.57 78.46 6540 8.59 P10 946.06 417.50 44.13 9240 4.52 ST-2684383.18 1639.30 37.40 24720 6.63 ST-269 7497.87 1593.21 21.25 36180 4.40ST-270 9151.79 1081.93 11.82 13260 8.16 ST-271 5954.34 641.61 10.78 514812.46 ST-272 9897.51 3335.76 33.70 36960 9.03 ST-274 8230.91 1894.2623.01 39180 4.83 ST-275 41461.29 11122.82 26.83 77400 14.37 ST-2767272.27 2139.90 29.43 33600 6.37

Example 16 Processing According to Example 2 of 24 Paraffin-EmbeddedFormalin-Fixed Samples Derived from Prostate or Breast Tissue, TubeScale

24 paraffin-embedded formalin-fixed tissue specimens (prostate: PETP1-P10 and ST-268-ST-276 and breast: PET B2-B10) were processedaccording to example 2. Two samples per specimen were processedresulting in 48 samples in total. Each sample consisted of 3 sections(each 10 μm) provided in 1.5 ml tubes. The DNA after bisulfite treatmentand subsequent purification was characterized according to example 10d(CFF1 assay; determination of the amount of DNA converted by bisulfitetreatment and of the amount of DNA not converted by the bisulfitetreatment and therefore represents genomic DNA) and according to example10c (C3 assay; determination of only DNA converted by bisulfitetreatment). Results of these quantifications are shown in Table 19, inFIG. 18 and in FIG. 19, respectively. TABLE 19 Processing of 24paraffin-embedded formalin-fixed tissue specimens. Results of C3 andCFF1 assay quantification (example 10c and 10d, respectively) and theratio thereof. All data are means of two independently processed samplesper specimen (example 16). Yield of Yield of DNA - CFF1 Standard DNA -C3 Standard Sample assay deviation assay deviation PET P1 31.51 5.3526.85 3.73 PET P2 307.22 42.33 143.93 9.34 PET P4 167.69 23.03 103.212.18 PET P5 176.06 33.61 86.27 17.43 PET P6 598.59 37.35 358.71 28.01PET P7 137.10 1.56 74.49 1.40 PET P8 511.88 79.05 219.63 25.52 PET P9189.48 42.02 121.15 36.88 PET P10 158.89 4.36 83.30 8.25 PET B2 3.570.76 1.86 0.58 PET B5 1.88 0.03 0.83 0.67 PET B6 34.20 1.56 10.17 2.18PET B7 48.11 15.50 21.81 5.51 PET B9 9.34 0.05 2.51 0.40 PET B10 2.572.18 0.56 0.61 ST-268 301.94 83.41 171.65 26.14 ST-269 304.14 151.26173.86 93.37 ST-270 106.51 25.52 0.29 0.21 ST-271 125.88 16.18 1.23 0.03ST-272 1422.66 1959.30 597.51 841.84 ST-273 205.11 6.22 3.83 0.75 ST-274521.57 3.11 271.13 13.07 ST-275 264.96 1.24 169.23 16.50 ST-276 547.9859.13 289.39 38.90

Example 17 Processing of 24 Paraffin-Embedded Formalin-Fixed SamplesDerived from Prostate or Breast Tissue, Plate Scale

24 paraffin-embedded formalin-fixed tissue specimens (prostate: PETP1-P10 and ST-268-ST-276] and breast: PET B2-B10) were processedaccording to example 1. Four samples per specimen were processedresulting in 96 samples in total. Each sample consisted of 3 sections(10 μm each) provided in 1.5 ml tubes. The resulting bisulfite treatedand purified DNA was characterized according to example 10d (CFF1 assay;determination of the amount of DNA converted by bisulfite treatment andof the amount of DNA not converted by the bisulfite treatment andtherefore represents genomic DNA) and according to example 10c (C3assay; determination of only DNA converted by bisulfite treatment).Results of these quantifications are shown in Table 20, FIG. 20 and FIG.21, respectively. TABLE 20 Processing of 24 paraffin-embeddedformalin-fixed tissue specimens. Results of C3 and CFF1 assayquantification (example 10c and 10d, respectively) and the ratiothereof. All data are means of four independently processed samples perspecimen. Yield of Yield of DNA - CFF1 Standard DNA - C3 Standard Sampleassay deviation assay deviation PET P1 71.03 3.65 85.42 7.50 PET P2920.67 203.57 556.83 129.87 PET P4 311.33 41.97 173.67 36.73 PET P5273.67 46.65 194.33 30.60 PET P6 263.33 31.26 181.50 17.29 PET P7 736.67116.22 398.50 60.04 PET P8 411.00 29.14 225.83 23.96 PET P9 319.83 98.97256.75 70.86 PET P10 230.00 44.73 139.50 15.17 PET B2 75.53 40.85 61.6939.48 PET B5 2.72 1.99 2.19 1.87 PET B6 7.79 5.25 9.07 12.10 PET B710.27 6.96 9.40 5.90 PET B9 6.47 2.25 3.02 3.07 PET B10 42.92 24.8515.53 9.48 ST-268 948.00 206.25 585.83 175.80 ST-269 969.00 135.27515.83 92.15 ST-270 2973.33 363.52 1075.83 134.40 ST-271 2983.33 441.331054.17 207.50 ST-272 1641.67 307.50 980.83 227.73 ST-273 5263.33 848.622598.33 357.87 ST-274 479.67 47.60 259.58 70.33 ST-275 3856.67 896.371794.17 470.42 ST-276 871.67 220.93 320.08 94.72

Example 18 Processing of Samples Derived from 150 Paraffin-EmbeddedFormalin-Fixed Breast Cancer Specimens

Samples of 150 paraffin-embedded formalin-fixed breast cancer specimens(E001-E150) were processed according to example 9. Each sample consistedof 3 sections (10 μm each) which were provided in 1.5 ml tubes. Yield ofgenomic DNA after extraction was determined using UV spectrophotometry(example 10a) und the CFF1 assay (example 10d). The yield of bisulfiteconverted DNA after bisulfite treatment and subsequent purification wasdetermined using the C3 assay (example 10c). TABLE 21 Yields ofbisulfite converted and non-bisulfite converted DNA derived fromparaffin-embedded formalin-fixed breast cancer specimens. DNA wasquantified according to example 10d (CFF1 assay), according to example10c (C3 assay) and according to example 10a (UV spectrophotometry).Genomic total yield DNA [ng] [ng] of bisulfite total in 70 ul Genomicconverted DNA extract DNA [ng] total in 50 μl eluate after (based on UVin 70 ul extract (based purification (based on determination; CFF1assay; example the C3 assay; example Sample example 10a) 10d) 10c) E00113545.0 1812.0 1760.6 E002 6125.0 688.6 215.8 E003 5760.0 348.9 140.0E004 20160.0 338.6 174.5 E005 6852.6 1017.9 514.2 E006 26460.0 11173.01541.6 E007 16905.0 8213.1 2410.4 E008 16012.5 9725.2 4452.0 E00915866.7 8657.4 1749.4 E010 27195.0 14169.6 200.6 E011 7680.0 4115.01009.2 E012 16380.0 2102.2 1032.4 E013 1866.7 1962.8 1374.3 E014 15225.02430.8 1028.0 E015 13835.3 1779.8 857.2 E016 17684.2 1866.5 894.2 E01710350.0 1240.1 240.1 E018 8085.0 1326.0 873.7 E019 16357.9 3256.2 1341.4E020 21123.5 3401.2 1785.1 E021 10278.9 1395.2 1201.2 E022 20432.44540.2 2970.8 E023 22976.5 2506.7 1651.6 E024 5250.0 1691.7 1027.4 E02524465.0 4408.7 2358.7 E026 17170.6 8749.5 3195.7 E027 17616.7 2819.41327.1 E028 4817.6 11498.9 4516.8 E029 30333.3 4922.3 2185.2 E03016305.9 16442.2 6160.9 E031 7455.0 3703.1 1278.7 E032 10005.9 4757.42073.8 E033 9173.7 4922.1 1628.7 E034 8715.0 4010.9 1686.4 E035 10994.16841.9 1496.6 E036 10500.0 4358.7 2828.2 E037 20650.0 5711.1 4439.0 E03830333.3 3311.1 2801.3 E039 9240.0 2956.5 2325.2 E040 6930.0 2261.9 981.5E041 8505.0 446.5 387.1 E042 4550.0 789.6 669.6 E043 3315.8 779.7 425.8E044 4095.0 845.1 489.5 E045 4089.5 795.8 531.4 E046 6052.9 107.2 164.8E047 11200.0 200.1 113.4 E048 5682.4 149.7 248.8 E049 3990.0 76.3 35.9E050 4531.6 235.4 85.7 E051 13042.1 6107.0 2887.2 E052 8295.0 3162.31063.5 E053 11235.0 4412.9 3815.7 E054 8866.7 3196.3 2329.3 E055 7245.02458.7 1452.5 E056 14595.0 3257.7 5484.6 E057 11970.0 3005.9 2533.5 E05817047.1 3892.1 2368.3 E059 13094.1 6094.4 4047.3 E060 35870.3 2849.63108.8 E061 22750.0 715.8 440.5 E062 13920.0 840.0 340.1 E063 14452.93292.1 3313.1 E064 4095.0 761.4 510.1 E065 3705.9 2855.2 3153.8 E0662625.0 244.7 11.2 E067 3383.3 417.2 362.6 E068 3088.2 718.6 321.9 E0692216.7 118.0 17.3 E070 11520.0 214.8 71.5 E071 10623.5 1463.9 1361.2E072 26950.0 2064.7 2121.6 E073 12723.5 2277.5 2169.1 E074 2333.3 3841.53249.4 E075 11488.2 1545.8 1235.2 E076 31360.0 14426.1 5108.5 E07718060.0 8039.9 3387.0 E078 23415.0 14134.2 6859.3 E079 14000.0 10264.35371.6 E080 21735.0 9167.2 2812.9 E081 6883.3 31543.5 25884.0 E08223730.0 12237.9 7183.1 E083 17541.2 7782.0 4135.6 E084 30836.8 19137.912754.5 E085 21466.7 13501.5 5589.2 E086 16026.3 3724.7 2177.5 E0879173.7 1701.5 1091.9 E088 27176.5 3309.1 1072.5 E089 19950.0 3831.91739.0 E090 23566.7 3985.7 3139.2 E091 2594.1 5222.6 5906.1 E092 19600.02055.6 1131.1 E093 10500.0 2585.4 1223.6 E094 15093.8 4220.0 300.6 E0959555.0 1630.1 840.0 E096 14700.0 2675.9 1076.2 E097 21525.0 4163.31840.9 E098 13416.7 4691.0 883.6 E099 13230.0 2024.5 1765.6 E100 12250.01903.4 852.3 E101 4725.0 4695.8 1007.1 E102 14910.0 6633.8 2066.2 E10319841.4 10410.8 3738.5 E104 22283.3 10963.4 4059.1 E105 31994.1 15319.93397.5 E106 6930.0 968.2 511.4 E107 5526.3 616.5 261.6 E108 5968.4 875.8175.0 E109 5906.3 753.1 234.5 E110 4830.0 782.8 594.2 E111 2625.0 4344.92081.4 E112 14880.0 4266.1 2366.6 E113 6090.0 2727.2 1636.4 E114 10710.04280.6 2824.6 E115 7665.0 3166.8 3354.9 E116 6176.5 342.0 64.5 E1172216.7 385.3 146.0 E118 50770.6 486.5 104.3 E119 4935.0 439.2 406.8 E12010266.7 929.9 516.2 E121 8925.0 2893.5 259.9 E122 13533.3 7499.9 3242.3E123 49411.8 16014.1 8003.4 E124 19010.5 6660.4 4336.0 E125 10383.32631.8 1100.9 E126 23231.3 8386.5 3450.2 E127 8820.0 2078.4 2172.0 E1282730.0 676.6 166.4 E129 32160.0 1465.8 606.5 E130 4083.3 Undetermined1068.5 E131 3045.0 396.5 181.0 E132 3780.0 507.3 515.9 E133 7669.6 526.0570.5 E134 6650.0 896.0 561.3 E135 6052.9 903.1 314.5 E136 22260.06770.9 2886.7 E137 19600.0 4402.2 1359.9 E138 8400.0 10852.0 4979.4 E13919635.0 6613.7 4495.2 E140 27650.0 9160.8 6587.8 E141 26194.7 8656.04678.9 E142 4550.0 10660.7 3116.2 E143 26600.0 9404.2 2983.5 E14433705.0 12358.5 4073.3 E145 10252.9 5114.6 2774.1 E146 31850.0 19365.95729.1 E147 24780.0 11532.6 6048.3 E148 21000.0 11540.2 4106.7 E1492400.0 13681.8 6231.2 E150 29750.0 18923.4 3814.9

Example 19 Processing of Laser Capture Microdissected Cells

Laser capture microdissected cells from a paraffin-embeddedformalin-fixed breast cancer specimen was bisulfite treated.

a) Microdissection.

The 10 μm section which was mounted on a microscopic slide was subjectedto a methylene blue staining procedure and subsequently laser capturemicrodissected. Microdissection was carried out using a Microbeaminstrument (P.A.L.M. Microlaser Technologies AG, Bernried, Germany). Twoareas of the section (each comprising approximately 0.25 mm²) weremicrodissected and collected in two 200 μl tubes with adhesive caps(Adhesive Caps 200, P.A.L.M. Microlaser Technologies AG, Bernried,Germany). Because of the microdissection no removal of paraffin isnecessary.

b) Lysis Step

Sample material sticked to the adhesive caps after microdissection andwas subjected to a lysis step. Therefore 20 μl lysis buffer (50 mmol/lTris-HCl, pH 8.0, 1 mmol/l EDTA, 0.5 v/v % Tween, 10 ng/μl poly-dA, 3mg/ml proteinase K) were carefully added to the caps. Four controlreactions were performed: two negative controls with tubes containing nosample but lysis buffer and two positive controls with tubes containinglysis buffer and 500 pg human genomic DNA (Promega, USA) Tubes wereclosed carefully avoiding a loosening of the drop from the cap. Thetubes were incubated 12 h at 60° C. in a Mastercycler PCR machine(Eppendorf, Germany). Since the sample material was located at the capsthe lid of the mastercycler was also set to 60° C. After incubationsamples were centrifuged in a table centrifuge for 30 s to transfer thelysed sample to the bottom of the tube.

c) Bisulfite Treatment

After this, samples were subjected to bisulfite treatment as follows. Todissolve any DNA which might remain at the cap, 19 μl bisulfite solution(470.8 g/l sodium disulfite [Merck] and 112.8 g/l sodium sulfite[Fluka]) were added to the cap, tubes were carefully closed andincubated for 5 min at room temperature. Samples were now centrifugedfor 30 s using a table centrifuge. The last step (adding bisulfitesolution to the cap, incubating and centrifuging) was repeated once. 6μl DME solution were added to each sample, the DME solution comprising aradical scavenger (125.3 g/l6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid) in DME(diethylene-glycoldimethylether Merck]). The samples were incubatedunder the following conditions: 5 min 99° C., 22 min 60° C., 3 min 99°C., 97 min 60° C., 3 min 99° C. and 177 min 60° C. Incubation wascarried out using a Mastercycler (Eppendorf).

d) DNA Purification

DNA purification after bisulfite treatment was carried out by means ofZymo-Spin IC columns (Zymo Research, USA). 166 μl AVL buffer (Qiagen,Germany) were added to the Zymo-Spin IC columns. Bisulfite reaction mix(64 μl total per sample) was added to the columns. The used pipett tipswere placed in the respective bisulfite reaction tubes for further usagein order to avoid DNA loss due to drops sticking at the tips. 90 μl ofAVL buffer were added to the empty bisulfite reaction tubes andafterwards transferred to the Zymo-Spin IC columns using the respectivepipett tips which were previously placed in the respective tubes.Bisulfite reaction mix and buffer AVL were mixed in the columns bypipetting up and down several times and incubated 10 min at roomtemperature. 250 μl ethanol were added to the columns and mixed with thepipett. Again, the same pipett was used for mixing in order to avoid DNAloss due to drops sticking at the tips as already explained above.Columns were centrifuged 1 min at 16,000×g. Columns were transferred toa new 2 ml collection tube and 500 μl desulfonation buffer (0.2 mol/lNaOH, 90% v/v ethanol) was added to each column. Columns werecentrifuged 1 min at 16,000×g. Columns were transferred to a new 2 mlcollection tube and 500 μl buffer AW1 (Qiagen, Germany) was added toeach column. Columns were centrifuged 1 min at 16,000×g. Columns weretransferred to a new 2 ml collection tube and 500 μl buffer AW2 (Qiagen,Germany) was added to each column. Columns were centrifuged 3 min at16,000×g. Columns were placed in a 1.5 ml collection tube for DNAelution. DNA was eluted by adding 12.5 μl water (prewarmed to 50° C.) tothe columns, incubating 1 min and centrifuging 1 min at 6,000×g. Theelution step was repeated resulting in approximately 20 μl eluate total(5 μl loss due to columns geometry and evaporation)

e) Subsequent Analysis

Thereafter, DNA was ready for subsequent PCR applications, for examplereal time PCR quantification, PCR and sequencing, etc. The six processedreactions (two samples, two negative controls and two positive controls)were subjected to HB14 real time PCR quantification using theLightCycler system (Roche, Germany) according to example 10b. Eachquantification was performed in duplicates (10 μl input in PCR reactioneach). Table 22 shows the results of this quantification. The yield ofDNA is in the range of 66% to 80% (based on positive controls with knownDNA inputs). Samples resulted in 175 pg and 73 pg DNA, respectively(Table 22). TABLE 22 Yield of bisulfite converted DNA derived from lasercapture microdissected cells and controls. DNA in 1. PCR DNA in 2. DNAtotal in (10 μl input) PCR (10 μl both Sample [pg] input) [pg] PCR [pg]yield [%] positive 192 206 398 79.6 control 1 (500 pg DNA) positive 23496.5 330.5 66.1 control 2 (500 pg DNA) negative 0 0 0 x control 1 (noDNA) negative 0 0 0 x control 0 (no DNA) sample 1 96.1 78.6 174.7 xsample 2 7.5 65.1 72.6 x

1. A method for providing DNA fragments derived from an archived sample,comprising: contacting an archived sample comprising DNA with a proteaseto provide for an amount of accessible protease-treated DNA, wherein thearchived sample comprises at least one of paraffin and a fixative agent,wherein the yield of accessible DNA after the protease treatment-step isat least 20% of that of the archived sample, and wherein amplicons ofabout 600 to about 1,000 base pairs in length are amplifiable therefrom.2. The method of claim 1, further comprising, inactivating the proteaseby heat, addition of a protease inhibitor, or both.
 3. The method ofclaim 1, further comprising extracting the protease-treated DNA from theprotease-treated sample.
 4. The method of claim 3, further comprising,after extracting the DNA: contacting the extracted DNA with a bisulfitereagent; desulphonating the bisulfite-treated DNA; and purifying thedesulphonated DNA using a suitable DNA purification method.
 5. Themethod of claim 1, wherein the yield of DNA after protease treatment isfrom 20% to about 60%, and wherein amplicons of about 600 base pairs inlength are amplifiable.
 6. A method for providing DNA fragments derivedfrom an archived sample, comprising: contacting an archived samplecomprising DNA with a protease to provide for an amount ofprotease-treated DNA; extracting the protease-treated DNA; treating theextracted DNA with a bisulfite reagent; purifying the bisulfite-treatedDNA, wherein the yield of the purified DNA is at least 20% of that ofthe archived sample, and wherein at least 5% of the purified DNA isamplifiable in a PCR reaction generating fragments of at least 110 bp inlength.
 7. The method of claim 6, wherein the yield of the purified DNAis between about 30% and about 50% of that of the archived sample. 8.The method of claim 6, wherein 5% to about 60% of the purified DNA isamplifiable in a PCR reaction generating fragments of at least 110 bp inlength.
 9. The method of claim 6, wherein an average of about 10% of thepurified DNA is amplifiable in a PCR reaction generating fragments of atleast 110 bp in length.
 10. The method of claim 6, wherein the archivedsample is at least one selected from the group consisting of; aparaffin-embedded tissue biopsy; a fixed tissue biopsy; aparaffin-embedded, fixed tissue biopsy; a paraffin-embedded tissuesection or portion thereof; a fixed tissue section or portion thereof; aparaffin-embedded, fixed tissue section or portion thereof.
 11. Themethod of claim 1, further comprising at least one step selected fromthe group consisting of; removing paraffin; extracting the DNA; treatingthe extracted DNA with a bisulfite reagent; purifying the DNA; andamplifying the DNA.
 12. The method of claim 10, further comprising atleast one step selected from the group consisting of: removing paraffin;and amplifying the DNA.
 13. The method of claim 12, wherein removingparaffin comprises dissolving the paraffin by an organic solvent, orcomprises dissolving the paraffin by an organic solvent and washing byanother organic solvent.
 14. The method of claim 13, wherein the organicsolvent for dissolving paraffin is a solvent selected from the groupconsisting of limonene, xylene and combinations of these solvents, andwherein the washing solvent is a solvent selected from the groupconsisting of ethanol, methanol, isopropanol and combinations of thesesolvents with each other or with water.
 15. The method of claim 13,wherein the paraffin removal step comprises: adding 0.1-3 ml of limoneneto the archived sample; incubating for at least 5 min at a temperaturein the range of out 10° C. to about 70° C.; centrifuging the incubatedsample; and removing of the limonene therefrom.
 16. The method of claim13, wherein the paraffin removal step comprises: adding about 1 ml oflimonene to the archived sample; incubating for about 10 min to about 1h at room temperature with mixing of the sample; centrifuging theincubated sample at a force of at least 5,000×g for about 5 min; andremoving the limonene therefrom.
 17. The method of claim 14, wherein thewashing solvent is ethanol, and wherein washing comprises: adding about0.1 to about 3 ml of ethanol; centrifuging the ethanol containingsample; removing the ethanol; and drying.
 18. The method of claim 17,further comprising, after addition of the ethanol, incubation for up to10 min at a temperature in the range of about 15° C. to about 30° C. 19.The method of claim 13, comprising: adding of about 1 ml ethanol;incubating for about 10 min at room temperature with mixing the sample;Centrifuging at a force of at least 5,000×g for about 5 min; removingthe ethanol; and incubating for a period of about 10 to about 30 min atabout 50° C.
 20. The method of claim 12, wherein the protease isselected from the group consisting of a serine protease, a thiolprotease, a carboxy protease, a metalloprotease, proteinase K andcombinations of these proteases.
 21. The method of claim 20, whereincontacting the archived sample with the protease comprises: adding about0.05 to about 1 ml of lysis buffer comprising about 50 mmol/ltris-hydroxymethyl-amino-methan pH 8.0, 1 mmol/l EDTA, 0.5% Tween 20 v/vto from 1 to about 10 deparaffinated formalin-fixed tissue sections, orto an equal amount of a deparaffinated formalin-fixed tissue biopsy;adding about 10 to about 100 μl of a proteinase K solution comprisingabout 10 to about 30 g/l proteinase K, and subsequently agitating thesample; and incubating for at least 2.5 h at a temperature of about 40to about 70° C.
 22. The method of claim 21, further comprising, afterincubating, inactivating the proteinase K by heating, by use of aninhibitor, or both.
 23. The method of claim 20, wherein contacting thearchived sample with the protease comprises: adding about 190 μl oflysis buffer to 1 to about 6 deparaffinated formalin-fixed tissuesections, or to an equal amount of a deparaffinated formalin-fixedtissue biopsy; adding about 20 μl of proteinase K solution comprisingabout 30 g/l proteinase K, with subsequent vortexing; incubating for aperiod of about 3 to about 48 h at a temperature of about 50° C. toabout 60° C. with mixing the sample; and incubation for about 10 min ata temperature of at least 95° C.
 24. The method of claim 23, furthercomprising, after incubating at about 50° C. to about 60° C. with mixingfor 24 h, adding of at least 20 μl proteinase K solution after the first24 h incubation at 50° C.-60° C., and prior to incubation at thetemperature of at least 95° C.
 25. The method according to claim 20,wherein contacting the archived sample with the protease comprises:adding about 50 to about 1,000 μl of lysis buffer to 1 to about 10deparaffinated formalin-fixed tissue sections, or to an equal amount ofa deparaffinated formalin-fixed tissue biopsy, the lysis buffer pH 8.0comprising about 50 mmol/l tris-hydroxymethyl-amino-methan, 1 mmol/lEDTA, 0.5% Tween 20 v/v; incubating for about 5 to about 20 min at atemperature of about 40 to about 75° C.; adding about 5 to about 40 μlof proteinase K solution, the proteinase K solution comprising about 30mg/ml proteinase K; and incubating for at least 2.5 h at a temperatureof about 40 to about 70° C.
 26. The method of claim 25, wherein thelysis buffer further comprises about 5 ng/μl poly-dA DNA.
 27. The methodof claim 25, wherein the proteinase K is activated by heating, by use ofan inhibitor, or both.
 28. The method according to claim 25, whereincontacting the archived sample with the protease comprises: adding about100 μl lysis buffer to 1 to about 6 deparaffinated formalin-fixed tissuesections, or to an equal amount of a deparaffinated formalin-fixedtissue biopsy; incubating for about 10 min at about 65° C. in athermomixer at 1,000 rpm; incubating at about 50° C. in a thermomixer atabout 1,400 rpm adding about 10 μl of proteinase K solution; incubatingfor about 3 to about 48 h at about 60° C. in a thermomixer at about1,000 rpm; and incubating for about 10 min at a temperature greater than95° C.
 29. The method of claim 12, wherein extracting the DNA comprisesbinding of DNA to silica surfaces, or silica membranes.
 30. The methodaccording to claim 29, wherein at least one kit is used in the DNAextraction step, and wherein the at least one kit is selected from thegroup consisting of DNeasy 96 Tissue Kit, QIAamp 96 DNA Blood Kit,QIAamp DSP 96 Virus MDX Kit, DNeasy Tissue Kit, QIAamp DNA Mini Kit, orQIAamp DNA Micro Kit, QIAamp Viral RNA Mini, and QIAamp DSP Virus Kit.31. The method of claim 30, wherein the DNA extraction step comprisesuse of at least one kit selected from the group consisting of the DNeasy96 Tissue Kit, the QIAamp 96 DNA Blood Kit, and the QIAamp DSP 96 VirusMDx Kit, and wherein use of the at least one kit comprises: adding about100 to about 600 μl of binding buffer AL/E, ATL/E or AVL/E to a lysatederived from 1 to about 10 deparaffinated formalin-fixed tissuesections, or to an equal amount of a deparaffinated formalin-fixedtissue biopsy; applying the mixture onto a plate; washing with washingpuffer AW1 and AW2; and eluting the DNA by addition of about 20 to about200 μl elution buffer AE, AVE, EB or water adjusted to a temperature ofabout 15 to about 80° C., incubating for at least 30 s at a temperatureof about 15 to about 40° C., and centrifugation.
 32. The method of claim31, comprising: adding about 400 μl of binding buffer AL/E, ATL/E orAVL/E to about 200 μl lysate derived from 1 to about 6 deparaffinatedformalin-fixed tissue sections, or from an equal amount of adeparaffinated formalin-fixed tissue biopsy; shaking for about 15 s withboth hands; applying the mixture onto a plate; centrifuging for about 10min at about 5790×g; applying about 500 μl washing puffer AW1, andsubsequently centrifuging at about 5,790×g for about 5 min; applyingabout 500 μl washing puffer AW2, and subsequently centrifuging at about5,790×g for about 5 min; drying of the column by centrifugation at about5,790×g for about 15 min; and eluting the DNA by addition of about 120μl elution buffer AE, AVE or EB or water preheated to about 70° C.,incubating for about 5 min at room temperature, and centrifuging forabout 2 min at about 5,790×g.
 33. The method of claim 30, wherein theDNA extraction step comprises use of at least one kit selected from thegroup consisting of the DNeasy Tissue Kit, the QIAamp DNA Mini Kit, theQIAamp DNA Micro Kit, the QIAamp Viral RNA Mini, and the QIAamp DSPVirus Kit, and wherein use of the at least one kit comprises: addingabout 150 to about 300 μl of binding buffer AL, ATL or AVL to the lysatederived from 1 to about 6 deparaffinated formalin-fixed tissue sections,or from an equal amount of a deparaffinated formalin-fixed tissuebiopsy; incubating for at least 5 min at a temperature of about 45° C.to about 80° C. while agitating the sample; adding about 150 to about300 μl of ethanol, subsequently agitating the sample, and centrifuging;applying the mixture onto a column; centrifuging; washing with washingbuffer AW1 and AW2; and eluting, in one or two steps, by addition of upto 180 μl elution buffer AE, AVE or EB or water adjusted to roomtemperature, incubating at room temperature, and centrifuging.
 34. Themethod of claim 33, further comprising, after washing with washingbuffer AW1 and AW2, centrifuging.
 35. The method of claim 31,comprising: a) adding about 200 to about 210 μl of binding buffer AL,ATL or AVL to about 210 μl lysate derived from 1 to about 6deparaffinated formalin-fixed tissue sections, or from an equal amountof a deparaffinated formalin-fixed tissue biopsy; b) incubating forabout 10 min at a temperature of about 56° C. to about 70° C. mixing thesample; c) adding about 200 to about 210 μl of ethanol, pulse-vortexingfor about 15 s, and centrifuging for about 5 s at about 5,000×g; d)applying the mixture onto a column; e) centrifuging for about 1 min atabout 6,000×g; f) applying about 500 μl washing buffer AW1, andsubsequently centrifuging at about 6,000×g for about 1 min; g) applyingabout 500 μl washing buffer AW2, and subsequently centrifuging at about20,000×g for about 3 min; and i) eluting by a first addition of about 35to about 120 μl elution buffer AE, AVE or EB or water adjusted to roomtemperature, incubating for about 1 to about 5 min at room temperature,and centrifugation for about 1 min at about 6,000×g.
 36. The method ofclaim 35, further comprising: after g) and prior to i), a step h)comprising centrifuging at about 20,000×g for about 1 min using newtubes; or further comprising, in i), an optional second addition ofabout 35 to about 60 μl elution buffer AE, AVE or EB or water adjustedto room temperature, incubating for about 1 to about 5 min at roomtemperature, and centrifuging for about 1 min at about 6,000×g; orfurther comprising both.
 37. The method of claim 36, wherein step h) andi) are replaced by the following steps k) and l), respectively: k)beating the column on a kleenex tissue on the bench with a subsequentcentrifugation at about 6,000×g for about 1 min; and l) eluting byaddition of about 50 to bout 150 μl of buffer AE or water preheated toabout 40° C., incubation for about 1 to about 5 min at room temperature,centrifugation at about 6,000×g for about 1 min, repeated application ofthis first eluate onto the column, incubation for about 1 min at roomtemperature and centrifugation at about 6,000×g for about 1 min.
 38. Themethod of claim 12, wherein treating the extracted DNA with a bisulfitereagent comprises: mixing of about 10 to about 60 μl of the solutioncontaining the genomic DNA with about 50 to about 120 μl of bisulfitesolution, the bisulfite solution having a pH in the range of about 5.45to about 5.50 comprising about 4.83 to about 4.93 mol/l hydrogensulfite;adding about 8 to about 45 μl of an organic radical scavenger solution,the organic radical scavenger solution comprising an organic solvent andabout 158 to about 500 mmol/l of6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid; and applying atemperature protocol for about 3 to about 8 h, wherein the reaction isconducted in a temperature range of about 0 to about 80° C. with about 2to about 5 additional temperature increases, in each case for about 1 toabout 10 min, to a temperature of about 85 to about 100° C. including aninitial temperature increase to a temperature of about 85 to about 100°C.
 39. The method of claim 38, wherein treating the extracted DNA with abisulfite reagent comprises: mixing of about 44 to about 50 μl of asolution containing the genomic DNA with about 83 to about 95 μl of thebisulfite solution; adding about 13 to about 15 μl of DME solution, theDME solution comprising about 500 mmol/l of6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid dissolved indiethyleneglycoldimethylether; and applying a temperature protocol forabout 4 to about 7 h, wherein the reaction is conducted in a temperaturerange of about 57 to about 65° C. with about 2 to about 5 additionaltemperature increases, in each case for about 3 to about 5 min, to atemperature of about 94 to about 100° C. including an initialtemperature increase to a temperature of about 94 to about 100° C. 40.Method according to claim 38, wherein treating the extracted DNA with abisulfite reagent comprises: mixing about 15 to about 20 μl of solutioncontaining the genomic DNA with about 60 to about 85 μl of the bisulfitesolution; adding about 25 to about 35 μl of dioxane solution, thedioxane solution comprising about 158 mmol/l of6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid dissolved in1,4-dioxane; and applying a temperature protocol for about 4 to about 7h, wherein the reaction is conducted in a temperature range of about 57to about 65° C. with about 2 to about 5 additional temperatureincreases, in each case for about 3 to about 5 min, to a temperature ofabout 94 to about 100° C. including an initial temperature increase to atemperature of about 94 to about 100° C.
 41. The method of claim 12,wherein purifying the bisulfite-treated DNA comprises use of at leastone kit, wherein the at least one kit is selected from the groupconsisting of the DNeasy 96 Tissue Kit, the QIAamp 96 DNA Blood Kit, theQIAamp DSP 96 Virus MDx Kit, the DNeasy Tissue Kit, the QIAamp DNA MiniKit, the QIAamp DNA Micro Kit, the QIAamp Viral RNA Mini, and the QIAampDSP Virus Kit, and wherein use of the at least one kit comprises: mixingof the bisulfite-treated sample with about 500 to about 620 μl bindingbuffer, wherein the binding buffer optionally comprises about 10 ng/μlRNA dissolved in the buffer AVL; adding about 500 to about 620 μlethanol; incubating at a temperature of about 0 to about 37° C. forabout 5 to about 20 min; binding of the DNA onto a respective plate ofat least one kit selected from the group consisting of the DNeasy 96Tissue Kit, the QIAamp 96 DNA Blood Kit, or the QIAamp DSP 96 Virus MDxKit or onto a column of the DNeasy T issue Kit, the QIAamp DNA Mini Kit,the QIAamp DNA Micro Kit, the QIAamp Viral RNA Mini, and the QIAamp DSPVirus Kit; washing with about 300 to about 1,000 μl washing buffer AW1;treating with about 450 to about 550 μl of a solution containing about0.2 mol/l sodium hydroxide and about 90% ethanol for about 10 to about25 min at a temperature of about 15 to about 26° C.; washing with about300 to about 1,000 μl washing buffer AW2; and eluting with about 50 toabout 150 μl of one of the elution buffers AE, AVE, EB or water.
 42. Themethod of claim 41, comprising: mixing of about 140 μl of bisulfitetreated sample with about 560 μl binding buffer; adding about 560 μlethanol; centrifuging at about 1,450×g for about 1 s; incubating at roomtemperature for about 10 min; applying the reaction mixture in one ortwo steps onto a plate of the respective at least one kit selected fromthe group consisting of DNeasy 96 Tissue Kit, the QIAamp 96 DNA BloodKit, or the QIAamp DSP 96 Virus MDx Kit or onto a column of the DNeasyTissue Kit, the QIAamp DNA Mini Kit, the QIAamp DNA Micro Kit, theQIAamp Viral RNA Mini, and the QIAamp DSP Virus Kit; centrifuging theplate at about 5.790×g for about 4 min, or of the column at greater than20,000×g for about 1 min; applying about 500 μl buffer AW1, andsubsequently centrifuging the plate at about 5.790×g for about 2 min orof the column at greater than 20,000×g for about 1 min; applying about500 μl of a solution containing about 0.2 mol/l sodium hydroxide andabout 90% ethanol, incubating for about 15 min at room temperature andsubsequent centrifugation of the plate at about 5.790×g for about 2 minor of the column at greater than 20,000×g for about 1 min, wherein thereis optional application of about 500 μl buffer AW1 and subsequentcentrifuging of the plate at about 5.790×g for about 2 min or of thecolumn at greater than about 20,000×g for about 1 min; applying about500 μl of buffer AW2 and subsequent centrifuging of the plate at about5.790×g for about 15 min or of the column at about 20,000×g for about 3min; centrifuging the column at about 20,000×g for about 1 min; andeluting the DNA from the plate by application of about 120 μl elutionbuffer AE, AVE or EB or water preheated to about 70° C., incubation forabout 5 min at room temperature and centrifugation for about 2 min atabout 5,790×g, or elution of the DNA from a column by a firstapplication of about 35 to about 120 μl elution buffer AE, AVE or EB orwater adjusted to room temperature, incubation for about 1 to about 5min at room temperature and centrifugation for about 1 min at about6,000×g, wherein there is an optional second application of about 35 toabout 60 μl elution buffer AE, AVE or EB or water adjusted to roomtemperature, incubation for about 1 to about 5 min at room temperatureand centrifugation for about 1 min at about 6,000×g.
 43. The method ofclaim 12, wherein purifying the bisulfite-treated DNA comprises use of aMicroron™ filter device, and further comprises: adjusting the sampleafter the bisulfite reaction with water to a volume of about 350 toabout 500 μl; binding of the DNA onto a Microron™ filter device;treating with about 25 to about 1,000 μl of about 0.2 mol/l sodiumhydroxide, wherein there is optional incubating for about 3 to about 25min at a temperature of about 15 to about 26° C.; washing with about 200to about 1,000 μl TE buffer, the TE buffer pH 8.0 comprising about 10mmol/l tris-hydroxymethyl-amino-methan and about 0.1 mmol/l EDTA;removing the DNA by means of about 30 to about 100 μl TE bufferpreheated to a temperature of about 40 to about 65° C. incubated forabout 5 to about 25 min at a temperature of about 10 to about 60° C. 44.The method of claim 43, wherein purifying the bisulfite-treated DNAcomprises: adjusting the sample after the bisulfite reaction with waterto a volume of about 400 μl; applying the mixture onto a Microcronfilter device and subsequent centrifugation at about 14,000×g for about15 min, wherein there are 1 to 2 optional repetitions of the followingwashing step: applying of about 400 μl TE buffer, the TE buffer pH 8containing about 10 mmol/l tris-hydroxymethyl-amino-methan and about 0.1mmol/l EDTA, subsequent centrifuging at about 14,000×g for about 12 min;applying about 100 to about 400 μl of about 0.2 mol/l sodium hydroxide,wherein there is optional incubating for about 10 min at roomtemperature, and subsequent centrifuging at about 14,000×g for about 10to about 12 min; applying, in 1 to about 4 repetitions, the following:applying of about 400 μl water or TE buffer and subsequent centrifugingat about 14,000×g for about 12 min; and eluting in one or two steps byapplication of about 37.5 to about 75 μl TE buffer preheated to about50° C., incubation for about 10 min at a temperature of about 15 toabout 50° C., and subsequent inversion of the Microron™ filter deviceand centrifugation at about 1,000×g for about 5 min.
 45. The method ofclaim 12, wherein amplifying the DNA comprises detecting at least oneposition that is methylated in the genomic DNA of the archived sample,at least one position that is unmethylated in the genomic DNA of thearchived sample, or both.
 46. The method of claim 12, wherein amplifyingthe DNA comprises use of at least one method selected from the groupconsisting of: the PCR method; the bisulfite sequencing method; theCOBRA method; the Ms-SNuPE (Methylation-sensitive Single NucleotidePrimer Extension) method; the MSP (Methylation Specific PCR) method; thenested MSP method; the HeavyMethyl™ method; the MethyLight™ method; andthe QM assay.
 47. A method for amplifying DNA derived from an archivedsample, comprising amplifying DNA in a DNA amplification step comprisinguse of at least one DNA amplification parameter selected from the groupconsisting of: a polymerase concentration in the range of about 0.05 toabout 0.3 U/μl; a concentration of each nucleotide in the range of about200 to about 800 μmol/l; and a time of an elongation step in the rangeof about 0.1 to about 1.0 s/bp.
 48. The method of claim 47, wherein theDNA amplification step comprises at least one DNA amplificationparameter selected from the group consisting of: a polymeraseconcentration of about 0.15 U/μl; a concentration of each nucleotide ofabout 400 μmol/l; and a time of an elongation step of about 0.5 s/bp.49. A test kit for carrying out a method according to any one of theclaims 1-48, comprising: a container; organic solvents for removal ofparaffin; proteinase K, buffer for lysis, or both; solutions for DNAextraction, devices for DNA extraction, or both; solutions for bisulfitetreatment, devices for bisulfite treatment, or both; solutions for DNApurification, devices for DNA purification, or both; solutions for DNAamplification, substances for DNA amplification, or both; and a manualfor carrying out the method of claim 12, a description for carrying outthe method, or both.
 50. Use of the method according to any one of theclaims 1-48 or of a test kit according to claim 49 for the detection ofthe DNA methylation status.
 51. Use according to claim 50, wherein DNAmethylation status is used for diagnosing a disease, for diagnosing apredisposition for a disease or for diagnosing a progression of adisease, and wherein the disease is a cell proliferative disease orcondition, or is cancer or associated disease.
 52. Use according toclaim 51, wherein the DNA methylation status is that of positions thatare methylated, or that of positions that are non-methylated compared tonormal conditions, and wherein a single defined disease exists.
 53. Useof a method according to any one of the claims 1-48, or of a test kitaccording to claim 38 for identifying an indication-specific target,wherein a) DNA of an archived sample originating from a diseased tissueis prepared and the DNA methylation status is determined: b) DNA of asample originating from a healthy tissue is prepared and the DNAmethylation status is determined; and c) a indication-specific target isdefined based on differences in the DNA methylation status of the DNAderived from the diseased tissue in comparison to the DNA derived fromthe healthy tissue.
 54. Use according to claim 53, wherein theindication-specific target is a protein, peptide or RNA.
 55. Useaccording to claim 54, wherein a per se known modulator of the protein,peptide or RNA is assigned to the specific indication of the diseasedtissue.
 56. Use of the modulator assigned according to claim 55 forpreparing a pharmaceutical composition in case of a specific indication,or a specific cancer indication.
 57. Use of the method according to anyone of the claims 1-48, or of a test kit according to claim 38 fordiagnosis, prognosis or both of adverse events for patients orindividuals, wherein the adverse events comprise at least one categoryselected from the group consisting of: undesired drug interactions;cancer diseases; CNS malfunctions; damage or disease; symptoms ofaggression or behavioral disturbances; clinical; psychological andsocial consequences of brain damages; psychotic disturbances andpersonality disorders; dementia and/or associated syndromes;cardiovascular disease of the gastrointestinal tract; malfunction,damage or disease of the respiratory system; lesion, inflammation,infection, immunity and/or convalescence; malfunction, damage or diseaseof the body as an abnormality in the development process; malfunction,damage or disease of the skin, of the muscles, of the connective tissueor of the bones; endocrine and metabolic malfunction, damage or disease;and headaches or sexual malfunction.
 58. Use of the method according toany one of the claims 1-48, or of a test kit according to claim 38 fordistinguishing cell types or tissue or for investigating celldifferentiation.